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Abstract 
Protein arginine methylation is a post-translational modification that plays important roles in 
cellular signalling, transcription and RNA splicing and transport. The enzymes responsible for 
arginine methylation, protein arginine methyltransferases (PRMTs), have been reported to 
be aberrantly expressed in a variety of cancers, including breast, lung, bladder, prostate, 
ovarian and mantle cell lymphoma. It has become evident that arginine methylation is also a 
regulator of the cell cycle and aberrant expression of PRMTs contributes to deregulation of 
the cell cycle, contributing to carcinogenesis. 
Grade IV Glioblastoma multiforme is one of the most aggressive types of brain cancer. The 5-
year survival rate for patients with brain cancer is only 20%. One of the difficulties in treating 
brain cancers is the low penetration of drugs across the blood-brain barrier. Hence, it is 
important to develop novel chemotherapy drugs to treat brain cancer which may be used 
alone or in combination with existing treatments. Protein arginine methylation is a potential 
target for novel drug development. In this thesis, protein arginine methylation in 
glioblastoma cell lines was characterised and the effect of the inhibition of two PRMTs was 
determined. 
The results showed, that although there were differences in the asymmetric and symmetric 
dimethylation of individual proteins, there were no consistent differences in the overall level 
of methylation between the control (non-cancerous) glial and glioblastoma (cancerous) cell 
lines. However, there were increases in the protein expression of the individual PRMTs in the 
glioblastoma cell lines when compared to the control glial cell line. Protein expression of 
PRMTs 1, 2, 5, 6 and 8 were all upregulated in A172 cells, PRMTs 5, 6 and 8 were 
upregulated in U87MG cells and PRMTs 5 and 6 were upregulated in T98G cells. A172 and 
T98G cells also had less protein expression of PRMT3 and PRMT1, respectively.  
   v 
Mass spectrometry analysis identified proteins with methylated arginine residues. Several 
proteins were identified to contain differentially methylated arginine residues in the four cell 
lines. Among these proteins, methylated arginine residues identified in the proteins, tubulin 
and Mortalin, have a functional significance which has been implicated in neurological 
malformations or disorders and cancer development, respectively, confirming that arginine 
methylation is an important regulator of cellular function. 
A recently described inhibitor of PRMTs 1 and 8 (trans-2, 3- dimethoxy-β- nitrostyrene) was 
used to determine the effect of PRMT1 and 8 inhibition in glial and glioblastoma cells. It was 
discovered that the PRMT1/8 inhibitor had a cytotoxic effect on control glial cells but a 
cytostatic effect on glioblastoma cells. The PRMT1/8 inhibitor caused a significant arrest in 
the S phase of the cell cycle in all cell lines except in the T98G cells. Cells treated with the 
PRMT1/8 inhibitor were more sensitive to UV exposure and took longer to recover according 
to cell number. This suggests that the PRMT1/8 inhibitor may be a potential novel 
therapeutic agent that could be used in combination with DNA damaging chemotherapy 
agents.  
In summary, protein arginine methylation and the expression of PRMTs differs between 
normal glial cells and glioblastoma cells. Control glial and glioblastoma cells were sensitive to 
the inhibition of PRMT1/8 in a PRMT1-dependent manner and this contributed to a delayed 
DNA damage response when the cells were exposed to UV. The newly gained insight 
supports that protein arginine methylation is a key regulator of carcinogenesis in 
glioblastoma and has identified PRMTs as a therapeutic target. The results may contribute to 
the future discovery of novel drugs that can be used for cancer treatment. 
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1 Introduction 
 Carcinogenesis 
Cancer is a disease of the cell cycle (Park & Lee 2003), and has six hallmarks involved in its 
development: uncontrollable proliferation, the ability to evade growth suppressors, 
resistance to cell death, gain of replicative immortality, induction of angiogenesis and 
activation of metastatic invasion (Hanahan & Weinberg 2011). Four of these six hallmarks 
are related to the regulation of the cell cycle, so it should be no surprise that cell cycle 
regulatory proteins are often found to be de-regulated in cancer. Protein arginine 
methylation is a post-translational modification often upregulated in cancer and other 
diseases (Manchado et al. 2012), contributing to the deregulation of the cell cycle, and 
therefore to carcinogenesis.  
In this thesis, the role of protein arginine methylation in glial and glioblastoma cell lines was 
investigated. 
 Protein Arginine Methylation 
Protein arginine methylation is a post-translational modification that may be just as 
important in cell cycle regulation as phosphorylation (Raposo & Piller 2018). During protein 
methylation, a methyl group is added to a specific protein residue to alter its binding to 
other proteins or to regulate its activity (Bedford & Clarke 2009). This can occur on lysine (K), 
histidine (H) or arginine (R) residues of both histones and non-histone proteins (Lee & 
Stallcup 2009). Protein arginine methyltransferases were discovered almost 50 years ago 
and while histone and non-histone protein lysine methylation have been extensively 
researched over the past 60 years, protein arginine methylation has only gained more 
attention in the past 20-25 years (Paik et al. 2007). 
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Protein arginine methylation has many documented regulatory roles including in signal 
transduction (Altschuler et al. 1999), transcription (Carr et al. 2015; Cheng et al. 2007), 
protein-protein interactions such as facilitating the interactions of Tudor domains with 
glycine arginine rich (GAR) and proline glycine methionine (PGM) motifs in proteins (Côté & 
Richard 2005), RNA transport (McBride et al. 2000), and RNA splicing (Friesen et al. 2001).  
 The Methylation Cycle 
Protein arginine methylation is an S-adenosyl methionine-dependent reaction whereby S- 
adenosyl methionine (AdoMet) is required as the methyl group donor, yielding S-adenosyl-
homocysteine (AdoHcy) (Katz et al. 2003). Figure 1.1 shows the methylation cycle in which 
homocysteine (Hcy) metabolism leads to methylation and the recycling of components 
following the methylation event (Esse et al. 2012). AdoMet first needs to be synthesized in a 
3-step process where a methyl group is transferred from a H4-folate derivative to 
homocysteine forming methionine (Sibani et al. 2002). Methionine requires the enzyme 
methionine adenosyltransferase (MAT) and ATP to form AdoMet (Miller 2003). Following 
substrate (protein arginine) methylation via one of the protein arginine methyltransferase 
(PRMT) family enzymes, AdoHcy can be recycled to form homocysteine and adenosine, 
which is recycled further to form 3 ADP molecules (Atkinson 1977). The total energy cost of 
methylation, by a methyl group originating from folate, has been calculated to 12 ATP 
equivalent per methylation event (Atkinson 1977), making methylation an energetically very 
expensive biological modification. If high levels of Hcy accumulate, AdoHcy will accumulate 
as well, preventing the methylation reaction in a negative feedback mechanism (Esse et al. 
2012). 
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Figure 1.1: The methylation cycle  
Following the transfer of a methyl group to homocysteine to form methionine, methionine adenosyltransferase 
(MAT) and adenosine triphosphate (ATP) are required to produce the methyl donor, S-adenosyl methionine. 
Following methylation of an arginine containing protein by a protein arginine methyltransferase (PRMT), S-
adenosyl homocysteine can be recycled to form homocysteine and adenosine. ADP: adenosine diphosphate; 
B12: vitamin B12, Cys: cysteine; Pi: inorganic phosphate, THF: Tetrahydrofolate, 5-CH3-THF: 5-methyl-
tetrahydrofolate. (Adapted from Esse et al. 2012) 
 Protein Arginine Methyltransferases 
In 1968, Paik and Kim attempted to purify the enzyme responsible for the methylation of 
histone lysine residues (Paik & Kim 1968). The enzyme they discovered, protein methylase I, 
was not a lysine methyltransferase, but actually a protein arginine methyltransferase or 
PRMT (Paik & Kim 1968), now known as PRMT1. There are currently eleven PRMTs which are 
divided into four enzyme types (Teyssier et al. 2010). Types I to III exist in mammalian cells 
and all catalyse the addition of a single methyl group onto a terminal nitrogen atom of 
arginine residues forming ω- NG-monomethylarginine (MMA). Type I enzymes are the most 
common (Yang & Bedford 2013) and catalyse the addition of another methyl group onto the 
same terminal nitrogen atom, forming ω-NG, NG-dimethylarginine or asymmetric 
dimethylarginine (ADMA) (Peng & Wong 2017). Type II enzymes catalyse the addition of 
another methyl group onto the other terminal nitrogen atom, producing ω-NG, N’G-
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dimethylarginine or symmetric dimethylarginine (SDMA) (Paik & Kim 1980). Type III enzymes 
only catalyse the formation of MMA (Zurita-Lopez et al. 2012). While Type IV enzymes also 
catalyse the formation of MMA, the methyl group is added to the internal (σ) guanidino 
nitrogen atom and this has so far only been described in yeast (Fisk & Read 2011). The 
structures of the three methylarginine types present in mammals (MMA, ADMA, and SDMA) 
are shown in Figure 1.2.  
 
Figure 1.2: Types of mammalian protein arginine methylation 
Arginine residues in proteins can be monomethylated by Type I, II and III PRMTs to form MMA, while Type I and 
II PRMTs further methylate to produce ADMA and SDMA residues, respectively. Red arrows indicate known 
methylation locations in mammalian cells; red circles indicate methyl groups. 
 
PRMTs have a core region of 310 amino acids which is conserved and includes the following 
features: a methyltransferase (MTase) domain which contains a S-Adenosyl methionine 
binding site; a β barrel which is unique to PRMTs and a dimerization arm (Cheng et al. 2005). 
The MTase domain contains motif I (VLD/EVGXGXG), post I (V/IXG/AXD/E), motif II 
(F/I/VDI/L/K), motif III (LR/KXXG), and a THW loop which are all highly conserved motifs in 
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other protein methyltransferases (Yang & Bedford 2013). Zhang and colleagues (Zhang et al.) 
found a deep acidic groove within the AdoMet binding site, that is lined with negatively 
charged residues along the bottom, and hydrophobic residues along the sides. The authors 
proposed this groove to be a pocket in which the target arginine is inserted for methylation 
as the linings fit well with the hydrophobic methylene groups and the basic guanidino group 
of arginine (Zhang et al. 2000). The structure, amino acid length and enzyme type of each 
PRMT is summarised Table 1.1. 
  
    7 
Table 1.1: Structure of mammalian PRMTs 
 
†The blue lines represent the PRMT motifs in the MTase core region (black) with the grey section representing 
the β-barrel. As well as the core regions, some PRMTs have additional motifs (shown in green): the SH3 domain 
(SH3), the Zinc finger (ZnF), myristylation (Myr), the FBox motif and the tetratricopeptide repeat (TPR) (Modified 
from Teyssier et al. 2010).  
 Roles of Protein Arginine Methylation 
Protein arginine methylation has many roles including regulation of signal transduction 
(Altschuler et al. 1999), transcription (Cheng et al. 2007), protein-protein interactions such as 
facilitating the interactions of Tudor domains with glycine arginine rich (GAR) and proline 
glycine methionine (PGM) motifs on proteins (Côté & Richard 2005), RNA transport (McBride 
et al. 2000) and RNA splicing (Friesen et al. 2001). The roles and localisation of each 
mammalian PRMT are summarised in the following sections. 
 
PRMTs Domain Structures† 
AA 
length 
Enzyme 
Type 
PRMT1 
 
361 Type I 
PRMT2 
 
433 Type I 
PRMT3 
 
531 Type I 
PRMT4/ 
CARM1  
608 Type I 
PRMT5 
 
637 Type II 
PRMT6 
 
375 Type I 
PRMT7 
 
692 
Type II/ 
III 
PRMT8 
 
394 Type I 
PRMT9 
 
843 Type II 
PRMT10 
 
845 
Not 
Classified 
PRMT11 
 
956 
Not 
Classified 
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1.2.3.1 PRMT1 
PRMT1 is the most abundant PRMT in mammalian cells (Tang et al. 2000). It is mainly 
cytoplasmic (Abramovich et al. 1997) although it has been reported in the nucleus as well 
(Tang et al. 1998) and can form homodimers as well as heterodimers with PRMT2 (Pak et al. 
2011) and PRMT8 (Pahlich et al. 2008). There are at least seven isoforms of PRMT1 (Goulet 
et al. 2007; Mathioudaki et al. 2008) with a further 34 mRNA transcripts predicted, by next-
generation sequencing, to encode for PRMT1 variants (Adamopoulos et al. 2019). PRMT1 
variants often differ in their localisation and substrate specificity in cancer (Baldwin et al. 
2015) as well as correlating with the progression (Adamopoulos et al. 2019) or invasiveness 
of cancer (Patounas et al. 2018). One PRMT1 isoform that has been found in cancer cell lines 
lacks the dimerization arm of the enzyme and is enzymatically inactive, however, it is still 
able to bind substrates thus acting as a competitive inhibitor of enzymatically active PRMT1 
(Patounas et al. 2018). 
PRMT1 methylation of the scaffold protein, Axin, prevents Axin degradation, leading to the 
negative regulation of the Wnt signalling pathway (Cha et al. 2011). Arginine methylation by 
PRMT1 is required for the lysosomal translocation of GSK substrates in a variety of cancer 
cell lines during Wnt signalling (Albrecht et al. 2018), further suggesting that arginine 
methylation is an important regulator of signalling pathways. PRMT1 also regulates 
transcriptional activation through the methylation of H4R3 (Strahl et al. 2001) and regulation 
of RNA maturation and transport via the methylation of Sam68 (Herrmann et al. 2004). More 
recently, PRMT1 was found to be important for muscle cell regeneration and proliferation 
following injury (Blanc et al. 2017), B cell activation and differentiation (Infantino et al. 
2017), and the inhibition of macrophage cell death through the arginine methylation of 
GAPDH (Cho et al. 2018). 
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1.2.3.2 PRMT2 
PRMT2 is localised to the nucleus (Krause et al. 2007) and is required for the co-activation of 
nuclear receptors, such as the estrogen receptor α (ERα) (Qi et al. 2002), androgen receptor 
(AR) (Meyer et al. 2007), progesterone receptor, peroxisome proliferator-activated receptor- 
γ and the retinoic acid receptor α (Qi et al. 2002). PRMT2 is also involved in transcriptional 
activation via the methylation of H3R8 (Blythe et al. 2010), in promoting apoptosis by 
inhibiting nuclear factor -κB (NF-κB) transcription (Ganesh et al. 2006) and in alleviating 
angiotensin II-induced proliferation and inflammation in vascular smooth muscle cells (Zeng 
et al. 2018). 
1.2.3.3 PRMT3 
PRMT3 is localised predominantly to the cytoplasm but is also present in the nucleus at 
lower levels (Tang et al. 1998). PRMT3 contains a zinc finger motif which interacts with the 
ribosomal protein, RPS2, to regulate ribosomal homeostasis (Swiercz et al. 2007; Swiercz et 
al. 2005). PRMT3 also regulates the current density of cardiac voltage gated sodium channels 
which resulted in sustained high pacing of action potentials in cardiac myocytes (Beltran-
Alvarez et al. 2013).  
1.2.3.4 PRMT4 
PRMT4 is localised mainly in the nucleus (Hong et al. 2004). It regulates mRNA splicing 
(Cheng et al. 2007; Ohkura et al. 2005) and transcriptional activation through the 
methylation of H3R17 (Schurter et al. 2001). Methylation of the heat shock protein HSP70 by 
PRMT4 also regulates transcription by enhancing the binding of HSP70 to the gene promoter 
of the retinoid acid receptor and induced its transcription (Gao et al. 2015). 
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1.2.3.5 PRMT5 
PRMT5 is the dominant type II PRMT in mammals and is localised in both the cytoplasm 
(Friesen et al. 2001) and the nucleus (Dacwag et al. 2007; Pal et al. 2004). PRMT4-mediated 
methylation has been suggested to be required for the formation of PRMT5 homodimers 
(Nie et al. 2018). PRMT5 regulates signal transduction (Jansson et al. 2008), RNA splicing  
(Bardot & Toledo 2017; Bezzi et al. 2013; Neuenkirchen et al. 2008) and transcriptional 
repression through the symmetric methylation of H4R3 (Pal et al. 2007) and H3R8 (Pal et al. 
2004). Co-factors, MEP50, RIOkinase and PlCln alter PRMT5 activity towards PRMT5 
substrates H2A and H4 (Wilczek et al. 2011), nucleolin (Guderian et al. 2011) and 
spliceosomal Sm proteins (Friesen et al. 2001), respectively. Recently, PRMT5 was reported 
to act as a transcriptional co-activator of the AR by forming a complex with the transcription 
factors, Sp1 and Brg1, at the proximal promoter region of the AR gene (Deng et al. 2017). 
PRMT5 is also involved in inflammatory pathways by regulating T helper cell proliferation 
and cytokine production (Webb et al. 2017) as well as by methylating the NF- κB subunit, 
p65, which affects chemokine gene expression (Harris et al. 2016). 
1.2.3.6 PRMT6 
PRMT6 is a nuclear methyltransferase (Frankel et al. 2002) that is regulated by 
automethylation (Frankel et al. 2002). It is involved in transcriptional regulation through the 
methylation of H3R2 (Guccione et al. 2007; Hyllus et al. 2007) leading to the transcriptional 
repression of thrombospondin I (Michaud-Levesque & Richard 2009). 
1.2.3.7 PRMT7 
PRMT7 is localised in the cytoplasm and the nucleus (Lee et al. 2005a; Miranda et al. 2004). 
PRMT7 is regulated by automethylation which plays a role in epithelial-mesenchymal 
transition (Geng et al. 2017). Studies have shown PRMT7 to be a type II enzyme (Lee et al. 
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2005a; Migliori et al. 2012), however numerous studies performing in vitro methylation 
assays have proposed PRMT7 to be a type III enzyme (Feng et al. 2013; Miranda et al. 2004; 
Zurita-Lopez et al. 2012).  It is possible that PRMT7 requires binding partners to catalyse 
dimethylation which would not have been present in the in vitro methylation assays 
mentioned. It is only recently that the substrates and functional significance of methylation 
by PRMT7 have been reported, adding further fuel to the debate over PRMT7 specificity 
Substrates of PRMT7 include myelin basic protein (Lee et al. 2005a), spliceosomal protein 
SmB (Lee et al. 2005a), as well as histones H2B (Feng et al. 2013), H3 (Migliori et al. 2012) 
and H4 (Ying et al. 2015). H3R2 is symmetrically dimethylated by PRMT7 leading to a 
euchromatin structure which regulates transcriptional activation following cell cycle exit 
(Migliori et al. 2012). PRMT7 regulates B cell development through the methylation of H4R3 
on the promoter region of the bcl6 gene to affect germinal centre formation (Ying et al. 
2015). Increased mono- and dimethylation of H4R3 in PRMT7- overexpressing cells (Ying et 
al. 2015) has been reported, while loss of PRMT7 automethylation (Geng et al. 2017) and 
depletion of PRMT7 (Blanc et al. 2016) lead to a decrease in H4R3 dimethylation and H4R3 
symmetric dimethylation, respectively (Geng et al. 2017). Ying et al. (2015) hypothesised 
that PRMT7 monomethylation of H4R3 “recruited” symmetric methylation at the same site 
(Ying et al. 2015), however the identity of the enzyme performing the dimethylation at H4R3 
was not further investigated in either study by Ying et al. (2015) or Geng et al. (2017). This 
highlights that the function of PRMT7 as a type 2 or 3 enzyme is still a controversial topic and 
requires further study.  
1.2.3.8 PRMT8 
PRMT8 is unique in that it is specific to the central nervous system (Kousaka et al. 2009; Lee 
et al. 2005b). Additionally, it is the only PRMT that is myristylated which allows it to embed 
in the plasma membrane (Lee et al. 2005b). PRMT8 is regulated by automethylation (Sayegh 
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et al. 2007) and can form homodimers (Kim et al. 2015a; Lee et al. 2005b) or heterodimers 
with PRMT1 (Sayegh et al. 2007). Its substrates include the Myelin basic protein (Sayegh et 
al. 2007) and the Ewings sarcoma (EWS) protein (Pahlich et al. 2008). Recently, PRMT8 has 
been implicated in neuro-protection against age-related cellular stress in post-mitotic 
motorneurons (Simandi et al. 2018) and in maintaining the pluripotency of embryonic stem 
cells (Jeong et al. 2017). Further, PRMT8 has been reported to possess phospholipase D 
activity independent of its arginine methyltransferase activity (Kim et al. 2015a). 
1.2.3.9 PRMT9 
PRMT9 is the second confirmed type II PRMT (Cook et al. 2006; Yang et al. 2015b) and is 
localised to the cytoplasm and nucleus (Wolf 2009). So far, PRMT9 appears to regulate 
alternative splicing by the methylation of the splicing factors, SF3B2 (SAP145) (Hadjikyriacou 
et al. 2015; Yang et al. 2015b) and SAP49 (Yang et al. 2015b). 
1.2.3.10 PRMT10 and PRMT11 
PRMTs 10 and 11 were identified by their sequence homology to other PRMTs (Esse et al. 
2012); however no enzymatic methylation activity or substrates have so far been identified. 
PRMT10 was recently reported to associate with the AR and to regulate AR-dependent cell 
proliferation in androgen-dependent prostate cancer cells (Harada et al. 2015), however the 
GenBank identification code provided (NM_138364) is actually the identifier for PRMT9. 
Thus, there are still no identified substrates of PRMT10. 
It should be noted that mammalian PRMT10 is not the same as the PRMT10 protein found in 
plant species (Plett et al. 2017). The nomenclature used in the literature should be revised in 
order to avoid confusion when discussing the two different PRMT10s. 
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 Demethylation and Regulation of PRMTs 
Although demethylation has been described for methylated lysine residues and the enzymes 
that are involved are well known, the demethylation of arginine residues is still a 
controversial topic.  
Initially Jumonji domain-containing 6 (JMJD6), which shares sequence homology with, and 
includes the JmjC domain found in histone lysine demethylases, was thought to be a histone 
arginine demethylase acting on H3R2 and H4R3 (Chang et al. 2007). However, Webby et al. 
(2009) reported that it did not act as a histone arginine demethylase but as a catalyst for 
lysine hydroxylation of the nuclear protein U2AF65. Further studies have shown that JMJD6 
may be associated with RNA complexes in the regulation of RNA splicing (Hahn et al. 2010) 
while Poulard et al. (2014) proposed that the enzyme demethylates asymmetric 
dimethylation on the Estrogen Receptor (ER) α at R260 and histone H4 at arginine 3 (H4R3) 
with further possible substrates also identified. As such the existence of arginine 
demethylases is a controversial area in the field of arginine methylation. 
It has been demonstrated that free methylated arginines can be converted to citrulline by 
dimethylarginine dimethylaminohydrolase (DDAH) (Ogawa et al. 1989). It was speculated 
that a similar enzyme may exist that can catalyse this reaction on methylarginine residues 
contained within proteins as well and efforts to identify such proteins were made. The 
enzyme peptidylarginine deiminase 4 (PAD4) was identified by its sequence homology to 
DDAH and is thought to either reverse the activity of PRMTs (Wang et al. 2004), or to 
deiminate unmodified and monomethyl arginine residues only (Cuthbert et al. 2004). PAD4 
was subsequently found to only deiminate unmodified protein arginine residues (Raijmakers 
et al. 2007) making the enzyme a regulator of methylation, as it prevents methylation from 
occurring, rather than an actual demethylase. 
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Phosphorylation is also a regulator of protein arginine methylation (Bedford 2007). The 
phosphorylation of CARM1 at serine 228 reduces the enzymes’ ability to bind to the methyl 
donor AdoMet leading to diminished methyltransferase activity (Higashimoto et al. 2007), 
while the phosphorylation of N-terminal PRMT5 tyrosine residues by oncogenic JAK2 kinase 
mutants (Liu et al. 2011) greatly impairs its methyltransferase activity by reducing PRMT5’s 
interaction with its cofactor MEP50 (Stopa et al. 2015), leading to the activation of cellular 
proliferation signalling pathways (Liu et al. 2011). Phosphorylation of MEP50 also alters 
PRMT5 function by increasing its affinity for histones (Aggarwal et al. 2010). Phosphorylated 
proteins also overlapped with proteins containing monomethylated arginine residues in 89% 
of proteins analysed (Yakubu et al. 2017), further suggesting layers of regulatory interplay 
between arginine methylation and other post-translational modifications. 
PRMTs themselves can also be regulated by arginine methylation. For example, PRMT4-
mediated methylation of PRMT5 at arginine 505 is required for the homodimerization of 
PRMT5 thus regulating the methyltransferase activity of PRMT5 (Nie et al. 2018).  
PRMT-binding proteins can also inhibit, activate, or change the substrate specificity of 
PRMTs. For example, the methylation of hnRNP protein by PRMT1 is more efficient when the 
enzyme is associated with TIS21 and BTG1 protein family members than when methylated 
by PRMT1 alone (Lin et al. 1996). The tumour suppressor gene DAL-1/4.1B interacts with 
PRMT3 to inhibit its ability to methylate GAR sequences (Singh et al. 2004). CARM1 forms a 
complex (Nucleosomal methylation activator complex: NUMAC) with at least eight SWI/SNF 
components, activating ER-dependent transcription (Xu et al. 2004), while PRMT7 forms 
complexes with the CCCTC-binding factor-like protein (CTCFL) to stimulate its 
methyltransferase activity (Jelinic et al. 2006).  
Folate and vitamin B12 from the diet are also regulators of the methylation cycle as they are 
required to provide the methyl group for methylation reactions (Esse et al. 2012), (shown in 
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Figure 1.1). A recent study in Gambia found that infants conceived in the rainy season had 
higher levels of DNA methylation than those conceived in the dry season due to the higher 
availability of folate-rich foods (Dominguez-Salas et al. 2014). Although the study focused on 
DNA methylation, the same methylation cycle is responsible for all methylation reactions, so 
diet would also have an impact on protein and RNA methylation as well. 
 Protein Arginine Methylation and Disease 
Protein arginine methylation is important for the normal functioning of cells. The following 
section outlines how disease states can be caused by the up- or down- regulation of PRMTs 
and/or their substrates. 
1.2.5.1 Viral Diseases 
A range of viruses require methylation of some of their proteins to facilitate viral replication 
and gene regulation (reviewed by Mirto & Piller 2010). Inhibition of methylation by 
Adenosine dialdehyde, oxidised (AdOx) decreased the infectivity of HIV-1 but increased viral 
production (Willemsen et al. 2006). Several HIV-1 proteins were shown to be methylated, 
with methylated arginine residues in the Transactivator of transcription (Tat) (Boulanger et 
al. 2005), Regulator of virion (Rev) (Invernizzi et al. 2006), and Nucleocapsid (NC) proteins 
(Invernizzi et al. 2007) confirmed as substrates of PRMT6. Methylation of the regulatory 
protein Tat may hinder Tat-TAR binding and alter the cellular localisation of Tat (Boulanger 
et al. 2005).  RNA recognition by Tat is thought to be affected by the position and type of 
methylation added to the arginine residues (Li et al. 2015). Viral RNA export is decreased by 
methylation of the Rev N-terminus which interrupts the nuclear localisation signal of Rev 
(Invernizzi et al. 2006). Methylation of the NC inhibits its function in reverse transcription 
resulting in a decrease of HIV-1 reverse transcriptase activity (Invernizzi et al. 2007). 
Methylation of H3R26 by PRMT4 acts as a regulator of HIV-1 latency and inhibition of PRMT4 
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reactivated HIV-1 transcription (Zhang et al. 2017b). In addition, previous work in the Piller 
lab has identified arginine residues in the matrix and integrase proteins to also be 
methylated (Mirto 2013). 
The small hepatitis delta antigen (S-HDAg) of the hepatitis delta virus is methylated in the 
RNA-binding domain and methylation by PRMT1 is required for viral RNA replication and 
also regulates the subcellular localisation of S-HDAg in the Huh7 human liver cancer cell line 
(Li et al. 2004). Recently, PRMT5 was found to regulate the replication of the hepatitis B virus 
by repressing transcription through methylation of H4R3 and by preventing the interaction 
of pre-genomic RNA with the viral polymerase protein (Zhang et al. 2017a). 
The Epstein-Barr virus requires methylation of its nuclear antigen EBNA2 for interaction with 
survival motor neuron protein and potentially implicates methylation in the transformation 
of B-cells by the Epstein-Barr virus (Barth et al. 2003). Methylation of the nuclear antigen 
EBNA1, on the other hand, regulates localisation of the antigen, which in turn regulates the 
replication and mitotic segregation of the virus genome (Shire et al. 2006). 
1.2.5.2 Cardiovascular Diseases 
Protein arginine methylation has also been linked to cardiovascular disease. Nitric oxide (NO) 
is an important signalling molecule which can protect cardiac vessels by the activation of 
vasodilation, LDL modification, leukocyte function and regulation of vascular homeostasis 
(reviewed by Cines et al. 1998). In addition to this, accumulation of NO can have cytotoxic 
properties, due to an unpaired electron which is highly reactive with free radicals (Chen et 
al. 2006) and can lead to oxidative stress and inflammation (Mommersteeg et al. 2015). 
NO is synthesised from its precursor, L-arginine, by the enzyme Nitric oxide synthase (NOS). 
Free ADMA, i.e. not within a protein but individual asymmetrically dimethylated arginine 
amino acids, produced by type I PRMTs, inhibits NOS function, preventing NO from exerting 
its protective functions (Vallance et al. 1992). At the same time, proinflammatory cytokines 
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and oxidative stress inhibit the destruction of free ADMA by DDAH (reviewed by 
Mommersteeg et al. 2015). Build-up of free ADMA, leads to decreased vasodilation in 
patients with atherosclerosis (Moncada & Higgs 1993). While patients with coronary heart 
disease were found to have increased free ADMA levels due to decreased expression of NOS 
and DDAH, as well as increased PRMT1 and PRMT3 expression levels of both mRNA and 
protein (Chen et al. 2006). The methionine precursor, homocysteine also directly inhibits 
DDAH and provides a methyl donor group, leading to a build-up of free ADMA (Stuhlinger et 
al. 2001), implicating methylation in the pathogenesis of cardiovascular disease.  
Arginine methylation has also been reported to play a role in the pathogenesis of Brugada 
syndrome and Long QT syndrome, which are both characterised by sudden cardiac death in 
adults (Wang et al. 1995; Yan & Antzelevitch 1999). These syndromes are known to be 
caused by mutations at R526 and R680, respectively, of the cardiac sodium channel Nav1.5 
(Bezzina et al. 1999). Methylation by PRMT3 and PRMT5 at R526 and R680, respectively, has 
been reported to increase the cell surface expression of the cardiac sodium channel (Beltran-
Alvarez et al. 2013); however the exact physiological implications of methylation of the 
Nav1.5 channel for Brugada and Long QT syndromes are yet to be determined. 
1.2.5.3 Nervous System Diseases 
Methylation of arginine residues may regulate phosphorylation of proteins, by α 
serine/threonine-protein kinase (AKT), which has been linked to the pathogenesis of 
Parkinson’s disease and polyglutamine neurodegenerative diseases, such as, Huntington’s 
disease and Spinal bulbar muscular atrophy (Basso & Pennuto 2015). PRMT5 deficiency may 
also mediate Huntington’s disease pathogenesis by a reduction in the symmetric 
methylation of histones H2A and H4 as reported in primary neurons and human brain tissues 
(Ratovitski et al. 2015). This leads to changes in the epigenetic regulation of gene 
    18 
transcription and contributes to abnormal protein interactions between the mutant gene 
product Htt and other proteins (Ratovitski et al. 2015). 
Morrison and colleagues (1996) reported decreased levels of the methyl donor, AdoMet, in 
patients with Alzheimer’s disease however, this was not due to an increase in methylation 
reactions as decreased levels of methylated proteins were reported in the brain (Morrison et 
al. 1996) and cerebrospinal fluid (Abe et al. 2001). While, other studies have reported 
increased free ADMA in the plasma of patients with Alzheimer’s disease (Arlt et al. 2008; 
Selley 2003). Knockdown of PRMT5 in neuronal cells overexpressing the amyloid precursor 
protein activated signalling pathways leading to increased apoptosis, suggesting that PRMT5 
may act as a negative regulator of amyloid-β induced toxicity (Quan et al. 2015). 
PRMT1 and PRMT8 have been implicated in the distribution of the fused in sarcoma (FUS) 
family of proteins in amyotrophic lateral sclerosis (ALS) and may contribute to the gain of 
function of FUS mutants by methylation of the FUS mutants (Scaramuzzino et al. 2013; 
Tradewell et al. 2012). In motor neuron-like cells that express mutant forms of FUS, 
endoplasmic reticulum stress is induced by the mutant FUS leading to the abnormal 
cytoplasmic localisation of FUS (Farg et al. 2012). Arginine methylation regulates the 
subcellular localisation of FUS (Fujii et al. 2016; Suárez-Calvet et al. 2016; Tradewell et al. 
2012) and inhibition of PRMT1 resulted in the sequestration of FUS to the nucleus (Tradewell 
et al. 2012). 
1.2.5.4 Cancer 
Altered expression of PRMTs has been documented in many cancer types. For example, 
protein levels of PRMT4 are increased in prostate cancer (Hong et al. 2004), melanoma 
(Limm et al. 2013) and colorectal cancer (Kim et al. 2010b); while PRMT5 protein levels are 
increased in ovarian cancer (Bao et al. 2013), and this is often associated with poor 
prognosis of survival (reviewed by Yang & Bedford 2013). 
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PRMT5 may play an important role in the NF-κB pathway through its interaction with the 
tumour necrosis factor receptor- associated factor 4 (TRAF4) (Yang et al. 2015a). In the 
nucleus, PRMT5 binds to the zinc-finger region of TRAF4 allowing PRMT5 to be upregulated, 
and promoting cell proliferation in breast cancer (Yang et al. 2015a). Protein levels of PRMT5 
were found to be higher in breast cancer stem cells and depletion of PRMT5 in ER positive 
xenografts reduced both tumour growth and the proportion of breast cancer stem cells 
(Chiang & Davies 2018; Chiang et al. 2017). 
Elevated expression levels of PRMT7 in breast cancer are associated with higher grade 
tumours and are able to promote epithelial-to-mesenchymal transition by binding the E-
cadherin promoter, thus inhibiting E-cadherin expression (Yao et al. 2014).  
Loss of PRMT8 in Grade IV brain cancer, glioblastoma multiforme, has been linked to the 
upregulation of several genes, such as cxcr4 and efemp1, which encode for chemokine 
receptors and extracellular matrix glycoproteins required for glial cell differentiation and 
gliomagenesis (Simandi et al. 2014).  
PRMTs 1, 2, 4 and 7 all have known isoforms caused by alternative splicing, found mainly in 
cancer cells, which impacts on their subcellular localisation, enzymatic activity and substrate 
specificity (Baldwin et al. 2014). 
In breast cancer, the estrogen receptor α (ERα) is methylated by PRMT1 at arginine 260, 
resulting in cytoplasmic localisation of ERα and indirectly preventing the downstream 
phosphorylation of AKT (Poulard et al. 2014). PRMT2 is another co-activator for the ERα and 
has been implicated in tumour cell growth and progression (Qi et al. 2002). 
The androgen receptor (AR) found in the prostate plays a role in regulating the G1/S phase 
transition of the cell cycle in prostate cancer (Knudsen et al. 1998). Methylation inhibition 
resulted in reduced expression of the AR and reduced cell proliferation (Shiota et al. 2012). 
PRMT2 acts as a co-activator of the AR, allowing translocation of both the AR and PRMT2 
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from the cytoplasm into the nucleus (Meyer et al. 2007). The AR also associates with 
PRMT9/10 (see section 1.2.3.10) in the prostate cancer cell line, LNCaP, and knockdown of 
PRMT9/10 suppressed both cellular growth and expression of the prostate specific antigen 
(PSA) (Harada et al. 2015). PRMT5 was recently found to function as an activator of the AR 
and regulator of AR-dependent proliferation in LNCaP cells and expression of PRMT5 also 
correlated with increased RNA and protein expression of the AR (Deng et al. 2017).  
Although it is not yet known if the AR is methylated itself, it is clear that PRMTs play an 
important role in AR-mediated cell cycle progression, through the association with the AR. 
Elevated expression levels of PRMTs have been found in many types of cancer (Poulard et al. 
2016; Wei et al. 2014). In particular, PRMT1 and PRMT6 protein levels have been shown to 
be overexpressed in a variety of cancers, including lung, testicular, bladder, breast, cervical 
and prostate cancers (Yoshimatsu et al. 2011). Further, microarray analysis following the 
knockdown of PRMT1 or PRMT6 affected multiple cellular pathways, implicating their 
importance in cell cycle and proliferation, cell cycle checkpoints and DNA replication 
(Yoshimatsu et al. 2011).  
Hence, protein arginine methylation appears to be involved in carcinogenesis through the 
regulation of the cell cycle.  
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Table 1.2: Summary of PRMTs in cancer 
 
PRMT 
 
Cancer 
Type 
Known 
Methylated 
Residues 
Result of Methylation or PRMT 
Interaction 
References 
1 Breast 
 
Lung 
Testicular 
Bladder 
Breast 
Cervical 
Prostate 
R260 
 
- 
Methylation of ER α leads to cytoplasmic 
localisation of the ER, preventing downstream 
phosphorylation of AKT 
PRMT1 is overexpressed in these cancers, 
regulating the cell cycle and proliferation 
(Poulard et al. 2014) 
 
(Yoshimatsu et al. 
2011) 
2 Prostate 
 
Breast 
- 
 
- 
Interaction with the AR reduces cell 
proliferation by regulating G1/S phase 
transition of the cell cycle 
Co-activator of the ER 
(Shiota et al. 2012), 
(Meyer et al. 2007) 
(Qi et al. 2002) 
3 Unknown    
4 Prostate 
Melanoma 
Colorectal 
- Increased PRMT4 protein expression (Hong et al. 2004), 
(Limm et al. 2013), 
(Kim et al. 2010b) 
5 Ovarian 
 
Breast 
Prostate 
- 
 
- 
- 
Increased PRMT5 protein expression is 
associated with poor prognosis 
Increased PRMT5 protein levels; depletion of 
PRMT5 reduced tumour growth 
Regulates AR-dependent proliferation 
(Bao et al. 2013) 
(Chiang & Davies 
2018); (Chiang et al. 
2017) 
(Deng et al. 2017) 
6 Lung 
Testicular 
Bladder 
Breast 
Cervical 
Prostate 
- PRMT6 is overexpressed in these cancers, 
regulating the cell cycle and proliferation 
(Yoshimatsu et al. 
2011) 
7 Breast - Elevated PRMT7 are associated with higher 
grade tumour and promotes epithelial-
mesenchymal transition 
(Yao et al. 2014) 
8 Brain - Loss of PRMT8 is linked to genes required for 
glial cell differentiation and gliomagenesis 
(Simandi et al. 
2014) 
9 Prostate - Regulates androgen receptor-dependent cell 
proliferation 
(Harada et al. 2015) 
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 The Cell Cycle 
As mentioned earlier, cancer is considered a disease of the cell cycle, so it is important to 
understand how the cell cycle works and how it is regulated, in order to understand when it 
is not functioning, such as in cancer.  
The cell cycle allows cells to divide and is characterised by the replication of DNA and the 
subsequent division of duplicated chromosomes into two daughter cells (Vermeulen et al. 
2003). Regulatory proteins including the tumour suppressor protein p53 and the 
retinoblastoma protein (pRb) monitor the cell cycle and initiate pathways in response to 
DNA damage (Nam & Kim 2008).  
 Cell Division 
The controlled regulation of cell division is essential in growth, repair and re-generation of 
healthy tissues and occurs via the cell cycle. The cell cycle is divided into non-overlapping 
stages or phases which are referred to as gap 1 (G1), synthesis (S), gap 2 (G2) and mitosis (M) 
phase (Norbury & Nurse 1992). These phases are summarised in Figure 1.3. In the G1 phase, 
the cell is preparing for DNA replication which then occurs in the S phase, while cells in the 
G2 phase are preparing for the M phase, where cell division takes place (Norbury & Nurse 
1992). M phase can be further divided into prophase, metaphase, anaphase, telophase and 
cytokinesis (Schafer 1998). Cells that are not actively dividing are said to be in G0, a resting or 
quiescent phase. Once cells have committed to DNA replication they cannot return to G0 
until the completion of the cell cycle where each daughter cell can enter G0 (Vermeulen et al. 
2003). To guarantee successful cell division without errors, the cell cycle is stringently 
regulated. 
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Figure 1.3: Phases of the Cell Cycle 
The cell cycle is depicted as a circle where each black arrow represents one phase of the cell cycle. Cells enter 
the cell cycle into the G1 phase, which is followed by the S phase, G2 phase and then mitosis (M). Mitosis is 
further differentiated into prophase, metaphase, anaphase, telophase and cytokinesis. Cells in G0 are in a 
quiescent phase and must re-enter the cell cycle to replicate. 
 Cell Cycle Regulation 
Regulation of the cell cycle is mainly achieved by a family of serine/threonine kinases called 
cyclin-dependent kinases (CDKs). However, full CDK activation only occurs upon the 
association of a CDK and a cyclin subunit (Collins & Garrett 2005). CDKs allow cell cycle phase 
transitions to occur (Maddika et al. 2007). Nine CDKs have been identified with five of them 
found to be active as complexes with various cyclin subunits during the cell cycle (Morgan 
1995; Pines 1995). CDK levels remain constant throughout the cell cycle, while the levels of 
cyclin proteins rise and fall to activate the CDKs when they are required during the cell cycle 
(Evans et al. 1983). The associations of the various CDKs and cyclins are summarised in Table 
1.3 and are shown in Figure 1.4 which depicts a schematic overview of the cell cycle phases 
and their regulation. 
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Table 1.3: CDK interactions with cyclins regulate specific cell cycle phases 
CDK Cyclin Cell Cycle Activity 
CDK4 Cyclin D1, D2, D3 G1 phase 
CDK6 Cyclin D1, D2, D3 G1 phase 
CDK2 Cyclin E 
Cyclin A 
G1/S phase transition 
S phase 
CDK1 Cyclin A 
Cyclin B 
G2/M phase transition 
Mitosis 
CDK7 Cyclin H CAK- all phases 
 
CDK activity is regulated by the post-translational modification, phosphorylation, on specific 
residues to induce conformational changes and enhance cyclin binding. For example, full 
activation of CDK2 requires phosphorylation on threonine 160 by the CDK7-cyclin H complex 
also called the CDK activating kinase (CAK) (Jeffrey et al. 1995). Inhibitory kinases, such as 
Wee1 and Myt1 can function as inactivators of CDK1 by phosphorylating it. 
Dephosphorylation, by phosphatases, is then required for CDK1 reactivation (Lew & 
Kornbluth 1996). 
Cyclin dependent kinase inhibitors (CDKIs) regulate CDK activity by binding to CDKs or the 
CDK-cyclin complex (Vermeulen et al. 2003). There are two families of CDKIs which have 
been discovered so far: Inhibitors of CDK4 (INK4) proteins and CDK interacting proteins/ 
Kinase inhibitory proteins (CIP/KIP) (Sherr 1994). The INK4 inhibitors (p15INK4b, p16INK4a, 
p18INK4c, p19INK4d) specifically inactivate the cyclin D-dependent CDKs, i.e. CDK4 and CDK6, by 
competitively binding these CDKs and preventing them from forming a complex with cyclin D 
(see Figure 1.4) (Hirai et al. 1995). The CIP/KIP inhibitors (p21CIP1, p27KIP1, p57KIP2) bind to and 
inactivate multiple G1 CDK-cyclin complexes (Polyak et al. 1994). p21 also binds to the 
proliferating cell nuclear antigen (PCNA), inhibiting DNA replication (Waga et al. 1997). CDKIs 
are themselves regulated by internal and external signals. For example, the p21 gene 
promoter encodes a p53 binding site allowing p53 to transcriptionally activate the p21 gene 
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(el-Deiry et al. 1993). The expression of p15 and activation of p27 both increase in response 
to transforming growth factor β (Polyak et al. 1994). 
 
Figure 1.4: Overview of the regulation of the cell cycle  
The cell cycle is regulated by CDKs (purple), their regulatory subunit cyclins (pink), CDK inhibitors such as p21 
(light blue), and other regulatory kinases, such as the checkpoint kinases 1 and 2 (Chk1 and Chk2) (yellow). The 
orange lines at the end of G1 and G2 and during S phase and mitosis indicate cell cycle checkpoints where the cell 
is monitored for defects during replication and can respond by the p53 (green) pathway or the ATM/R (red) 
pathway, among others (Raposo & Piller 2018).  
1.3.2.1 Cell Cycle Checkpoints 
In addition to the cell cycle regulation by CDKs and CDKIs, there are several checkpoints, 
such as the DNA repair checkpoints that regulate G1/S and G2/M phase transitions (see 
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Figure 1.4), where cell size, extracellular growth signals (Park & Lee 2003), and progression 
through the cell cycle are monitored to prevent defects or to repair any DNA damage which 
may have occurred during DNA synthesis (Malumbres & Barbacid 2009). It is these DNA 
defects, which if left unrepaired, are passed onto daughter cells during cell division and 
contribute to the deregulation of the cell cycle and may lead to the unrestrained cell 
proliferation characteristics of cancer (Vermeulen et al. 2003). 
DNA damage checkpoints occur before cells enter the S phase (G1-S checkpoint) where cell 
cycle arrest induced by DNA damage is p53 dependent; or after DNA replication, which can 
occur with or without p53 activation (G2-M checkpoint) (Levine 1997). The checkpoint kinase 
proteins, Chk1 and Chk2, phosphorylate the cell division cycle phosphatases, Cdc25, to 
regulate the phosphorylation of CDK1 and CDK2, and therefore regulate G1 into S phase and 
S phase into G2/M transitions, respectively (Nam & Kim 2008). DNA damage repair is also 
monitored during S phase to block replication (known as the intra-S phase checkpoint), if 
damaged DNA has escaped the G1/S phase checkpoint without undergoing repair (Paulovich 
& Hartwell 1995). 
The spindle assembly checkpoint (SAC) detects the improper alignment of chromosomes on 
the mitotic spindle and can stop the cell cycle in metaphase, if required, to prevent the 
formation of cells with the incorrect number of chromosomes (Kops et al. 2005). This 
checkpoint is controlled by the mitotic-arrest deficient (mad) and the budding uninhibited by 
benzimidazole (bub1) families of genes (Hoyt et al. 1991; Li & Murray 1991). The mitotic 
checkpoint complex (MCC) consists of MAD2, BUBR1 and BUB3 proteins and negatively 
regulates the activity of cell division cycle protein 20 (CDC20) (Fang et al. 1998; Malureanu et 
al. 2009; Shannon et al. 2002; Sudakin et al. 2001). CDC20 binds to the ubiquitin ligase 
anaphase-promoting complex/cyclosome (APC/C) (Malureanu et al. 2009), preventing the 
APC/C from exerting its ubiquitinylation activity on securin and cyclin B (Hagting et al. 2002). 
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Securin is an inhibitor of the protease separase which is required to cleave the cohesion 
complex which holds sister chromatids together (Hauf et al. 2001), while cyclin B is required 
to activate CDK1 to promote exit of the cells from mitosis (D'Angiolella et al. 2003). Thus, 
inhibition of the APC/C by the MCC prevents cells from entering anaphase. Other important 
SAC proteins include MAD1, BUB1, MAPK and Aurora B, which promote recruitment of the 
SAC proteins to the kinetochores (Ditchfield et al. 2003). Aurora B is also involved in 
correcting aberrant merotelic attachment of kinetochores to microtubules from opposite 
poles to prevent the division of cells with the improper number of chromosomes (Hauf et al. 
2003). Ubiquitin-associated protein 2-like (UBAP2L) is also necessary for proper kinetochore/ 
microtubule attachment and depletion of UBAP2L activated SAC signalling, delaying 
progression into anaphase (Maeda et al. 2015).  
1.3.2.2 DNA Damage Repair 
DNA damage can be induced via a variety of triggers (including UV radiation, chemicals, and 
stress) and if left unrepaired can lead to cancer. Therefore, cells respond to unrepairable 
DNA damage by stopping cell cycle progression or by initiating programmed cell death via 
several pathways. 
Depending on the type of DNA damage, five major pathways of DNA repair are utilised by 
cells including: direct repair, base excision repair, nucleotide excision repair, mismatch and 
recombinational repair, and double strand break repair (Sancar et al. 2004). These repair 
pathways will be briefly explained in the following sections.  
In mammalian cells, alkylation damage is repaired by direct repair alkyltransferases.  O6-
methylguanine-DNA methyltransferase is the main enzyme facilitating direct repair by 
transferring a methyl group from the DNA backbone into the active site of the enzyme 
(Demple et al. 1982). 
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Three excision repair mechanisms remove specific types of damage: Firstly, base excision 
repair (BER) specifically recognizes base damage. It most commonly deals with base damage 
that occurs during normal aerobic metabolism via reactive oxygen species (most common 
base damage: dihydro-8-oxoguanine). BER requires removal of the damaged DNA base by a 
specific DNA glycosylase to initiate the process (Krokan et al. 1997). Short nucleotide gaps 
are then re-synthesized via APE1, DNA polymerase β (Kubota et al. 1996) and the Ligase 
3/XRCC1 complex; while longer breaks of 2-10 nucleotides are repaired by the RFC/PCNA-
DNA polymerase δ/ε complex (Mayanagi et al. 2009). Secondly, nucleotide excision repair 
(NER) is the major pathway for the removal of bulky DNA lesions formed by exposure to 
environmental sources, ultraviolet radiation or chemicals (de Laat et al. 1999). In humans, 
the process of nucleotide excision repair involves damage recognition, incision around the 
lesion to release a 24-32 nucleotide oligomer and repair of the resulting gap by DNA 
polymerase δ/ε and ligation. In humans, nucleotide excision repair requires more than 30 
proteins to successfully execute the repair (Schafer 1998). Repair proteins including XPA, 
RPA, XPC, TFIIH, XPG and XPF-ERCC1 perform these functions (Araújo et al. 2001; He et al. 
1995; O'Donovan et al. 1994). Thirdly, mismatch repair functions to repair errors such as 
mismatches, insertions or deletions that can occur during replication (Kunkel & Erie 2005). 
Double strand breaks (DSBs) are the most lethal type of damage to the cell. DSB damage 
occurs when cells are exposed to ionizing radiation and during normal cellular recombination 
and immunoglobulin class-switching processes (Chu 1997). DSBs can be repaired via 
homologous recombination (HR) or non-homologous end-joining (NHEJ) (Ferguson & Alt 
2001). HR occurs at a homologous stretch of DNA on a sister chromatid serving as a template 
to guide repair of the broken strand, while NHEJ requires enzymes to capture the ends of the 
broken DNA, bringing them together in a DNA-protein complex, then the DNA break is 
repaired via ligation (Weterings & Chen 2008). Both require the proteins NBS1 (Tauchi et al. 
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2002), MRE11 (D'Amours & Jackson 2002), and Rad50 (Baumann & West 1998). HR also 
requires the heterodimer MUS81-MMS4 (Sancar et al. 2004), BRCA1 and BRCA2 (Davies et 
al. 2001), while NHEJ requires DNA-PKCs and the heterodimer Ligase 4-XRCC4 (Lees-Miller & 
Meek 2003). 
DNA strand crosslinks can be induced by many chemotherapeutic drugs and can stall DNA 
replication, leading to cell death (Dronkert & Kanaar 2001). Depending on the type of cross-
link, they are processed either by NER (intra-strand cross-link) or converted into a double-
stranded DNA break and processed by HR (inter-strand crosslink) (McHugh et al. 2001). 
Hence, the same repair proteins are utilised, such as XPF-ERCC1 to degrade one of the cross-
linked strands (Kuraoka et al. 2000); or the recombination proteins Rad51 and Rad52 to 
promote homologous DNA pairing and strand exchange (Baumann & West 1998). 
DNA damage repair can also be initiated by tumour suppressor proteins which can induce 
cell cycle arrest to either initiate repair or mark the cell for apoptosis. Two such proteins that 
regulate the major pathways of apoptosis and cellular progression are p53 and pRb, 
(Maddika et al. 2007). Between them, these two proteins can initiate differentiation, DNA 
repair, cell cycle arrest or progression and induction/inhibition of apoptosis. The p53 and 
pRb pathways are summarised in the following sections. 
1.3.2.3 p53 
p53 is normally expressed at low levels but rises within cells in response to various stimuli, 
such as DNA damage, hypoxia and oncogene activation, to activate various pathways that 
initiate differentiation, DNA repair, cell cycle arrest, inhibition of angiogenesis and apoptosis 
(Finlan & Hupp 2005). There are three main responses that p53 can initiate: 1) facilitate cell 
cycle arrest by inducing the expression of p21, 14-3-3 proteins, Cdc25C and GADD45 (Peng 
et al. 1997); 2) stimulate DNA repair by inducing the expression of p21, GADD45 and p48 
(Maddika et al. 2007); and 3) induce apoptosis by upregulating the transcription of BAX and 
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other apoptotic proteins (Kim et al. 2006). Low levels of stress or DNA damage induce p53-
mediated cell cycle arrest, while high levels of stress activate p53-mediated apoptotic 
pathways (Giono & Manfredi 2006). Further, different protein kinases such as Ataxia-
Telangiectasia Mutated (ATM) and Ataxia-Telangiectasia and Rad3 related (ATR) 
phosphorylate p53 in response to DNA damage, leading to p21 arresting the cell cycle at the 
G1-S checkpoint (Abraham 2001; Siliciano et al. 1997) (see Figure 1.4). Inactivation of the p53 
gene results in the dysfunction of proteins that would normally inhibit cell cycle proliferation 
(Vermeulen et al. 2003). The inactivation of the p53 gene through mutations is the most 
commonly occurring loss of a pro-apoptotic regulator and is seen in more than 50% of 
cancers (Hanahan & Weinberg 2000). p53 translocation into the nucleus is prevented by the 
binding chaperone protein Mortalin to p53. This prevents p53 from wielding its apoptotic 
activity (Wadhwa et al. 1998). 
1.3.2.4 Retinoblastoma Protein 
pRb interacts with proteins involved in transcriptional control such as the E2F proteins that 
are regulators of gene expression and genes involved in DNA replication, DNA repair and 
G2/M progression (Knudsen & Knudsen 2006) (see Figure 1.4). pRb regulates cell cycle arrest 
by binding to E2F. E2F and its heterodimer, the transcription factor DP, are mediators of the 
p16/pRb pathway of G1 cell cycle arrest (Lukas et al. 1995). However, only unphosphorylated 
forms of pRb can interact with E2F proteins (Chellappan et al. 1991). Thus, phosphorylation 
of pRb carried out by the CDK4-cyclin D1 complex regulates pRb function (Connell-Crowley 
et al. 1997). pRb is found to be unphosphorylated during G0 and G1 phase and 
phosphorylated during the remainder of the cell cycle (Buchkovich et al. 1989). 
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1.3.2.5 Regulation of the Cell Cycle & DNA Damage Repair by Arginine Methylation 
A number of key regulatory proteins of the cell cycle have been identified to interact with 
several PRMTs and/or methylated residues have been identified (for summary see Table 
1.4). While there had been earlier indications that arginine methylation may be involved in 
cell proliferation, a study by Kim et al. (Kim et al. 2010a) was one of the first to describe the 
involvement of protein arginine methylation in the different phases of the cell cycle in HeLa 
cells. The following sections will summarise the involvement of the individual PRMTs in the 
regulation of the cell cycle and the significance of this regulation in cancer. 
1.3.2.5.1 PRMT1 
As the most abundant PRMT (Tang et al. 2000), the majority of PRMT1 activity can be 
described as anti-proliferative and/or tumour-suppressor-inducing. Recent work has 
revealed that PRMT1 binds to the tumour suppressor, BGT2, to play a role in pre-B cell 
differentiation (Dolezal et al. 2017). The BGT2-PRMT1 complex destabilizes the binding of 
CDK4 to cyclin D3 through the methylation of CDK4 at arginines 55, 73, 82 and 163, halting 
cell cycle progression and leading to pre-B cell differentiation (Dolezal et al. 2017). E2F1 is 
competitively methylated by PRMT1 and PRMT5 (Zheng et al. 2013). Methylation by PRMT1 
stabilizes E2F1 during DNA damage (Glorian et al. 2017) and assists in E2F1-dependent 
apoptosis (Zheng et al. 2013), while methylation by PRMT5 promotes cellular proliferation 
(Cho et al. 2012; Zheng et al. 2013). Interestingly, recent publications have brought to light 
the interplay between arginine methylation and serine phosphorylation, adding an extra 
layer of complexity to the regulation of the cell cycle. For example, methylation of p16 at 
arginine 138 by PRMT1 increases as phosphorylation of p16 at serine 140 decreases, and 
vice versa in 293T cells (Lu et al. 2017). These modifications work antagonistically to regulate 
the interaction of p16 with CDK4 (Lu et al. 2017), thus regulating cell proliferation and 
apoptosis.  
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1.3.2.5.2 PRMT2 
It is unclear at this stage whether PRMT2 has pro-proliferative or anti-proliferative functions 
in cancer. Arginine methylation of pRb by PRMT2 contributes to E2F1 transcriptional 
regulation for progression into S phase (Yoshimoto et al. 2006) by impairing pRb/E2F1 
binding (Kim et al. 2015b). Recently, PRMT2 levels were found to be decreased in breast 
cancer cells, while knockdown of PRMT2 correlated with increased expression of both p21 
(Oh et al. 2014) and cyclin D1 (Zhong et al. 2014) indicating a regulatory role for PRMT2 in 
cell cycle progression. Further studies are needed to clarify the exact functions of PRMT2 in 
cell cycle progression.  
1.3.2.5.3 PRMT4 
PRMT4 appears to have pro-proliferative functions and may have a pro-oncogenic role in 
some cancers. Expression of Cyclin E1 rises sharply leading into S phase to allow transition 
into the S phase (Schafer 1998), and levels of cyclin E1 are frequently deregulated in breast 
cancer (Dobashi 2005). PRMT4 is a positive regulator of the Cyclin E1 gene, by acting as a 
transcriptional co-activator of ACTR coinciding with histone methylation of the CCNE1 
promoter region (El Messaoudi et al. 2006).  PRMT4 is essential for estrogen induced cell 
cycle proliferation in breast cancer by the positive regulation of E2F1 RNA and protein 
expression (Frietze et al. 2008).  In addition, increased expression of PRMT4 may contribute 
to the development of prostate cancer, as it correlates with the androgen independence 
required for the progression of aggressive tumours (Hong et al. 2004). Interestingly, a 
decrease in PRMT4-mediated methylation of pRb led to a decrease in phosphorylation, 
suggesting arginine methylation can increase pRb-mediated cell proliferation (Kim et al. 
2015b). 
1.3.2.5.4 PRMT5 
The most studied type II PRMT, PRMT5, has pro-proliferative and pro-oncogenic roles, as 
described below, even though it appears to have the opposite effect in Fanconi anemia 
    33 
patients (Du et al. 2016). This highlights that the effect of specific PRMTs and their inhibition 
may not be the same in all types of cancers and may differ in individual patients. 
PRMT5 is essential for cell proliferation (Pal et al. 2004) and correlates with increased 
protein expression of the G1 phase regulators CDK4 and CDK6 (Wei et al. 2012). Deficiency of 
PRMT5 triggers cell-cycle arrest in the G1 phase (Scoumanne et al. 2009). Overexpression of 
PRMT5 correlates with increased cell proliferation and knockdown of PRMT5 results in cell 
cycle arrest leading to apoptosis (Yan et al. 2014). CDK4 interacts with PRMT5 in HepG2 cells 
which regulates phosphorylation of pRb, thus regulating pRb/E2F- mediated transcription 
(Yang et al. 2016). Disruption of the PRMT5/CDK4 interaction revealed PRMT5 knockdown 
HepG2 cells to be more sensitive to the CDK4 inhibitor fascaplysin, marking the combination 
of PRMT5 and CDK4 inhibition as a potential cancer therapy (Yang et al. 2016). PRMT5 
deficiency also led to apoptosis in differentiated glioblastoma cells however, in glioblastoma 
neurospheres it led to G1 cell cycle arrest through increased protein expression of p27 and a 
decrease in phosphorylation of pRb (Banasavadi-Siddegowda et al. 2017). PRMT5 expression 
correlated with cyclin D1 protein levels, while also inversely correlating with p16 levels 
(Kumar et al. 2017). Nuclear PRMT5/p16-negative tumours were associated with poor 
prognosis in oropharyngeal squamous cell carcinoma when compared to nuclear PRMT5-
negative/p16- positive tumours (Kumar et al. 2017). PRMT5 is found to be overexpressed in 
many cancer types, including glioblastoma (Han et al. 2014; Yan et al. 2014), lung (Gu et al. 
2012a), mantle cell lymphoma (Pal et al. 2007), ovarian (Bao et al. 2013), prostate cancer 
(Gu et al. 2012b) and breast cancer stem cells (Chiang et al. 2017). In all these studies, 
knockdown of PRMT5 slowed or inhibited cell proliferation, indicating the enzyme may be 
affecting key regulators of cell proliferation.  
p53 target specificity is altered by PRMT5-mediated methylation of p53 at arginines 333, 335 
and 337  enhancing p53-dependent cell cycle arrest(Jansson et al. 2008), while reduced 
    34 
expression of p53 during the DNA damage response is triggered by PRMT5-deficiency 
(Scoumanne et al. 2009). Although the methylation of p53 at arginine 213 may be 
controversial (Jung et al. 2008), mutation of this residue resulted in a decrease of p21 RNA 
and protein expression directly affecting the S phase of the cell cycle (Zhang et al. 2014). This 
indicates that p21 activation by p53 may be mediated by arginine methylation of R213 
(Zhang et al. 2014). PRMT5-dependent methylation of RUVBL-1 stimulates the histone 
acetyltransferase activity of TIP60, leading to the acetylation of H4K16 and the removal of 
53BP1 from DNA DSBs and allowing HR to continue (Clarke et al. 2017). 
Fanconi anemia is a genetic disorder characterized by a high risk of developing cancer, 
among other clinical characteristics, due to a cellular hypersensitivity to DNA cross-linking 
agents and faulty DNA damage repair pathways (Cheung & Taniguchi 2017). Fanconi anemia 
proteins, FANCA-C, E-G, L and M, form a “core complex” which activates DNA repair 
pathways. In Fanca-/- and Fancc-/- mice, arginine methylation of p53 by PRMT5 was 
decreased in response to oncogenic stress (Du et al. 2016). Interestingly, forced expression 
of PRMT5 led to the delayed onset of leukemia in irradiated mice (Du et al. 2016), indicating 
that PRMT5 may play a tumour suppressor role in Fanconi anemia patients.  
1.3.2.5.5 PRMT6 
PRMT6 may have pro-proliferative and pro-oncogenic functions in both colon and lung 
cancers. PRMT6 inhibits p21 along with p27, allowing cell cycle progression through the 
cyclin dependent kinases 1 and 2 (CDK1/2) (Kleinschmidt et al. 2012; Phalke et al. 2012; Stein 
et al. 2012). Methylation at arginine 156 of the p21 protein by PRMT6 increased the 
cytoplasmic localisation of p21 and resulted in HCT116 colon cancer cells becoming more 
resistant to the chemotherapy drug, doxorubicin (Nakakido et al. 2015). Methylation of p16 
at arginine 138 by PRMT6 caused reduced binding of p16 to CDK4, leading to increased 
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cellular proliferation in A549 cells (Wang et al. 2012b). Further studies are required to 
determine the function of PRMT6 in other cell types and cancers. 
The remaining PRMTs have not been identified to play a role in the regulation of the cell 
cycle and require further investigation. 
Therefore, protein arginine methylation may represent a novel target in the development of 
anti-cancer drugs. Brain cancer is notoriously difficult to treat due to the inability of drugs to 
cross the blood-brain barrier, hence the development of new drugs to target brain cancer is 
an ongoing priority for future cancer treatment. 
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Table 1.4: Key Cell Cycle Regulators known to be Substrates and Interacting Partners of 
PRMTs 
Protein Interacting PRMT 
Known 
Methylated 
Residues 
Result of Methylation or PRMT 
Interaction Reference 
BGT2 PRMT1 - BGT2 regulates PRMT1 activity in pre-B 
cells 
(Dolezal et al. 
2017) 
CDK4 PRMT1 R55, R73, 
R82, R163 
Destabilization of CDK4-Cyclin D3 
complex leading to pre-B cell 
differentiation 
(Dolezal et al. 
2017) 
Cyclin 
D1 
PRMT2 - Knockdown of PRMT2 correlates with 
increased Cyclin D1 
(Zhong et al. 
2014) 
PRMT5 - Increased nuclear PRMT5 correlates with 
increased Cyclin D1 protein levels 
(Kumar et al. 
2017) 
E2F1 
 
PRMT1 R109 Assists E2F1-dependent apoptosis during 
DNA damage 
(Glorian et al. 
2017; Zheng et 
al. 2013) 
PRMT4 - Regulates E2F expression (Frietze et al. 
2008) 
PRMT5 R111, R113 Promotes cell proliferation (Cho et al. 2012; 
Zheng et al. 
2013) 
Fanca PRMT5 - Regulation of PRMT5-mediated 
methylation of p53 
(Du et al. 2016) 
p16 
 
PRMT1 R138 Regulates p16 and CDK4 interaction to 
regulate cell proliferation 
(Lu et al. 2017) 
PRMT5 - Increased nuclear PRMT5 negatively 
correlates with p16 protein expression 
and is associated with poor survival 
(Kumar et al. 
2017) 
PRMT6 R22, R131, 
R138 
Methylation of p16 reduces binding of 
p16 with CDK4 
(Wang et al. 
2012b) 
p21 PRMT2 - Knockdown of PRMT2 correlates with 
increased p21 expression 
(Oh et al. 2014) 
PRMT6 
- Inhibition allowing cell cycle progression (Kleinschmidt et 
al. 2012) 
R156 Increased cytoplasmic localisation of 
p21, resulting in resistance to 
doxorubicin 
(Nakakido et al. 
2015) 
p27 PRMT6 - Inhibition allowing cell cycle progression (Kleinschmidt et 
al. 2012) 
p53 PRMT5 R333, R335, 
R337 
Affects promoter specificity of p53 and 
enhances p53-dependent cell cycle 
arrest 
(Jansson et al. 
2008) 
unknown R213 Mediates p21 activation for cell cycle 
progression 
(Zhang et al. 
2014) 
pRb PRMT2 - Repression of E2F transcriptional activity 
and cell cycle progression by binding to 
pRb 
(Yoshimoto et 
al. 2006) 
PRMT4 R775, R787, 
R798 
Decreases binding of pRb to E2F-1 
leading to increased cell proliferation 
(Kim et al. 
2015b) 
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 Brain Cancer 
Brain cancer is one of the most aggressive types of cancer (Australian Institute of Health and 
Welfare 2012). While mortality rates in Australia for lung, bowel and breast cancers 
improved by up to 50% when comparing the twenty years leading up to 2007, mortality 
rates for brain cancers saw negligible changes (Sitas et al. 2013). Due to their aggressive 
nature, the 5 year survival rate for patients in Australia with brain cancer is only 25% 
(Australian Institute of Health and Welfare 2017). 
Primary brain tumours are graded I-IV according to their severity (Louis et al. 2007). Two of 
the most aggressive forms of brain cancer fall under the category of glioma: anaplastic 
astrocytoma (Grade III) and glioblastoma multiforme (Grade IV) (Louis et al. 2007). Glioma or 
glioblastoma are derived from astrocyte brain cells and are characterised by significant cell 
proliferation and infiltration, vascular proliferation and necrosis (reviewed by Furnari et al. 
2007). High grade gliomas have been reported to have deletions at the INK4A locus which 
encode the tumour suppressor genes known to inhibit cellular proliferation by arresting cells 
in the G2 phase of the cell cycle (Labuhn et al. 2001). High grade gliomas have also been 
reported to express high levels of focal adhesion kinase (FAK), a key regulator of cell 
migration and adhesion, when compared to lower grade tumours. Overexpression of the 
focal adhesion targeting domain inhibited FAK activation in glioblastoma cell lines with 
tumour suppressor gene deletions (Jones et al. 2001a). A recent study reported that protein 
arginine methyltransferase 1 (PRMT1) is recruited into a complex termed the methylosome 
to initiate the methylation of arginine 3 of Histone 4 to activate the transcription of 
glioblastoma genes, such as EGFR, AKT3, and CDK6 (Takai et al. 2014). Inhibition of FAK was 
found to inhibit the epidermal growth factor receptor (EGFR) required for glioblastoma 
migration (Jones et al. 2001b). Methylation of EGFR by PRMT1 enhances binding of EGFR to 
EGF and regulates signalling pathways which are mediated by EGFR (Liao 2015).  
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PRMT1 protein was upregulated in glioblastoma compared to non-cancerous glial cells 
(Wang et al. 2012a). PRMT5 increases during glial cell maturation and expression levels 
peaked in adult mice (Huang et al. 2011). Studies have shown PRMT5 protein expression and 
SDMA expression to be lower in non-cancerous glial tissue than in glioblastoma (Han et al. 
2014). It has also been suggested that PRMT5 may be a biomarker for glioblastoma as 
expression of PRMT5 correlated with the grade of tumour malignancy (Han et al. 2014). Loss 
of PRMT8 in glioblastoma multiforme has been linked to the upregulation of several genes, 
such as cxcr4 and efemp1, which encode for chemokine receptors and extracellular matrix 
glycoproteins required for glial cell differentiation and gliomagenesis (Simandi et al. 2014). 
 Brain Cancer Treatment  
As mentioned earlier, glioblastoma patients have an extremely low survival rate. Median 
survival time is only 14 months even with aggressive radiation and chemotherapy treatment 
(Friedman et al. 2000). One of the main chemotherapy drugs used to treat glioblastoma is 
temozolomide, a second generation imidazotetrazine DNA alkylating agent that can activate 
pro-autophagic and pro-apoptotic pathways and is less toxic than previous drugs (Friedman 
et al. 2000). However, patients with tumours that do not contain a methylated O6-
methylguanine-DNA methyltransferase promoter were less responsive than those with the 
methylated promoter region (Lefranc et al. 2009). Temozolomide is also less successful in 
patients with tumour mutations in PTEN/PI3K signalling pathways, retinoblastoma cell cycle 
pathways and p53-mediated apoptosis pathways (Furnari et al. 2007). Hence combination 
therapies using temozolomide with other drugs or with immunotherapies such as 
bevacizumab, a monoclonal antibody to VEGF-A are being trialled (Ajaz et al. 2014). 
One of the current difficulties in treating brain cancer is the low penetration of drugs across 
the blood-brain barrier which protects the brain from toxins circulating in the blood but also 
prevents chemotherapy drugs from gaining access to the brain (Groothuis 2000). Studies in 
    39 
patients with glioma and mouse models have led to the understanding that chemotherapy 
drugs do not efficiently cross the blood-brain barrier due to efflux transporters, such as, P-
glycoprotein at the apical membrane of brain endothelial cells (Breedveld et al. 2006). 
Research is focussing on developing transporters to overcome the poor penetration of 
chemotherapy drugs (Reviewed by Geldenhuys et al. 2011). Efflux inhibitors, such as 
elacridar which inhibits P-glycoprotein, are also being developed to increase brain 
penetration of chemotherapy drugs by reducing the ability of these transporters to expel the 
drug from the brain (van Tellingen et al. 2015). However, patients treated with injections of 
chemotherapy drugs directly to the brain tumour site showed varying efficacy (Chang et al. 
2001) suggesting that the poor penetration of chemotherapy drugs across the blood-brain 
barrier and/or the action of the efflux transporters is not the only explanation for their poor 
efficacy in the treatment of brain cancer. 
Hence, it is important to develop novel chemotherapy drug development to treat brain 
cancer which may be used alone or in combination with existing treatments. Current efforts 
are focussed on histone deacetylase inhibitors (Singh et al. 2015), proteasome inhibitors 
(Manton et al. 2016), lysine demethylase inhibitors (Singh et al. 2011), alone or in 
combination, as potential therapeutic agents. Protein arginine methylation is a potential 
target for novel drugs, however the role of arginine methylation in glioblastoma and in 
carcinogenesis needs to first be further characterised and fully understood. 
 Significance and Aims 
Arginine methylation is a post-translational modification that plays an essential role in many 
cellular functions. Numerous studies have been performed to investigate the cellular 
pathways in which methylated proteins are involved. However, no studies have been 
performed comparing the role of protein arginine methylation between glial and 
glioblastoma cells. Therefore, this study aimed to characterise the role of protein arginine 
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methylation in human brain cancer cell lines, including identifying possible proteins modified 
by methylation, which may play a role in the cell cycle and carcinogenesis of these cell lines. 
The characterisation of the PRMT1/8 inhibitor CID5380390 in mammalian cell lines is 
important in order to determine if the drug is viable as cancer treatment. A better 
understanding of the molecular pathways and regulation via protein arginine methylation is 
vital in order to develop new treatments for cancer.  
Hypothesis 1: Protein arginine methylation and expression of PRMTs differs between glial 
(control) and glioblastoma (cancer) cell lines (see Chapter 3). 
Aims: 
 To characterise the differences in methylation patterns between glial and 
glioblastoma cell lines using Western blotting. 
 To identify protein residues which are differentially methylated using mass 
spectrometry. 
 To compare protein and RNA expression levels of PRMTs between glial cells and 
glioblastoma cell lines using Western blotting and RT- qPCR. 
Hypothesis 2: PRMT1 is responsible for the methylation of cell cycle-related and DNA 
repair proteins in glioblastoma cell lines and contributes to the regulation of the cell cycle 
(see Chapter 4). 
Aims:  
 To characterise the effect of the PRMT1/8 inhibitor on the cell cycle of glial and 
glioblastoma cells using cell counting, cell cycle analysis by flow cytometry and 
fluorescent confocal microscopy. 
 To identify protein residues which are differentially methylated during PRMT1/8 
inhibition using mass spectrometry. 
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2 Materials and Methods 
 Reagents and Antibodies 
Ethanol and ammonium bicarbonate (ammonium hydrogen carbonate) were sourced from 
Chem-Supply; Formic Acid from Scharlau; 2-Iodoacetamide (IAA), acetonitrile, dimethyl 
sulfoxide (DMSO), dithiothreitol (DTT), glycerol, methanol, sodium dodecyl sulphate (SDS) 
were purchased from Sigma-Millipore Australia. The methylation inhibitor, trans-2, 3-
dimethoxy-ß-nitrostyrene or CID5380390 was purchased from Sigma- Millipore Australia. 
Antibodies used for Western blot analysis were sourced from Abcam, Sapphire Bioscience, 
Sigma-Millipore Australia and Thermo Scientific as per Table 2.1. The dilutions used for 
Western blotting (Wb) and immunocytochemistry (ICC) are also indicated in Table 2.1. 
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Table 2.1: List of antibodies used 
Name Primary or 
Secondary 
Animal 
Origin 
Dilution Supplier Product 
Number Wb ICC 
Asym24 antibody Primary Rabbit 1:500 1:200 Sigma-Millipore 
Australia 
07-414 
Sym10 antibody Primary Rabbit 1:500 1:200 Sigma-Millipore 
Australia 
07-412 
Anti-GAPDH 
antibody 
Primary Rabbit 1:1000 N/A Sigma-Millipore 
Australia 
ABS16 
Anti-PRMT1 Primary Rabbit 1:500 1:200 Sigma-Millipore 
Australia 
07-404 
Anti-PRMT2 Primary Rabbit 1:500 N/A Sigma-Millipore 
Australia 
HPA018976-
100UL 
Anti-PRMT3 Primary Rabbit 1:500 N/A Sigma-Millipore 
Australia 
SAB2101882-
100UL 
Anti-PRMT4 Primary Rabbit 1:1000 N/A Sigma-Millipore 
Australia 
SAB1305432-
40TST 
Anti-PRMT5 Primary Rabbit 1:1000 N/A Sigma-Millipore 
Australia 
07-405 
Anti-PRMT6 Primary Rabbit 1:500 N/A Sigma-Millipore 
Australia 
ABE124 
Anti-PRMT8 Primary Rabbit 1:1000 N/A Abcam Ab168134 
Anti-phospho-
H2A.X 
Primary Rabbit N/A 1:1000 Cell Signalling 9718 
Anti- β-Tubulin Primary Rabbit 1:500 N/A Abcam Ab6046 
Anti-Rabbit IgG 
(whole molecule)- 
Biotinylated 
antibody 
Secondary Goat 1:2500 N/A Sigma-Millipore 
Australia 
B7389 
Anti-Rabbit IgG, 
conjugated to 
Alexa Fluor 555 
Secondary Goat N/A 1:500 Life 
Technologies 
Australia 
R37116 
 
 Phylogenetic Tree Construction 
PRMT protein sequences from human (Homo sapiens; (Venter et al. 2001)), mouse (Mus 
musculus; (Dietrich et al. 1996)), cow (Bos taurus; (Fries et al. 1993)), African clawed frog 
(Xenopus laevis; (Roe et al. 1985)), zebrafish (Danio rerio; (Woods et al. 2000)), fruit fly 
(Drosophila melanogaster; (Adams et al. 2000)), yeast (Saccharomyces cerevisiae; (Mewes et 
al. 1997)), Thale cress (Arabidopsis thaliana; (Lamesch et al. 2011)), rice (Oryza sativa; 
(Ouyang et al. 2006)) and Eucalyptus (Eucalyptus grandis; (Myburg et al. 2014)) were 
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retrieved using the PANTHER protein classifications PTHR11006 and PTHR10738. A 
phylogenetic tree was constructed using the online tool ‘Phylogeny.fr’ (Dereeper et al. 
2008). The sequences were aligned using MUSCLE (default settings) and the phylogenetic 
tree was reconstructed using the maximum likelihood method (PhyML program v3.1/3.0 
aLRT). All of the PRMT-like protein sequences were downloaded from the Phytozome 
database (Phytozome v10.3:phytozome.jgi.doe.gov: accessed 27/02/2018) for plant 
sequences and Uniprot (www.uniprot.org: accessed 27/02/2018) for all other sequences.  
 Cell Lines 
A variety of brain cancer cell lines was used for all aims and compared with a non-cancerous 
brain “control” cell line. The cancerous cell lines were chosen for their differences in 
molecular characteristics (shown in   
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Table 2.2), which are important for the tumorigenesis of many cancer types. The p53 gene 
(tp53) is the most commonly mutated gene in many cancers, including colon, breast, 
prostate and brain cancers (Louis 1994); while mutations of the phosphatase and tensin 
homolog gene (PTEN) are the second most common after p53 (reviewed by (Karsy et al. 
2015)). The A172 (#88062428), T98G (#92090213) and U87MG (#89081402) cell lines were 
purchased from the European Collection of Authenticated Cell Cultures (ECACC) via Sigma-
Aldrich, Australia while the SVG p12 (#ATCCRL8621) cell line was purchased from In Vitro 
Technologies, Australia. 
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Table 2.2: The background of the origin of the cell lines used and their molecular 
characteristics*  
Cell Line SVG p12 A172 T98G U87MG 
Cell Line Background 
Cell Type Brain Human 
glioblastoma (IV) 
Human 
glioblastoma 
multiforme (IV) 
Human 
Glioblastoma 
astrocytoma 
(IV) 
Age at 
Diagnosis/Sex 
Foetal,  
first trimester 
53/ M 61/ M 44/ M  
Tumour 
location 
N/A Not available Not available Occipital 
Molecular Characteristics 
BRCA2 N/A N.D C5455T; protein 
P1819S 
N.D 
CCNA2  N/A N.D G413C; protein 
R138T 
N.D 
CDKN2A 
(p16INK4A) 
N/A Homozygous del. 
suspected 
Homozygous del. 
suspected 
Homozygous 
del. Suspected 
CDKN2A 
(p14ARF) 
N/A Homozygous del. 
suspected 
Homozygous del. 
suspected 
Homozygous 
del. suspected 
FANCA N/A G2029A; Protein 
V677M 
N.D N.D 
PTEN N/A Homozygous 
Deletion- No 
protein detected 
T125G; protein 
L42R 
Mutation- 
Splice Del. Exon 
3 
RAD50 N/A N.D N.D A1127G; 
protein D376G 
A1544G; 
protein D515G 
RAD51AP1 N/A A782C; protein 
K261T 
N.D N.D 
SETD2 N/A N.D G435T, protein 
K145N 
N.D 
TP53 N/A N.D G711A; protein 
M237I 
G423A; protein 
M144I 
N.D 
* N/A: not applicable, N.D: No changes detected from wild type 
 Controversy of the U87MG Cell Line 
The U87MG cell line used widely in research today was recently reported to differ from the 
original cell line submitted to the American Type Culture Collection (ATCC) (Allen et al. 
2016). The cell line was originally isolated and characterised by Pontén and Macintyre in 
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Uppsala, Sweden (Pontén & Macintyre 1968) and has become one of the most commonly 
used and well-studied glioblastoma cell lines, including characterisation of the genomic 
sequence (Clark et al. 2010). The preserved source tumour, U87MG cells from the Uppsala 
lab and U87MG cells from the ATCC were compared using short tandem repeat (STR) 
profiling and mitochondrial DNA analysis. This revealed differing genotypes between the two 
cell lines suggesting a mix-up or misidentification sometime following the deposit of the cells 
into the ATCC repository (Allen et al. 2016). Although the origin of the current U87MG cell 
line is unknown, Allen et al. (Allen et al. 2016) suggest that the cell line is of CNS origin and is 
still likely to be a human glioblastoma cell line. This has also been confirmed by the ECACC 
from whom the cell line was purchased (personal communication; Appendix Figure 7.1), 
hence it was decided to continue with the use of the U87MG cell line for this thesis. 
 Cell Culture 
All cell lines were cultured in 75 cm2 culture flasks (Corning) with complete media containing 
Dulbecco’s Modified Eagle Media (A172; Gibco Invitrogen Australia) or Eagle’s Minimum 
Essential Medium (SVGp12, T98G, U87MG; Sigma- Aldrich Australia) supplemented with 10% 
fetal bovine serum (JRH Biosciences) 2 mM L-Glutamine (Gibco Invitrogen Australia) and 1% 
Penicillin/Streptomycin (Gibco Invitrogen Australia). Eagle’s Minimum Essential Medium was 
also supplemented with 1% Non-essential amino acids (Sigma- Aldrich Australia). The cells 
were maintained at 37°C in a 5% CO2 atmosphere.  
 Cell Passaging 
Cells were passaged when approximately 80% confluent. The media was removed and the 
cells were washed twice with sterile cell culture grade phosphate buffered saline (PBS) 
(Sigma-Aldrich Australia). To detach adherent cells, they were washed in 2-3 mL of trypsin-
EDTA (Sigma-Aldrich Australia) in PBS, and cells were incubated at 37°C for 5 min. The cells 
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were resuspended in 5 mL of complete media. A172 and T98G cells were transferred into 
new flasks at a 1/10 or 1/20 ratio, while U87MG and SVGp12 cells were transferred into new 
flasks at a 1/5 or 1/10 ratio, and cultured in 10 mL of complete media. 
 Cell Harvesting 
Cells were harvested for use in further experiments, either at 90% confluency or at specific 
time points after treatment depending on the experiments. The media was removed and 
cells were washed twice with sterile cell culture grade PBS. Adherent cells were detached 
using trypsin as per section 2.4.1 and resuspended in 5 mL of PBS. Cells were centrifuged at 
400 x g for 5 min and the supernatant was discarded. Cells were washed with 5 mL of PBS by 
pipetting up and down and centrifuging at 400 x g for 5 min. The supernatant was discarded 
and the cell pellet was stored at -20°C until further use. 
 Methylation Inhibition 
The methylation inhibitor, trans-2, 3-dimethoxy-ß-nitrostyrene or CID5380390, originally 
discovered to selectively inhibit only PRMT1 and PRMT8 in a high-throughput assay (Dillon et 
al. 2012) was chosen as a selective PRMT inhibitor for this thesis and is referred to as 
PRMT1/8 inhibitor throughout this thesis.  
Cells were cultured and harvested as described in section 2.4, then 2 x 105 cells were seeded 
into T25 flasks (Corning) in 5 mL of the appropriate media or 1.5 x 105  were seeded in each 
well of a six well plate (Corning) in 3 mL of the appropriate media. Cells were allowed to 
adhere for 24 h before they were treated with 2, 3 or 4 µM PRMT1/8 Inhibitor CID5380390 
(Sigma-Aldrich Australia) which was reconstituted in 100% DMSO. Control flasks contained a 
vehicle control of complete media with 0.02% DMSO (Sigma-Aldrich Australia). The cells 
were incubated at 37°C and 5% CO2 for 24 or 48 h. Media was replaced after every 24 h of 
treatment with the appropriate treatment or control media. Following treatment time, 
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images of cells were taken using an inverted microscope (Olympus) with a ISH500 eyepiece 
camera (Luminoptic) and ISCapture software (Tucsen Photonics Co., Ltd.; version 3.6.9.3_N) 
before harvesting as described in section 2.4.2 for further analysis. 
 Cell Viability 
Cells were washed with PBS, harvested as per section 2.4.2, then collected and counted 
using 0.4% Trypan Blue (Sigma-Aldrich Australia). A Neubauer Bright-Line Haemocytometer 
was used to obtain the ratio of live to dead cells as per established methods (Briggs & Jones 
2005). Cells were then used in further assays, such as, cell cycle analysis (described in section 
2.7), Western blotting (described in section 2.8) or RNA expression analysis (described in 
section 2.10). 
 Data Analysis 
Following cell counting, the mean cell numbers from a minimum of three independent 
experiments was used to create a bar diagram. Data were analysed as described in section 
2.13. 
 Cell Cycle Analysis Based on DNA Content 
Cell cycle analysis by flow cytometry can determine the DNA content of each cell, allowing 
the percentage of cells in each phase of the cell cycle to be determined (Darzynkiewicz et al. 
2001). This can be achieved by staining the cells with a fluorescent dye which binds to DNA. 
Propidium iodide (PI) is one such dye that, when excited by light of a particular wavelength 
(535 nm) will emit light at another wavelength (619 nm) that is detected by the flow 
cytometer (Pozarowski & Darzynkiewicz 2004). Cells in G1 phase have one set of 
chromosomes and will emit low fluorescence intensity, while cells in G2 and M phases have 
two sets of chromosomes and will emit twice the fluorescence intensity than those in G1. 
Cells in S phase have between one and two sets of chromosomes and will emit a 
    50 
fluorescence intensity between that seen for G1 and G2/M phases (Darzynkiewicz et al. 
2001). As G2 and M phase cells both have two sets of chromosomes, it is not possible to 
differentiate them using only PI staining of cells. When the fluorescence is graphed on a 
histogram as cell count vs. PI intensity, the populations of the different phases can be 
identified (Wersto et al. 2001). 
 Cell Preparation and Data Collection 
Cells were seeded in T25 flasks and treatment was applied as described in section 2.5. 
Following treatment, cells were fixed in 70% ethanol (Sigma-Aldrich Australia), 30% milli-Q 
water solution by pulse vortexing and were kept fixed in ethanol at 4°C for up to 14 days 
before analysis. However, cells were usually analysed within 48 h unless the flow cytometer 
was unavailable. 
On the day of analysis, fixed cells were washed with PBS, stained with PI solution: 50 µg/mL 
PI (Sigma-Aldrich Australia), 3U RNase A (Sigma-Aldrich Australia) in PBS; and incubated at 
37°C for 30 min to 1 h in the dark. Following incubation, the PI solution was removed. The 
cells were resuspended in PBS and then filtered into 12 x 75 mm tubes with 35 μm nylon 
mesh cell strainer caps (Cat. No. 352235; BD Falcon). Samples were detected by the BD FACS 
Canto II at a low to medium flow speed to record approximately 200 cell events per second. 
A total of 10,000 events were recorded for each sample.  
DNA content was analysed on the flow cytometer with the FACS Diva software (BD; version 
6.1.3). Data were collected in linear mode using the 488 nm blue laser and 585/42 detector 
with area, width and height parameters in FACS Diva software. A dot plot of Side scatter- 
Area (SSC-A) vs. Forward scatter- Area (FSC-A) was setup and the voltage was adjusted to 
show cells at a 45-degree angle (see Figure 2.1). A second dot plot was set up of B_585/42-A 
vs. B_585/42-W. This is the PI intensity and cell size, respectively, detected by the blue laser 
and was used to gate out any doublets during later analysis. Doublets are two cells in G1 
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phase which are clumped together and appear to have the same DNA content as one cell in 
G2/M phase, however, doublets have a different size and shape and hence can be detected 
and then excluded by gating (Wersto et al. 2001). A histogram of Count vs. B_585/42-A gives 
a basic cell cycle profile. Figure 2.1 shows a screenshot of the setup in FACS Diva for cell 
cycle analysis including gating for doublets (B, C) and the basic cell cycle profile (D). The data 
were then exported and analysed for cell cycle distribution using FlowJo software as 
described in section 2.7.2. 
 
Figure 2.1: Screenshot of the set-up in FACS Diva Software for cell cycle 
Dotplots of Area vs. Height and Area vs. Width can be used to identify doublets so that they can be excluded by 
gating for a more precise cell cycle analysis. Dotplots of SSC-A vs. FSC-A (A) and B_585/42-A vs. B_585/42-W 
(B) were used to gate out doublets and cellular debris. The B-585/42-A vs. B_585/42-H (C) dotplot was used to 
gate and exclude doublets and debris from analysis. A histogram of Count vs. B_585/42-A (D) depicting the basic 
cell cycle distribution of cells from the P1 gate (B). 
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 Cell Cycle Data Analysis 
FlowJo Software (TreeStar; version 10.0.7) was used to analyse the data collected by FACS 
Diva. First, the SSC-A vs. FSC-A was gated on the main population to exclude cellular debris 
(Figure 2.2A), then the FSC-H vs. FSC-A was gated to exclude doublets (Figure 2.2B).  This 
population was isolated and put into a histogram of Cell no vs. B_585/42 (Figure 2.2C) to 
isolate the live cell population. This gating method was chosen as it is more accurate for 
gating cancer cells which can have broad signals in both Area vs. Height and Area vs. Width 
dot plots (Wersto et al. 2001). Lastly, the cell cycle analysis function of the software was 
selected (Figure 2.2D) and performed on the live, singlet population isolated by gating. The 
cell cycle analysis uses algorithms to apply Gaussian curves to the G1/G0 and G2/M 
populations. The Watson (pragmatic) model was applied to the data as it makes no 
assumptions about the shape of the S phase distribution and fits the S phase under the 
curve, while the Dean-Jett-Fox model assumes that the S phase can be modelled by a 
second-degree polynomial and requires a G2 peak (Mahoney 2012).  
If the model could not fit curves to the data, the G0/G1 peak was manually placed in the 
centre of the peak. Ideally, the G2/M peak is located at twice the x-value of the G0/G1 peak. 
However, due to differences in DNA levels and intensities between cells, a ratio of 1.95- 2.05 
can be applied. The FlowJo software automatically applies a ratio of 1.95 and this option was 
selected for all data analysed. 
A ratio was created for each phase of the cell cycle of the mean of the non-cancerous cell 
line and the three cancerous cell lines to determine the fold change from the control, i.e. the 
difference between the fold change of cells in each phase of the cell cycle between 
cancerous and non-cancerous cells. The mean of three independent experiments was used 
to create a bar diagram. Data were analysed as described in section 2.13. 
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Figure 2.2: Cell cycle analysis gating set-up for FlowJo software.  
SSC-A vs. FSC-A was gated to exclude cell debris and doublets. Cells inside the P1 and P2 gates represent live 
cells (A) and single cells (B), respectively. B_585/42-A vs. B_585/42-W was used to gate on the live cell 
population (C), then cell cycle analysis was performed on the live singlet population (D) where blue is the G0/G1 
phase, green is the G2/M phase and yellow is the S phase. 
 Western Blot Analysis  
 SDS-PAGE and Transfer 
Cells were cultured and harvested as described in sections 2.4.1 and 2.4.2, and lysed by 
adding Pierce’s lysis buffer (25 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% 
glycerol, in PBS) with protease inhibitors (Thermo Scientific). The volume of buffer depended 
on the size of the cell pellet to be lysed and ranged from 200-800 µL. The pellet was 
incubated on ice for 10 min, then centrifuged at 15000 x g for 10 min to remove insoluble 
fragments. 
A 
C D 
B 
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The pellet was discarded and protein concentration of the lysate was determined by 
Bicinchoninic Acid (BCA; Sigma-Aldrich Australia) assay using bovine serum albumin (BSA; 
Sigma-Aldrich Australia) standards with a range of 0.125-2.0 mg/mL. A 1:5 dilution of 
reducing sample buffer (0.5 M Tris, 10% v/v Glycerol, 0.028 M SDS, 4% v/v β-
mercaptoethanol, and 0.00015 M Bromophenol blue in Milli-Q water) was added to 30-
40 µg of protein and boiled for 5 min. The actual amount of protein loaded is specified in the 
results section. 
Mini-Protean Plus TGX 4-20% gels (Bio Rad) or 10% sodium dodecyl polyacrylamide gels with 
a 4% stacking gel were loaded with 4 µL of PageRuler Plus ladder (Thermo Scientific) and up 
to 40 µL of the previously prepared sample/buffer solution which contained normalized 
protein concentrations. Proteins were electrophoresed for 55 min at 150 V with Tris-Glycine-
SDS running buffer (192 mM glycine, 25 mM Tris, 1% SDS in Milli-Q water). 
Proteins were transferred to polyvinylidene difluoride (PVDF) membranes with 0.2 μm pore 
(Millipore) using the semi-dry blot system (Owl HEP-1; Thermo Scientific). The membranes 
were activated in methanol, then sandwiched with the gel in between filter paper 
dampened with transfer buffer (192 mM glycine, 25 mM Tris in Milli-Q water). Bubbles and 
excess buffer were removed using a roller, before the transfer was performed for 70 min at 
constant 0.2 A per SDS gel. 
 Probing with Antibodies 
Following transfer, the membranes were blocked overnight by soaking in 5% skim milk 
solution in PBS and were then washed in 5 mL of PBST (PBS with 1% Tween-20) for 5 min. 
The membranes were probed with the primary antibody in PBST and incubated for 2 h at 
room temperature. Thereafter the membrane was washed three times with PBST and 
probed with the appropriate secondary antibody in PBST for 1-2 h. Details of the antibodies 
and the dilutions used are listed in Table 2.1. The membranes were then washed as 
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described previously. Membranes were incubated with ExAP (Sigma-Aldrich, Australia) at a 
concentration of 1:5000 for 30 min. BCIP/NBT- Blue liquid substrate (Sigma-Aldrich Australia) 
was then added to the membranes (1 mL per membrane) to visualise proteins. Electronic 
scans were processed by Adobe Photoshop to adjust background colour. In all cases, 
adjustments were applied to the entire membrane. If empty or irrelevant lanes were 
electronically removed a gap is shown in the Figures between the membranes. A 
representative full membrane for each antibody used is shown in Appendix 7.2.2. 
 Densitometric Analysis of Western Blot Bands 
ImageJ software (National Institute of Health, USA; version 1.51p) was used to quantify the 
optical density of Western blot bands. The images were imported into ImageJ and 
transformed into 8-bit images for processing. Each band to be quantified was selected by 
placing a rectangle selection around the band and the profile of the peak density was plotted 
using the “Plot Lanes” function (Figure 2.3A). If the image contained bands from more than 
one Western blot (such as in Figure 2.3), only one horizontal row of protein bands was 
measured at a time. The background was removed from the peak using a straight line (Figure 
2.3B) and the “Wand tracing tool” was used to select the area for measurement which then 
produced a numerical value for each peak (Figure 2.3C) corresponding to the densitometry 
of each protein band.  
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Figure 2.3: Protein band densitometric analysis using Image J software 
Bands were selected using a rectangle (A), then the profile of the peak density selected using the “Plot Lanes” 
function. The area to be measured was isolated from the background using a straight line and the area selected 
using the “Wand tracing tool” (B) to produce a numerical value of the selected area under the curve 
corresponding to the density of the band (C). 
A ratio was produced of the density value of the protein band of interest and the density 
value of the loading control protein band. Following this, a ratio was produced of the density 
of the non-cancerous cell line and each cancerous cell line to allow comparison of protein 
densities between cell lines or treatment conditions.  
The mean optical densities from three independent Western blots were then used to create 
bar diagrams. Data were analysed as described in section 2.13. 
A B 
C 
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 Mass Spectrometry 
 SDS-PAGE and Protein Staining 
Whole cell lysates were separated by SDS-PAGE as described in section 2.8.1. The gels were 
stained overnight with Brilliant Blue G- Colloidal stain (Sigma-Aldrich Australia) and 20% 
methanol, followed by de-staining in milli-Q water for 3 h. Protein bands were excised and 
further destained for 10 min in a 1:1 solution of 25 mM ammonium bicarbonate and 
acetonitrile. This was repeated until bands appeared colourless, and was followed by 
incubation with acetonitrile for 20 min. 
 Reduction and Alkylation  
The gel bands were incubated with 10 mM DTT in milli-Q water for 1 h at 37°C to reduce 
cysteine residues, then with 25 mM IAA in milli-Q water for 1 h at 37°C to alkylate the 
cysteine residues. 
The gel bands were washed 3 times each with 200 µL milli-Q water, 200 µL 25 mM 
ammonium bicarbonate and 200 µL acetonitrile. 
 Protein Digestion 
Proteins were digested by the addition of trypsin or chymotrypsin to the bands. 
For Trypsin digestion, a 1:1 solution of Trypsin Gold (Promega) and 25 mM ammonium 
bicarbonate was added to a final enzyme concentration of 5 μg/mL and incubated overnight 
at 37°C. Trypsin digestions were performed on bands from three independent experiments 
and data obtained were collated to produce one data set. 
For Chymotrypsin digestion, a 1:1 solution of Chymotrypsin, Sequencing Grade (Promega) 
and 25 mM ammonium bicarbonate was added to a final enzyme concentration of 0.5–
1 μg/mL and incubated overnight at room temperature. Chymotrypsin digestions were 
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performed on bands from one experiment, however mass spectrometry analysis did not 
yield any results from these samples. 
 Peptide Collection 
The digestion solution was collected into new low-binding tubes (Sigma Aldrich, Australia) 
and peptides were further extracted by adding a 1:1 solution of acetonitrile and 0.1% formic 
acid and sonicating for 10 min. The extraction solution was collected into the low binding 
tubes and the process was repeated to maximise the amount of peptides collected. 
Peptides were dried under a vacuum using a speed vac (Waters) and were then resuspended 
in 10 µL of 0.1% formic acid.  
 Peptide Analysis 
Prior to analysis the resuspended peptide fragments were centrifuged at 14000 x g for 
10 min and placed in 12 x 32 mm Total recovery glass vials (Waters). 
LC-MS/MS analysis was performed on a Xevo QToF mass spectrometer from Waters 
(Micromass,UK) fed by a nanoAquity UPLC (Waters Corp., Milford, MA, USA) at the Western 
Sydney University mass spectrometry facility. 3 µL of digested peptides were loaded onto a 
nanoAquity UPLC Symmetry C18 trapping column (1.7 µm, 180 µm × 20 mm) and then 
separated and eluted from the column using a binary gradient program at a flow rate of 
5 µL/min and desalted at this flow rate for 3 min. The peptides were washed off the trap at 
400 nL/min onto a Waters C18 BEH analytical column (75 μm x 100 mm), packed with 1.7 μm 
particles with 130 Å pore size.  After separation, the peptides were analysed using tandem 
mass spectrometry, implementing an emitter tip that tapers to 10 µm at 2300 V. Mobile 
phase A was 0.1% formic acid in water; and mobile phase B was 0.1% formic acid in 
acetonitrile. The nano-UPLC gradient was as follows: 0 min, 97:3 A/B; 5 min, 97:3 A/B; 
75 min, 40:60 A/B; 85 min, 10:90 A/B; 97 min, 97:3 A/B; 110 min, 97:3 A/B. The mass 
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spectrometer was operated in positive ESI mode with capillary voltage of 3.5 kV, cone 
voltage of 40 V, source temperature of 80°C. Targeted MS/MS data or DDA (data dependent 
acquisition) data were acquired by continuously scanning for peptides of charge state 2+ to 
4+ with an intensity of more than 50 counts per second; with a maximum of three ions in 
any given 3 s scan.  Selected peptides were fragmented and the product ion fragment 
masses were measured. The data were acquired by the software Masslynx (Version 4.1, 
Micromass, UK). 
The acquired DDA data from Masslynx with “RAW” extension were converted to PKL files by 
Proteinlynx Global Server (PLGS) for analysis using the Mascot Daemon database (Australian 
Proteomics Computational Facility, Melbourne, Australia). 
The MS/MS data files were matched using the Swissprot database via Mascot Daemon 
(Australian Proteomics Computational Facility). The following search parameters were 
selected for identification of the peptides: Trypsin or Chymotrypsin as the enzyme, 
maximum missed cleavages of 3, peptide charge states of 2+ to 4+, peptide mass tolerance 
of 0.5 Da, carbamidomethyl (C) as a fixed modification, and methylation and dimethylation 
of arginine (R) as the variable modifications. An ion score of 10 was applied to filter out low 
probability matches. 
 qRT-PCR 
 RNA Extraction 
RNA was extracted from cells using the Isolate II RNA Mini kit (Bioline). Cell pellets were 
resuspended in 350 µL Lysis buffer RLY with 3.5 µL of β-mercaptoethanol. Lysates were 
loaded onto an Isolate II Filter column and centrifuged for 1 min at 11 000 x g. All further 
centrifugation steps were performed at 11 000 x g for the times specified. The filter column 
was discarded and 350 µL of 70% ethanol was added to the filtered lysate. The lysates were 
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then loaded onto an Isolate II RNA Mini column and centrifuged for 30 s. The flow-through 
was discarded and the column membrane was desalted by the addition of 350 µL of 
Membrane Desalting Buffer. The column was centrifuged for 1 min. DNA was digested by the 
addition of DNase I to the column membrane and incubated for 15 min at room 
temperature. The lysate-containing column was then washed once with Wash buffer RW1 
and twice with Wash buffer RW2, centrifuging the column for 30 s, in between washes. The 
membrane was dried with a final centrifugation step of 2 min. RNA was eluted from the 
column by the addition of 60 µL of RNase-free water onto the membrane, and collected into 
a nuclease-free tube by centrifugation for 1 min. 
The concentration of RNA was determined using a Nanodrop 2000 spectrophotometer 
(Thermo Scientific, Australia). Nuclease-free water was used as a blank. The 260/280 and 
260/230 ratios were also recorded to determine the purity of the eluted RNA. Ratios close to 
2 indicate pure RNA and RNA with ratios between 2.06 and 2.18 for 260/280 and between 
2.02 and 2.13 for 260/230 were used in this thesis.  
 cDNA Synthesis 
cDNA was generated from the extracted RNA using the SensiFAST cDNA synthesis kit 
(Bioline). 500 ng RNA (up to 15 µL) was added to 4 µL of 5x TransAmp buffer and 1 µL of 
Reverse Transcriptase. The solution was made up to a total of 20 µL with Nuclease-free 
water.  
The reaction was performed using the Veriti Thermal Cycler (Applied Biosystems) with the 
following cycling conditions: primer annealing at 25°C for 10 min, followed by reverse 
transcription at 42°C for 15 min and lastly, an inactivation step at 85°C for 5 min.  
Following cDNA synthesis, the solution was diluted 1:5 with nuclease-free water and stored 
at -20°C until further analysis. 
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 qPCR 
qPCR was performed using the SensiFAST SYBR Lo-ROX Kit (Bioline). 1 µL of template DNA 
was added to 5 µL of 2x SensiFAST SYBR Lo-ROX Master Mix, 400 nM of forward and reverse 
primers and made up to 10 µL with nuclease-free water. Non-template controls were used 
with nuclease-free water replacing the volume of DNA. 
The qPCR reaction was performed on the 7500 FAST Real-time PCR system (Applied 
Biosystems) with 2-step cycling conditions: polymerase activation for 2 min at 95°C and 40 
cycles of denaturation at 95° C for 3 s, followed by a combined annealing/extension step at 
60°C for 3 s. A melt curve was performed at the end with: 95°C for 15 s, 60°C for 1 min, a 1% 
gradient increase to 95°C for 15 s and a further 15 s at 60°C. The CT baseline and threshold 
were set by the 7500 Software v2.0.6 as cycles 3-15 and 0.2, respectively.  
Amplification data, melt curves and CT values were obtained for analysis. Relative expression 
was calculated using the Pfaffl method, which takes into account differing amplification 
efficiencies of the target and reference genes (Pfaffl 2001). For example: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  (𝐸𝐸𝑡𝑡𝑡𝑡𝑟𝑟𝑔𝑔𝑔𝑔𝑡𝑡)∆𝐶𝐶𝑇𝑇 ,𝑡𝑡𝑡𝑡𝑟𝑟𝑔𝑔𝑔𝑔𝑡𝑡 (𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑟𝑟𝑐𝑐𝑐𝑐−𝑡𝑡𝑔𝑔𝑠𝑠𝑡𝑡)(𝐸𝐸𝑟𝑟𝑔𝑔𝑟𝑟)∆𝐶𝐶𝑇𝑇 ,𝑟𝑟𝑔𝑔𝑟𝑟 (𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑟𝑟𝑐𝑐𝑐𝑐−𝑡𝑡𝑔𝑔𝑠𝑠𝑡𝑡)  
 
The mean relative expression from four independent qRT-PCR reactions was then used to 
create a bar diagram. Data were analysed as described in section 2.13. 
 Primers 
All primer sequences were selected from previously published work (as indicated in Table 
2.3) and were purchased from Sigma-Aldrich, Australia. 
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Table 2.3: Primer sequences used for qPCR 
Primer 
Target Primer Sequences (5'-3') 
Primer 
length 
(bp) 
Tm 
(°C) 
% 
GC 
Amplicon 
size (bp) Reference 
PRMT1 Forward: CTCTGGTATAAGGCGGTCCC 20 64.5 60.0 
149 
(Hernandez 
& Dominko 
2016)  
Reverse: GCTCATCCCATTAGCCAAGGT 21 66.2 52.4 
PRMT2 Forward: TCCAGAGCCTGCAGGAGGGG 20 73.3 70.0 
198 
(Limm et al. 
2013)  Reverse: CAGCCCAGCTCAGAGCCACA 20 71.5 65.0 
PRMT3 Forward: CTTCGCCCCAGCTTTA 16 60.1 56.2 
168 
(Limm et al. 
2013) Reverse: TACGGGCATTATGGGAT 17 58.7 47.1 
PRMT4 Forward: CACACCGACTTCAAGGACAA 20 63.8 50.0 65 (Limm et al. 2013) Reverse: AAAAACGACAGGATCCCAGA 20 63.4 45.0 
PRMT5 Forward: CAATGAGGTCCGAGCCTGTAG 21 65.9 57.1 160 (Zhang et al. 2015) Reverse: GCGGTTGTTGTCAATCATAGGA 22 65.8 45.5 
PRMT6 Forward: CTGCTGCGCTACAAAGTGG 19 64.8 57.9 77 (Phalke et al. 2012) Reverse: AGAAAAGGCAACGCTCAGTC 20 63.4 50.0 
PRMT8 Forward: AAGCCCGTGCAATGCGTCCAT 21 74.6 57.1 181 (Limm et al. 2013) Reverse: TCCGGTAAGTGAGAGTCCGCACC 23 72.3 60.9 
β-actin Forward: CTACGTGGCCCTGGACTTCGAGC 23 73.6 65.2 385 (Limm et al. 2013) Reverse: GATGGAGCCGCCGATCCACACGG 23 80.6 69.6 
2.10.4.1 Primer Efficiency 
A standard curve was generated for each primer set using six 5-fold serial dilutions of cDNA 
template. 1 µL of each cDNA dilution was added to the reaction mixture and qPCR was 
performed as described above. Each cDNA dilution was analysed in duplicate and the mean 
of the resulting CT values was used to generate a standard curve. 
The slope and R2 values were calculated and the primer efficiency was then calculated (Table 
2.4) using the following formula: 
𝐸𝐸𝐸𝐸𝐸𝐸𝑅𝑅𝐸𝐸𝑅𝑅𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 =  ((𝑑𝑑𝑅𝑅𝑑𝑑𝑑𝑑𝑅𝑅𝑅𝑅𝑅𝑅𝐸𝐸 𝐸𝐸𝑅𝑅𝐸𝐸𝑅𝑅𝑅𝑅𝑓𝑓−1 𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑔𝑔⁄ ) − 1) 𝑥𝑥 100 
Where the dilution factor equals 5.  
The standard curve of each primer set was graphed using CT mean vs. (Log) cDNA starting 
quantity. The slope, R2 value and the efficiency as a percentage for each primer set are 
summarised in Table 2.4. The raw data are shown in the Appendix in Table 7.1 & Figure 7.2. 
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Table 2.4: Slope, R2 and efficiency for primer sets from Table 2.3 
Primer Set Slope R2 Efficiency 
(%) 
PRMT1 -1.541 0.984 87.02 
PRMT2 -1.365 0.975 85.35 
PRMT3 -2.045 0.980 90.21 
PRMT4 -2.154 0.974 90.71 
PRMT5 -2.617 0.964 91.04 
PRMT6 -1.565 0.913 87.22 
PRMT8 0.019 0.001 1157.28 
β-actin -2.225 0.980 91.01 
 
2.10.4.2 Optimisation of qPCR Conditions 
Initial testing of primers revealed multiple peaks in some products and therefore, 
optimisation of the qPCR conditions was required. From Table 2.4, the standard curves of 
PRMT1, PRMT6, PRMT8 and β-actin are not linear based on the R2 value and the visible lack 
of linearity of the standard curve (shown in Appendix Figure 7.2). The melt curves for the 
amplification with these primers also revealed multiple Tm peaks. The qPCR amplicons were 
separated on 2% agarose gels, stained with 0.5 µg/mL ethidium bromide solution and 
visualised with Gel Logic Imaging System with Carestream Molecular Imaging Software to 
verify a singular product (Figure 2.4). 
 
 
Figure 2.4: Analysis of qPCR amplicons 
2% agarose gel electrophoresis was used to separate amplicons produced by qPCR with an annealing 
temperature of 60°C. Gels were stained with 0.5 μg/mL ethidium bromide solution and visualised using Gel Logic 
Imaging System with Carestream Molecular Imaging Software. Size markers are indicated on the left in base 
pairs (bp). 
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Multiple bands were visible for PRMT1, PRMT2, and β-actin, while the PRMT8 bands were 
not resolved with a fuzzy appearance. The cycling conditions were modified to optimise the 
conditions required for the ideal primer-binding efficiency of 100 ± 10% (Raymaekers et al. 
2009). The annealing temperatures were changed as follows: PRMT1 was amplified at 60 
and 65°C, PRMT8 was amplified at 60, 65, 68, 70 and 72°C. β-actin was amplified at 60 and 
72°C due to the high Tm of both primers. However, this did not resolve the issue of two melt 
curve peaks. 
Therefore, new primer sets were purchased for PRMT1 and PRMT8 (Sigma-Aldrich, 
Australia), designated as PRMT1 v2 and PRMT8 v2, respectively. A new reference gene 
primer set was also purchased, TATA binding protein (TBP; Sigma-Aldrich, Australia). See 
Table 2.5 for primer sequences and characteristics. 
Table 2.5: Replacement primer sets for PRMT1, PRMT8 cyclin B1 and TBP 
Primer 
Target Primer Sequences (5'-3') 
Primer 
length 
(bp) 
Tm 
(°C) 
% 
GC 
Amplicon 
size (bp) Reference 
PRMT1 
v2 
Forward: GAGGCCGCGAACTGCATCAT 
Reverse: TGGCTTTGACGATCTTCACC 
20 
20 
64.2 
66.1 
44.0 
46.1 385 
(Mathioudaki 
et al. 2008) 
PRMT8 
v2 
Forward:  CCAAGTGCCACAAGAAA 
Reverse: TGGATATGGTCCCGTAGAT 
17 
19 
58.2 
59.2 
47.0 
47.3 132 
(Gao et al. 
2010) 
TBP Forward:  GAACCACGGCACTGATTTTC 
Reverse: CCCCACCATGTTCTGAATCT 
20 
20 
64.4 
63.8 
50.0 
50.0 158 
(Xie 2016) 
 
Standard curves were generated as described in section 2.10.4.1. The standard curve of each 
primer set was graphed using CT mean vs. (Log) cDNA starting quantity. The slope, R2 value 
and efficiency for each primer set are summarised in Table 2.6. The raw data are shown in 
the Appendix in Table 7.2 & Figure 7.3 
PRMT1 v2 and TBP primers displayed efficiencies of 90.1% and 91.4% (Table 2.6), 
respectively, and produced singular melt curves, thus it was decided that these primers were 
suitable to continue experimentation. The standard curve of PRMT8 v2 is not linear based on 
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the R2 values (Table 2.6) and the visible lack of linearity of the standard curve (shown in 
Appendix Figure 7.3). The melt curve with these primers also revealed multiple Tm peaks. 
The qPCR amplicons of PRMT1 v2 and TBP were separated on 2% agarose gels, stained with 
0.5 µg/mL ethidium bromide solution and visualised with Gel Logic Imaging System with 
Carestream Molecular Imaging Software to verify a singular product (Figure 2.5).  
Table 2.6: Slope, R2 and efficiency for primer sets from Table 2.5 
Primer Set Slope R2 Efficiency 
(%) 
PRMT1 v2 -2.024 0.963 90.117 
PRMT8 v2 0.019 0.001 1157.28 
TBP -2.332 0.946 91.425 
 
 
Figure 2.5: Analysis of qPCR amplicons obtained with new primer sets 
2% agarose gel electrophoresis was used to separate amplicons produced by qPCR with an annealing 
temperature of 60°C. Gels were stained with 0.5 μg/mL ethidium bromide solution and visualised using Gel Logic 
Imaging System with Carestream Molecular Imaging Software. Size markers are indicated on the left in base 
pairs (bp). 
A third PRMT8 primer set (Table 2.7; designated PRMT8 v3) was then purchased from Sigma 
Aldrich, Australia with a guaranteed efficiency of 91.4%. Standard curves were generated as 
described in section 2.10.4.1. The standard curve was graphed using CT mean vs. (Log) cDNA 
starting quantity. The slope, R2 value and efficiency for each primer set are summarised in 
Table 2.8. The raw data are shown in the Appendix in Table 7.3 & Figure 7.4. 
Table 2.7: PRMT8 v3 primer set 
Primer 
Target 
Primer Sequences (5'-3') Primer 
length (bp) 
Tm 
(°C)  
% GC Amplicon 
size (bp) 
PRMT8 v3 Forward: GTTTGATAAAGGAGGTGGAC 
Reverse: TGGAAAACCCCATTTTCTTG 
20 
20 
53.60 
54.22 
45.0 
40.0 
159 
bp 
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Although this primer set did not amplify a product in the lower dilutions of cDNA (Appendix 
Table 7.3), the standard curve generated from the higher dilutions was fairly linear based on 
the R2 value and produced a single melt curve. Separation of the qPCR product on 2% 
agarose gels, stained with 0.5 µg/mL ethidium bromide solution and visualised with Gel Logic 
Imaging System with Carestream Molecular Imaging Software also revealed a single product 
(Figure 2.6), thus it was decided that this primer set (PRMT8 v3) was acceptable for use in 
experimentation, even though the efficiency in our conditions (85.5%) was lower than 
guaranteed by Sigma Aldrich.  
Table 2.8: Slope, R2 and efficiency for primer sets from Table 2.7 
Primer Set Slope R2 Efficiency 
(%) 
PRMT1 v2 -1.380 0.748 85.504 
 
 
 
Figure 2.6: Analysis of qPCR amplicons obtained with PRMT8 v3 primer set 
2% agarose gel electrophoresis was used to separate amplicons produced by qPCR with an annealing 
temperature of 60°C. Gels were stained with 0.5 μg/mL ethidium bromide solution and visualised using Gel Logic 
Imaging System with Carestream Molecular Imaging Software. Size markers are indicated on the left in base 
pairs (bp). 
 Sequencing of qPCR Products 
 Extraction and Purification of PCR Products 
Bands from the 2% agarose gel shown in Figure 2.4, were excised and prepared for 
sequencing of the PCR products. The bands excised are indicated by orange boxes in Figure 
2.7. 
bp 
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Figure 2.7: Bands excised for sequencing 
qPCR was performed and products were separated on a 2% agarose gel. Orange boxes indicate bands excised 
for sequencing. Size markers are indicated on the left in base pairs (bp). 
The gel slices were ground with a pestle, 500 µL of phenol was added then the slices were 
frozen at -80°C for 20 min. After thawing gel slices at room temperature, 500 µL of phenol 
was added and centrifuged at 14000 x g for 10 min. This step was then repeated to remove 
traces of the gels from the samples. 500 µL of 1:1:1 Phenol: chloroform: isoamyl alcohol was 
added and centrifuged as before. 500 µL of chloroform was then added and centrifuged as 
before. 30 µL of 3 M sodium acetate was added and vortexed for 15 s; then 660 µL of 96% 
ethanol was added to precipitate the DNA. The DNA was incubated overnight at -80°C. 
Following overnight incubation, precipitated DNA was allowed to thaw at room temperature 
and was then centrifuged at 14000 x g for 15 min. The supernatant was discarded and the 
DNA was washed with 70% ethanol and centrifuged as per previous step. The DNA pellet 
was allowed to dry at room temperature for 15 min until ethanol was completely 
evaporated. The DNA was resuspended in 20 µL of nuclease free water. The concentration of 
DNA was determined using a Nanodrop 2000 spectrophotometer. Nuclease-free water was 
used as a blank.  
 Ligation and Cloning of qPCR Products 
The pGEM-T Easy vector system (Promega) was used to clone the selected PCR products, 
which were purified as described in section 2.11.1. Between 6.4 and 14.4 ng of purified PCR 
product was added into a ligation reaction with 2.5 µL of 2x Rapid ligation buffer (C6171A; 
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Promega), 25 ng of pGEM-T Easy vector (A137A; Promega), 1.5 units/µL of T4 DNA ligase 
(M180A; Promega) and made up to a total reaction volume of 5 µL with nuclease- free 
water. The ligation reaction was incubated at room temperature for 1 h. 
Following ligation, 2 µL of ligation mixture was added to OmniMax chemically competent 
E. coli cells (Thermo Scientific) and incubated on ice for 30 min. OmniMax cells were then 
heat shocked at 42°C for exactly 30 s. LB buffer was added to the transformed cells and the 
cells were incubated at 37°C for 1 h. The transformed cells were then plated on LB agar 
plates with 100 mg/L ampicillin to select for cells that had been successfully transformed. 
Plates were incubated at 37°C overnight.  
A least 3 colonies were selected from each plate and placed in PCR tubes. qPCR mastermix 
was prepared as per section 2.10.3 with primers from Table 2.3. Cycling conditions were as 
described in section 2.10.3. From the results of the qPCR, one colony per sample was chosen 
to be cultured in 3 mL of LB media supplemented with ampicillin at 37°C overnight. 
 Plasmid Purification, Sequencing and Data Analysis 
Following overnight culture, the transformed cells were vortexed to ensure an even 
suspension of colonies, 2 mL was collected and centrifuged at 4000 x g for 4 min. The LB 
media was removed and 600 µL of nuclease- free water was added for purification. The 
Zippy Plasmid Miniprep kit (D4020; Zymo Research) was used according to the 
manufacturer’s instructions to purify the plasmids. 
The concentration of DNA was measured using a Nanodrop 2000 spectrophotometer. 
Purified plasmids, the pGEM-T Easy vector and universal primers for the pGEM-T Easy vector 
were sent to Next Generation Sequencing Facility (Hawkesbury Institute for the 
Environment, Sydney, Australia) for sequencing. 
SnapGene software was used to view the sequence files. The sequence was aligned with the 
FASTA format sequence of the pGEM-T Easy vector using the online EMBOSS stretcher 
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alignment tool to determine which part of the sequence was the vector and which part of 
the sequence was the target gene. SnapGene software was then used to align the result 
sequence with the target sequence. The bases were then viewed to identify any changes 
between the result and target sequences and the base peaks were then viewed to 
determine the reliability of any changes, for example, broad defined peaks were identified as 
true mutations/changes, while narrow, undefined peaks were identified as artefacts.  
 Fluorescent Microscopy 
 Preparation of Cells for Fluorescent Microscopy 
Cells were seeded onto sterile glass coverslips (24 mm x 24 mm) placed into 6 well plates. 
For localisation experiments, 100 000 cells were seeded and allowed to grow until 80% 
confluency was achieved. For DNA damage experiments, 100 000 cells were seeded then 
incubated overnight at 37°C before treatment with PRMT1/8 inhibitor as described in 
section 2.5 .  
Media was removed from each well and the cells were briefly washed with 2 mL PBS. Cells 
were fixed using fixing solution (4% formaldehyde in PBS) for 10 min at room temperature. 
The fixing solution was removed and the cells were washed with PBS. The cells were 
permeabilised by incubation with 0.2% (v/v) Triton-X 100 in PBS for 5 min at room 
temperature, washed with PBS, and then blocked with 3% (w/v) BSA in PBS for 30 min. All 
further wash steps consisted of 3 washes with 0.03% (v/v) Triton-X 100 in PBS for 5 min 
each.  
Primary and secondary antibodies were diluted in 3% (w/v) BSA as per Table 2.1. 300 µL of 
primary antibody was added to each well and incubated for 1-2 h. For each cell line and 
experiment, a control slide was prepared that was not incubated with a primary antibody, 
instead the cells were incubated with PBS for the same amount of time as other cells 
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incubated with a primary antibody. All other steps remained the same. Following incubation, 
antibody solution was discarded and the cells were washed as mentioned above. Anti-rabbit 
secondary antibody conjugated to either Alexa488 or Alexa555 was then added to each well 
and incubated for 1 h. Following incubation, antibody solution was discarded and the cells 
were washed as mentioned above.  
Coverslips were removed from each well, inverted and mounted onto glass slides (24 mm x 
24 mm) using one drop of Prolong Gold anti-fade reagent with DAPI (Thermo Scientific, 
Australia) and allowed to cure in darkness at room temperature for 24 h before being sealed 
with nail polish. Slides were stored at 4°C for up to 2 weeks or at -20°C. 
 Confocal Microscopy Imaging 
Cells were visualised using a Zeiss LSM-5 Exciter Laser Scanning Confocal microscope with an 
Axiovert 200M inverted optical microscope and Zen Black 2009 software. Alexa555 labelled 
proteins were imaged using a 543 nm laser and BP 560-615 nm filter. DAPI-stained nuclei 
were visualised using a 405 nm laser and a BP 420-480 nm filter.  
The control slide with no primary antibody was imaged first and the gain setting of the 
BP560-615 nm channel was adjusted so that no fluorescence was detected (see Appendix 
Figure 7.5 for representative control images). This gain setting was then kept constant for 
sequential slides analysed to minimise background or non-specific staining. 
A scan speed of 9 was applied while the field of view and the focus were adjusted, to 
prevent quenching of the fluorophores. The scan speed was then lowered to 5 while images 
were captured to allow for more detail to be captured. Resolution of images captured was 
1024 x 1024.  
The percentage of cells with foci from the total cell number was calculated for each 
experimental condition. A minimum of 100 cells and four fields of view per slide were 
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analysed, with a minimum of 3 individual slides analysed per experimental condition. The 
data set for each condition was then used to create a box and whiskers plot. 
 Statistical Analysis 
IBM SPSS software was used to analyse the distribution of each data set by checking the 
skewness and kurtosis and Q-Q plots were created to check for normal distribution. As data 
were parametric, a One-way ANOVA with Tukey’s post-hoc test was performed to compare 
multiple means. The level of significance is indicated as *p< 0.05, **p< 0.005, ***p<0.0005. 
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3 Characterising Protein Arginine Methylation and PRMT 
Expression in lial and lioblastoma Cel l Lines 
Glioblastoma cell lines, A172, T98G and U87MG, were compared with a non-cancerous glial 
“control” cell line, SVG p12, (refer to section 2.3 and Table 2.2 for details of the cell lines 
used). 
To begin comparing protein arginine methylation in glial and glioblastoma cell lines, a 
Western blot was performed to compare the banding patterns of methylated proteins. 
Whole cell lysates of the four cell lines were separated by SDS-PAGE, transferred to PVDF 
membranes (section 2.8.1), then immunoblotted with ASYM24, SYM10 or β-tubulin primary 
antibodies (section 2.8.2). In the Western blot (Figure 3.1A), more bands were visible 
between 35 to 75 kDa using the ASYM24 antibody, while probing with the SYM10 antibody 
(Figure 3.1C), detected strong banding at ~50 kDa and additional lower bands at ~15 kDa. 
There are visible differences in the bands present and banding intensity between the four 
cell lines (indicated by orange arrows), however there is no clear difference in the total 
amount of methylation between non-cancerous and cancerous cell lines. Nevertheless, two 
asymmetrically dimethylated proteins at ~25 kDa were only strongly methylated in the 
control glial cells and were barely detected in the three glioblastoma cell lines (Figure 3.1A). 
The Western blot probed with the ASYM24 antibody (Figure 3.1A) was compiled from the DMSO 
control lanes of each cell line in (Figure 4.3) as the banding patterns of asymmetrically 
methylated protein were most visible. The Western blot in Appendix Figure 7.6 also displays 
a similar trend in banding patterns, however the bands are not as visible due to differences 
in antibody production lots from the manufacturer. 
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Figure 3.1: Protein arginine dimethylation patterns in glial and glioblastoma cell lines 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with ASYM24 (A) or SYM10 (C). 
10 μg of protein was loaded for each sample for the loading control, β- tubulin (B/D). Orange arrows indicate 
differences in methylation between the cell lines. Gaps in between lanes are indicative of removed lanes as per 
section 2.8.2. 
 Identification of Methylated Proteins in Glial and Glioblastoma Cell 
Lines 
To identify the methylated proteins detected in the Western blots (Figure 3.1) and to detect 
the location of the methylated arginine residues, whole cell lysates from SVG p12, A172, 
T98G and U87MG cells were separated by SDS-PAGE. Bands in the region of ~25- 150 kDa 
were excised and prepared for analysis by mass spectrometry (section 2.9). Following mass 
spectrometry analysis, peptide fragments were matched using the Mascot Daemon database 
as per criteria specified in section 2.9.5. Mascot assigns an ion score to each detected 
peptide and an overall score for the protein based on the probability, p, that the match is a 
random event. To reduce the identification of “false positives”, the ion score was increased 
from 0 to 10 and all peptides with an ion score <10 were excluded from the analysis. 
Mass spectrometry analysis identified between sixty and eighty proteins for each of the four 
cell lines. These include ribosomal proteins (heterogenous nuclear ribonucleoproteins); 
mitochondrial proteins (ATP synthase subunit alpha and heat shock proteins); and structural 
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components (β-actin and β-actin-binding proteins, and various tubulin chains). The full list of 
all proteins identified by mass spectrometry, including the protein accession number, 
number of peptides matched, the exact peptides matched and the percentage of protein 
sequence coverage for each cell line are listed in Appendix 7.2.1 (Figures 7.4-7.7).  
Of the total proteins identified, thirty-seven proteins were found to contain methylated 
arginine residues. Forty-one methylated arginine residues were identified in SVG p12 cells, 
twenty-four in A172 cells, thirty-one in T98G cells, and thirty-two in U87MG cells. The 
overlap of the methylated arginine residues within the different cell lines is depicted in 
Figure 3.2. There were five methylated arginine residues that were consistent across all four 
cell lines as indicated in the centre of the Venn diagram (Orange circle; Figure 3.2). These 
were R63 and R313 of β-actin-like protein, R79 of tubulin α- 3C/D, R16 of Heat shock protein 
75 kDa, and R63 of Putative annexin-A2-like protein. There were thirteen proteins identified 
with methylated residues in only the glioblastoma cell lines. These proteins are shown in 
Table 3.2. Of the thirteen proteins, 46.2% were related to metabolism, 38.5% were 
structural proteins and 15.3% were chaperone proteins. Of the thirty-four methylated 
arginine residues identified, 20.9% were identified as dimethylated overall, with 22.8%, 
11.7%, 35.7%, and 12% dimethylated in SVG p12, A172, T98G and U87MG cells, respectively.  
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Figure 3.2: Distribution of methylated arginine residues across cell lines 
The number of unique methylated arginine residues is indicated in each of the ovals for SVG p12 (blue), A172 
(purple), T98G (green) and U87MG (yellow) and the overlapping areas indicate the number of residues which 
were the same between the different cell lines. The orange circle indicates identified residues which were 
identified as methylated across all cell lines. The numbers in parentheses indicate the number of residues 
identified in that cell line that were not covered or detected in the other cell lines. 
The thirty-seven proteins were then classified into five groups based on the biological 
function of the protein (Table 3.1): cytoskeletal proteins (designated as group 1); protein 
folding molecular chaperone, protein transport or degradation (designated as group 2); 
metabolism (designated as group 3); and transcription/translation (designated as group 4); 
signalling, apoptosis, calcium binding (designated as group 5). The percentage of detection 
was calculated as the number of times the peptide was detected as methylated out of the 
total number of independent experiments (n= 3) x 100. For example, a detection percentage 
of 33% indicates the peptide was detected in one of three experiments. 
Within the signalling, apoptosis, calcium binding and the transcription/translation groups 
there were no differences in the position of the methylated residues detected across the 
four cell lines, for example, monomethylation of R63 within Putative annexin A2-like protein 
was detected in all four cell lines. However, the percentage of detection was 100% in SVG 
p12 and A172 cells but only 33% and 67% in T98G and U87MG cells, respectively. There also 
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was not adequate coverage of these proteins to confirm if arginine residues identified in one 
cell line were also methylated in the other cell lines, for example, the arginine residues 
identified to be methylated in HNRNPs Q and U were only detected in SVG p12, and in SVG 
p12 and A172, respectively, as the proteins were not detected at all in the T98G or U87MG 
cell lines.  
Within groups 1-3, some residues were found to be methylated in all four cell lines, for 
example R63 and R313 of Beta-actin-like protein 2 and R16 of Heat shock protein 75 kDa 
were found to be methylated in all the cell lines. There were also differences found in the 
methylation status of arginine residues, most strikingly between the non- cancerous cell line, 
SVG p12, and the cancerous cell lines, A172, T98G and U87MG. Notable examples include 
the methylation of arginine 49 of Heat shock cognate 71 kDa protein in all cell lines, except 
in T98G cells (Figure 3.3), while Stress-70 protein (also known as Mortalin) was identified as 
monomethylated at arginine 513 in A172 and T98G cells but not methylated in U87MG cells 
(Table 3.1 & Figure 3.4). The Mortalin peptide detected in the glioblastoma cell lines was not 
detected in SVG p12 cells, so the methylation status of residue R513 could not be 
determined in this cell line. Arginine residues 39, 206 and 254 of Actin, cytoplasmic 2 (also 
known as γ-actin) were identified as methylated in the T98G cell line and were identified as 
non-methylated in the SVG p12 cell line (Figure 3.5). Arginine 254 of γ-actin was also 
identified as monomethylated in the A172 and U87MG cell lines, indicating differences 
between non-cancerous and cancerous cells. Arginine 156 of tubulin-βIII was identified as 
monomethylated in all cell lines except T98G cells, while arginine 79 of tubulin-α1B and 
tubulin-α1C was un-methylated in all cell lines, except in U87MG cells (Table 3.1 & Figure 
3.6). Arginine residue 149 of ATP synthase subunit α was also detected as unmethylated in 
all cell lines, except in the T98G cells where it was detected as monomethylated in all three 
independent experiments (Table 3.1 & Figure 3.7). 
    78 
Table 3.1: Methylated arginine residues identified by Mass Spectrometry* 
 
 
SVG p12 A172 T98G U87MG
R39 N.M R39 N.M R39 R39 N.M
R206 N.M R206 N.M R206 R206 N.M
R254 N.M R254 R254 R254
R312 R312 N.M R312 R312 N.M
Alpha-actinin-2 103 N.D N.C R438, R442
R306 R306 N.C R306 N.C
R314 R319 N.C R319 N.C
R740 R740 R740
R752 R752 R752
R63 R63 R63 R63
R255 N.M R255 R255 N.M R255
R313
  
R313 R313
  
R313
Dihydropyrimidinase-related protein 2 62 N.D N.D N.D R16
Talin-1 270 N.D R2210 N.D N.D
Tubulin alpha-1B chain 50 R79 N.M R79 N.M R79 N.M R79
R79 N.M R79 N.M R79 N.M R79
R390 R390 N.C R390 N.C R390 N.C
Tubulin alpha-3C/D 49 R79 R79 R79 R79
Tubulin beta-3 chain 50 R156 R156 N.D R156
Tubulin beta-6 chain 49 R390 R390 N.D R390
Heat shock 70 kDa protein 6 70 R519 R519 N.M N.C R519 N.M
R49 N.M R49 N.M R49 R49 N.M
R264 N.C R264 N.C R264 R264 N.C
R469 N.C R469 R469 N.C R469
R509 N.C R509 R509 N.C R509 N.M
R14 R14 N.C R14 R14
R16 R16 R16 R16
R20 R20 N.M R20 R20
Heat shock protein HSP 90-alpha 90 R345 R345 N.C R345
Protein disulfide-isomerase A3 58 R107 N.M N.D R107 N.C
Serpin H1 46 N.C N.C R339 N.C
Stress-70 protein, mitochondrial 71 N.C R513 R513 N.M
Transitional endoplasmic reticulum ATPase 89 R239 R239 N.M N.D N.C
N.D
Heat shock protein 75 kDa, mitochondrial 75
Tubulin alpha-1C chain 49
Heat shock cognate 71 kDa protein 71
Protein
Protein 
size 
(kDa)
Alpha-actinin-3 103
Actin, cytoplasmic 2 41
Methylated Arginine Residues
1. Cytoskeletal proteins
2. Protein folding molecular chaperone, protein transport or degradation
Beta-actin-like protein 2 42
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* N.M = not methylated, N.C = no peptide coverage, N.D = protein not detected. Monomethylated arginines are 
shown as underlined R and dimethylated arginines are shown as bold R. The percentage of detection was 
calculated as the number of times the peptide was detected as methylated divided by the total number of 
independent experiments x 100. Red squares indicate a decrease in methylation from the control cell line SVG 
p12, while green squares indicate an increase compared to the control cell line. Orange boxes indicate proteins of 
interest. 
 
 
 
 
SVG p12 A172 T98G U87MG
Protein
Protein 
size 
(kDa)
Methylated Arginine Residues
 
   
   
 
  
 
  
   
      
  
     
   
   
 
  
  
       
   
   
  
   
 
 
    
   
 
  
     
ADP/ATP translocase 3 32 N.D N.D R152 N.D
R17 N.C N.C N.C
R149 N.M R149 N.M R149 R149 N.M
R253 N.C N.C N.C
Cytochrome b-c1 complex subunit 2, 
mitochondrial 48 N.D N.D R12 N.D
GAPDH 36 R248 N.M R248 N.M R248 R248 N.M
Glucose-6-phosphate isomerase 36 R75, R80 N.D N.D N.C
R106 R106 N.C R106 R106 N.C
R112 R112 N.M R112 R112 N.M
L-lactate dehydrogenase B chain 37 R170 N.M R170 N.M R170 N.M R170
R196 N.C R196 N.C R196
R954 N.M R954 R954
POTE ankyrin domain family member F 121 R196, R207 N.D N.D N.D
Pyruvate kinase 57 R376 N.M R376 N.M N.C R376
Transaldolase 38 N.D N.C R313 N.C
Elongation factor 1-alpha 1 50 R166 N.C N.C N.C
Eukaryotic initiation factor 4A-I 46 R368 N.C N.D N.C
Heterogeneous nuclear ribonucleoprotein Q 70 R546, R548, R551 N.D N.D N.D
R709 N.C R709
R733 R733 N.C
R739 R739 N.C
14-3-3 protein zeta/delta 27 N.C N.C R80, R83 N.C
Calcium-binding mitochondrial carrier 
protein Aralar2 13 N.D N.D R170, R174 N.D
R63 R63 R63 R63
R205 R205 N.C R205 R205 N.C
N.DHeterogeneous nuclear ribonucleoprotein U 120 N.D
N.D
L-lactate dehydrogenase A chain 37
ATP synthase subunit alpha, mitochondrial 59
     
Putative annexin A2-like protein 38
  
      
POTE ankyrin domain family member E 42
4. Transcription/translation
5. Signalling, apoptosis, calcium binding
 
 
  
  
  
        
3. Metabolism
  
    80 
Table 3.2: Cancer-specific methylated arginine residues identified by Mass Spectrometry 
 
Some of the methylated arginine residues were detected by qToF following the fractionation 
of the peptide ions and the ion peaks were used to generate the MS/MS spectrum. 
Therefore, the specific methylated arginine residue is visible as a peak on the spectrum (for 
example, as seen in Figure 3.5B). Other peptides were predicted to be methylated, by 
Mascot Daemon, when the total mass of the peptide shifted by +14 kDa for 
monomethylated residues or by +28 kDa for dimethylated residues (for example as seen in -
Figure 3.3C). This occurred even if the ion was not detected by qToF. In the case of peptides 
which were predicted to have methylated arginine residues, peptides which contained lysine 
residues were only included for analysis if the peak of the lysine residue was detected in 
order to rule out false prediction of methylated arginine residues due to methylated lysine 
residues. Representative spectra of Heat shock cognate 71 kDa protein, Stress-70 protein 
(Mortalin), γ- actin, Tubulin- α 1B/C and ATP synthase subunit α are shown in Figures 3.3- 
3.74, where the detected arginine ions are indicated by arrows.  
A172 T98G U87MG
R39 N.M R39 R39 N.M
R206 N.M R206 R206 N.M
R254 R254 R254
Beta-actin-like protein 2 R255 R255 N.M R255
Talin-1 R2210 N.D N.D
Tubulin alpha-1B chain R79 N.M R79 N.M R79
Tubulin alpha-1C chain R79 N.M R79 N.M R79
Heat shock cognate 71 kDa protein R49 N.M R49 R49 N.M
Protein disulfide-isomerase A3 N.D R107 N.C
ATP synthase subunit alpha, mitochondrial R149 N.M R149 R149 N.M
GAPDH R248 N.M R248 R248 N.M
L-lactate dehydrogenase B chain R170 N.M R170 N.M R170
POTE ankyrin domain family member E R954 N.D R954
Pyruvate kinase R376 N.M N.C R376
Transaldolase N.C R313 N.C
Actin, cytoplasmic 2
Protein
Methylated Arginine Residues
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Figure 3.3: Mass spectra of methylated and unmethylated peptides of Heat shock cognate 
71 kDa protein 
MS/MS spectra of unmethylated arginine residue R49 in SVG p12 cells (A), A172 cells (B), U87MG cells (D) and 
the corresponding methylated arginine residue R49 in T98G cells (C). The ion scores of the peptides were 84 (A), 
74 (B), 71 (C), 88 (D). Arrows indicate the methylated or unmethylated arginine ion detected. 
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Figure 3.4: Mass spectra of methylated and unmethylated peptides of Stress-70 protein 
(Mortalin) 
MS/MS spectra of methylated arginine residue R513 in A172 cells (A), T98G cells (B) and the corresponding 
unmethylated arginine residue R513 in U87MG cells (C). The ion scores of the peptides were 21 (A), 77 (B), 88 
(C). Arrows indicate the methylated or unmethylated arginine ion detected. The peptide was not detected in SVG 
p12 cells (see Table 3.1). 
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Figure 3.5: Mass spectra of methylated and unmethylated peptides of γ- actin  
MS/MS spectra of unmethylated arginine residues in SVG p12 cells (A, C, E) and the corresponding mono or 
dimethylated arginine residues in T98G cells (B, D, F). Arginine residues identified were R39 (A-B), R206 (C-D) 
and R254 (E-F). The ion scores of the peptides were 72 (A), 27 (B), 55 (C), 11 (D), 113 (E), and 38 (F). Arrows 
indicate the methylated or unmethylated arginine ion detected. 
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Figure 3.6: Mass spectra of methylated and unmethylated peptides of Tubulin- α 1B/C 
MS/MS spectra of unmethylated arginine residue R79 in SVG p12 cells (A), A172 cells (B), T98G cells (C) and 
the corresponding monomethylated arginine residue R79 in U87MG cells (D). The ion scores of the peptides were 
101 (A), 103 (B), 71 (C), 95 (D). Arrows indicate the methylated or unmethylated arginine ion detected. 
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Figure 3.7: Mass spectra of methylated and unmethylated peptides of ATP synthase 
subunit α 
MS/MS spectra of unmethylated arginine residue R149 in SVG p12 cells (A), A172 cells (B), U87MG cells (D) and 
the corresponding monomethylated arginine residue R149 in T98G cells (C). The ion scores of the peptides were 
90 (A), 67 (B), 67 (C), 79 (D). Arrows indicate the methylated or unmethylated arginine ion detected. 
 Homology of PRMTs in Different Species 
It has been claimed that mammalian PRMTs are highly homologous with their counterparts 
in other eukaryotic species, however there have been no studies to support this. A 
phylogenetic tree was constructed to determine the homology of PRMTs in several 
eukaryotic species.  
A phylogenetic tree (section 2.2) was used to compare the sequence of PRMT proteins in 
multiple eukaryote species. Not surprisingly, the human PRMT proteins were most 
homologous to the other mammalian species (mouse and cow), while the plant PRMTs were 
closely related (E. grandis, A. thaliana, and O. sativa) (Figure 3.8). PRMT1 and PRMT8 were 
closely related to PRMT3 and were distant from the other PRMTs. The plant specific PRMT10 
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was most closely related to PRMT4 and PRMT5. PRMT7 (Type III) and PRMT9 (Type II) 
appeared closely related to each other and more distant from the Type I PRMTs, while 
PRMT5 (the dominant Type II PRMT) appeared to be distant from the other PRMTs (Figure 
3.8). The fruit fly (Drosophila) and yeast (S. cerevisiae) PRMTs appeared to be the least 
related to the other species, with Drosophila PRMT2, PRMT6 and PRMT9 grouped together 
and PRMT8 was most similar to PRMT2 of the other species. Yeast PRMT2 was the most 
distant from the other species and appeared to be the earliest common ancestor of all other 
PRMTs in this tree (Figure 3.8). 
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Figure 3.8: Phylogenetic tree of PRMT proteins 
Phylogenetic tree of PRMT proteins from human (Homo_sapiens), mouse (Mus-musculus), cow (Bovin), Xenopus 
laevis (Xenopus), African clawed frog (Danio_rerio), fruit fly (Drosophila), Saccharomyces cerevisiae (Yeast), 
Arabidopsis thaliana (AT), Orzya sativa (rice; LOC_Os) and Eucalyptus (Eucgr). The length of the lines indicate 
the relationship and distance between the PRMT proteins. Known PRMT number groupings and enzyme type are 
indicated on the right.  
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 Characterising PRMT Expression in Glial and Glioblastoma Cell 
Lines 
Due to the differences in methylation patterns visible on the Western blot (Figure 3.1) and 
the differences in methylation detected by mass spectrometry (Table 3.1), it was 
hypothesised that these differences could be due, at least partially, to differential expression 
of the PRMTs. Therefore, the protein and RNA expression of the PRMTs was investigated. 
 Expression of PRMT Proteins in Glial and Glioblastoma Cells 
Western blotting was performed using whole cell lysates to characterise the protein levels of 
the PRMTs in the four cell lines (see section 2.8). Densitometric analysis was performed 
using Image J software to quantify each protein band (see section 2.8.3) and a ratio was 
calculated from the corresponding GAPDH loading control band. The ratios for the 
glioblastoma cell lines, A172, T98G and U87MG, were then normalised to the non-cancerous 
cell line, SVG p12, to allow comparison of the levels between the cell lines.  
The representative Western blot (Figure 3.9) and densitometric analysis (Figure 3.10) from 
three independent experiments show that there is significantly more PRMT1 protein in A172 
cells and significantly less PRMT1 protein in T98G cells, compared to SVG p12 cells (Figure 
3.10A). There was also significantly more PRMT2 protein in A172 cells than in SVG p12 and 
U87MG cells (Figure 3.10B). There was significantly less PRMT3 protein in A172 cells than in 
SVG p12 cells (Figure 3.10C). There was no significant difference in PRMT4 protein 
expression between all four cell lines (Figure 3.10D). There was significantly more PRMT5 
protein in all the glioblastoma cell lines compared to SVG p12 cells (Figure 3.10E). There was 
also significantly more PRMT6 (Figure 3.10F) and PRMT8 (Figure 3.10G) protein in both A172 
cells and U87MG cells, compared to SVG p12 cells. Overall, there appeared to be higher 
levels of PRMT protein expression in the glioblastoma cell lines, than in the non-cancerous 
glial cells (Figure 3.9 & Figure 3.10). Although there were differences in the levels of PRMT 
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protein expressed between the glioblastoma cell lines as well. For example, there was 
significantly more PRMT6 protein expression in U87MG cells than in the other glioblastoma 
cell lines and the glial control cell line (Figure 3.10F). The raw data used to generate Figure 
3.9 and Figure 3.10 are available in Appendix 7.2.2. 
 
Figure 3.9: PRMT protein expression in glial and glioblastoma cell lines 
Representative Western blots of cell lysates probed for PRMT1, PRMT2, PRMT3, PRMT4, PRMT5, PRMT6, 
PRMT8 (30 μg of total protein was loaded) and GAPDH as loading control (20 μg of total protein was loaded). 
Western blots of each PRMT were chosen which best represented the mean shown in Figure 3.10. Replicates are 
available in Appendix 7.2.2. 
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Figure 3.10: Statistical analysis of PRMT protein expression in glial and glioblastoma cell 
lines 
Image J was used to obtain the optical density of each band in Figure 3.9. The mean of three independent blots 
for PRMT1 (A), PRMT2 (B), PRMT3 (C), PRMT4 (D), PRMT5 (E), PRMT6 (F) and PRMT8 (G) was calculated 
and normalised to GAPDH. The expression of non-cancerous cell line, SVG p12 (blue), was adjusted to 1 and a 
ratio was calculated with the glioblastoma cell lines, A172 (purple), T98G (green) and U87MG (yellow), to obtain 
the relative protein expression. Data used to generate graphs are available in Appendix 7.2.2.  A one-way 
ANOVA with Tukey’s post-hoc test was performed using IBM SPSS 25 software. n=3, error bars represent S.D, 
*= p<0.05, **= p<0.005, ***= p<0.0005. 
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 RNA Expression of PRMTs in Glial and Glioblastoma Cells 
To determine if there was a difference in the RNA expression of the PRMTs between glial 
and glioblastoma cell lines, RNA was extracted and reverse transcribed to create cDNA (see 
sections 2.10.1 and 2.10.2). qPCR was performed to quantify the expression of each PRMT in 
each cell line (see section 2.10.3). The relative expression was then calculated using the 
Pfaffel method (see section 2.10.4) and the means of four independent experiments were 
statistically analysed using a One-way ANOVA with Tukey’s post-hoc test (see section 2.13). 
There were no significant changes in RNA expression for PRMT1 (Figure 3.11A), PRMT3 
(Figure 3.11C) and PRMT4 (Figure 3.11D).  
Relative RNA expression of PRMT2 (Figure 3.11B) was significantly decreased in T98G cells 
compared to SVG p12 control cells, while there was no change in PRMT2 expression in A172 
or U87MG cells from control SVG p12 cells. PRMT5 relative RNA expression was significantly 
lower in U87MG cells compared to all other cell lines and in T98G cells compared to the non-
cancerous SVG p12 cells (Figure 3.11E). PRMT6 relative RNA expression (Figure 3.11F) was 
significantly lower in A172 and U87MG cells, compared to SVG p12 cells. PRMT8 relative 
RNA expression (Figure 3.11G) was significantly decreased in A172 cells compared to SVG 
p12 and T98G cells. The data used to create Figure 3.11 are available in Appendix 7.2.3. 
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Figure 3.11: Relative RNA expression in glial and glioblastoma cell lines 
RNA was extracted from the glial cell line, SVG p12 (blue), and glioblastoma cell lines, A172 (purple), T98G 
(green) and U87MG (yellow). RNA was reverse transcribed into cDNA and analysed by qPCR to determine the 
RNA expression levels of PRMT1 (A), PRMT2 (B), PRMT3 (C), PRMT4 (D), PRMT5 (E), PRMT6 (F), and PRMT8 
(G). The Pfaffl equation was used to calculate the mean relative RNA expression of each cell line. Data used to 
generate graphs are available in Appendix 7.2.3. A one-way ANOVA was performed using IBM SPSS 25 
software. n=4, error bars represent S.D, *= p<0.05, **= p<0.005, ***= p<0.0005. 
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 Discussion 
This study aimed to characterise the differences in methylation between a non-cancerous 
glial cell line, SVG p12, and three glioblastoma cell lines, A172, T98G and U87MG. Western 
blotting showed differences in asymmetric and symmetric dimethylation between the 
control glial and glioblastoma cell lines. Further investigation revealed there to be an overall 
increase in the protein levels of the PRMTs in the glioblastoma cell lines when compared to 
the control glial cells, while though RNA levels of some PRMTs appeared to be decreased in 
the glioblastoma cell lines. Arginine residues of several proteins were identified as di- or 
monomethylated by mass spectrometry and differences were identified across the four cell 
lines. 
 Glial and Glioblastoma Cells show Different Methylation Patterns 
Western blot analysis of whole cell lysates revealed differences in methylation patterns 
between glial, SVG p12, and glioblastoma, A172, T98G and U87MG, cell lines (Figure 3.1). 
One reason for these differences could be the fact that these cell lines were derived from 
unrelated patients so differences in familial genetic and epigenetic traits may have 
contributed to some of the differences seen. However, it is plausible that the observed 
differences in methylation patterns of proteins between the cell lines reflect that regulation 
of methylation is indeed different between different cell lines. While there are differences in 
asymmetric and symmetric dimethylation patterns between the four cell lines, there is no 
clear difference in the amount of methylation between the non-cancerous and cancerous 
cells except for the two proteins of ~25 kDa which were strongly visible in the control glial 
cells and barely visible in the glioblastoma cell lines (Figure 3.1A).   
Interestingly, all four cell lines appear to have more asymmetric dimethylation than 
symmetric dimethylation. While this could be due to different affinities of the antibodies 
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used, it could also be explained by the fact that there are six type I PRMTs and the results are 
consistent with reports that PRMT1, a type I PRMT, performs over 90% of methylation in 
mammalian cells (Yang & Bedford 2013), although this value has been never verified 
experimentally. PRMT1 was reported to be the dominant PRMT in RAT1 cells and its activity 
was quantified (Tang et al. 2000), however this activity was only compared to the rat 
methyltransferase, FDH, and demonstrated on GST-GAR substrates. It is now known that 
PRMTs methylate substrate motifs other than GAR motifs (Cheng et al. 2007), and in a plant 
model only 12% of methylated arginine residues identified by mass spectrometry were on 
GAR motifs (Plett et al. 2017). In this study, only 15% of methylated arginine residues 
identified were located within GAR motifs (Appendix 7.2.1), suggesting that the homology of 
plant and mammalian PRMTs (Figure 3.8) extends to motif specificity. It further suggests that 
the claim of PRMT1 performing over 90% of methylation needs to be re-evaluated. While 
PRMT5 has long been thought to be the only active type II PRMT, it was only recently that 
PRMT9 was reported to also catalyse symmetric methylation reactions (Hadjikyriacou et al. 
2015; Yang et al. 2015b). Overexpression of PRMT5 has been detected in several cancer 
types such as ovarian (Bao et al. 2013), lung (Gu et al. 2012a; Shilo et al. 2013), and gastric 
cancers (Kim et al. 2005), as well as lymphoma (Pal et al. 2007) and leukemia (Wang et al. 
2008). Hence, it is interesting that there appears to be less symmetric methylation in 
glioblastoma cell lines than in the non-cancerous glial cell line (Figure 3.1) even though 
PRMT5 protein expression was increased in glioblastoma cell lines compared to the non-
cancerous glial cells (see Figure 3.10E).  
The increased PRMT protein expression in the glioblastoma cell lines compared to the non-
cancerous cell line could explain why there were methylated arginine residues identified by 
mass spectrometry in the glioblastoma cell lines that were not methylated in the non-
cancerous glial cells. T98G and U87MG cell lines each had seven methylated residues that 
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were not methylated in the SVG p12 cells, while the A172 cells had three methylated 
residues that were not methylated in SVG p12 cells (see Table 3.1). Further, there was an 
increase in PRMT1, 2, 5, 6 and 8 protein expression in A172 cells, while T98G cells had 
increased PRMT5, 6 and 8 protein expression and U87MG cells had increased PRMT2, 5, 6 
and 8 protein expression, compared to the non-cancerous SVG p12 cells (see Figure 3.10). 
 Methylated Proteins Identified by Mass Spectrometry 
Mass spectrometry results from glial and glioblastoma cell lysates identified several proteins 
as having either monomethylated or dimethylated arginine residues (Table 3.1). Proteins 
identified as dimethylated from whole cell lysates could be either asymmetric or 
symmetrically dimethylated as mass spectrometry analysis does not allow differentiation 
between the two types. Some peptide match sequences were found to have a better match 
to non-human species, such as chicken or giant octopus, due to changes in amino acid 
sequence. Minor variations from the human sequences in the database are to be expected 
due to the cancerous nature of the glioblastoma cell lines. All results shown in Table 3.1 
are based on matches to the human sequence and yielded high scores and high percentages 
of sequence coverage, confirming the validity of the results. The score and sequence 
coverage of all proteins identified are available in Appendix 7.2.1. 
The score is calculated based on the probability that the match between the experimental 
data and the database is a random event (Fenyo & Beavis 2003). When a higher number of 
peptides are matched to one protein in the database, the probability of the match being 
random is reduced and therefore the score increases to reflect this – hence the higher the 
score the more likely that the identified peptide is from the indicated protein in the 
database. 
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A recent report found the use of stains containing methanol and isopropyl alcohol in sample 
preparations could lead to the false detection of methylated arginine or lysine residues 
(Hart-Smith et al. 2015). Although a methanol-containing stain was used in the sample 
preparation, the mass spectrometry method used in this thesis is different to the one used 
by Hart-Smith et al. (Hart-Smith et al. 2015) and the results were validated by obtaining 
identical results without using staining in the sample preparation. Furthermore, the analysis 
of bacterially expressed tubulin-β (which lacks methylation), using stained or unstained 
sample preparation, yielded unmethylated peptides from both preparation protocols. This 
confirms that the proteins and methylated arginine residues identified in this thesis are real 
matches and not false positives, based on the sample preparation and true mass shifts 
detected. 
Of the proteins identified by mass spectrometry in this study, a large number were 
cytoskeletal proteins, chaperone proteins or enzymes involved in metabolism (see Table 
3.1). Several of these proteins have been previously reported to be methylated, which 
further validates the results presented here. These include the heterogenous nuclear 
ribonucleoprotein (hnRNP) family (Rajpurohit et al. 1994), stress-70 protein (Lim et al. 2010), 
and tubulins α and β (Guo et al. 2014) (Reviewed by Wei et al. 2014).  
Interestingly, there were differences in the methylated arginine residues detected between 
the different cell lines, which will be discussed further in the following sections. 
3.4.2.1 Structural Proteins 
A large proportion of the methylated arginine residues identified belonged to structural 
proteins, such as actin (Figure 3.5), alpha-actinin-2 and -3, dihydropyrimidinase-related 
protein 2 and tubulin (Table 3.1). Actin dynamics are altered by numerous post 
translationally modifications (Reviewed by Terman & Kashina 2013), while tubulin is also 
heavily modified by various post-translational modifications (Song & Brady 2015), although 
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the significance of arginine methylation is not fully understood. The significance of tubulin 
methylation will be further discussed in the following section. 
3.4.2.1.1 Tubulin 
In this thesis, methylated arginine residues were detected on tubulin α and β. In tubulin α, 
R79 was detected as methylated on the tubulin α-3 chain in all cell lines but was detected as 
unmethylated on the tubulin α-1 chain in all cell lines except for U87MG cells (Figure 3.6). In 
the tubulin β-3 chain, R156 was detected as methylated and in the tubulin β-6 chain, R390 
was detected as methylated in all cell lines where the peptide was detected (Table 3.1). 
Methylation of the detected arginine residues appears to be conserved in many cell types 
and organisms. Previous studies in the Piller lab have identified the methylation of R79 of 
tubulin α and R156 and R390 of tubulin β in mouse neuronal cells (Jwad 2015) and human 
prostate cells (Livio 2014), while other studies have found R79 of tubulin α and R156 of 
tubulin β to be methylated in plant systems (E. grandis; (Plett et al. 2017). This suggests that 
the methylation of tubulin on arginine residues is evolutionarily important and makes it 
more interesting to note that tubulin α-1 chains are unmethylated in glial cells. It is currently 
unknown what the functional significance of an unmethylated tubulin α-1 chain may be. 
3.4.2.1.1.1 Significance of Tubulin Methylation 
Although the significance of methylation on arginine residues of tubulin is unknown at a 
cellular level, mutations of arginine residues are often associated with abnormal brain 
development. The mutation of R156 was reported to be the possible cause of 
hypomyelinating leukodystrophies (Purnell et al. 2014) that affect the development of the 
white matter in the central nervous system (Maria et al. 2003). Mutations at R262, R380 
(Tischfield et al. 2010) and R390 (Kumar et al. 2010; Zanni et al. 2013) in tubulin β resulted in 
axonal neuropathy (Tischfield et al. 2010), asymmetrical polymicrogyria (Zanni et al. 2013) or 
lissencephaly (Kumar et al. 2010). These mutations affect the tubulin dimerization process 
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due to their external location in the secondary structure of tubulin and microtubules 
containing mutated tubulin were less stable (Poirier et al. 2010). Mutations of R380 in 
tubulin β-2B have also been identified in patients with polymicrogyria and are predicted to 
prevent the interaction of microtubules with the microtubule-associated protein DCX 
(Cushion et al. 2013). The lack of methylation at R380 of tubulin β, rather than the mutation 
itself, may prevent the interaction of tubulin β with DCX. DCX is involved in neurite 
outgrowth and neuronal migration (Gdalyahu et al. 2004), thus suggesting that impaired 
interaction with microtubules leads to improper axon formation during neuronal 
development. Interestingly, high expression of DCX has been detected in aggressive 
glioblastoma and neuroblastoma tumours and is associated with poor prognosis due to its 
involvement in cellular migration (Bernreuther et al. 2006; Daou et al. 2005).  
Mutations in tubulin β have also been linked to drug resistance in cancer treatment, with the 
mutation of R282 implicated in the resistance of tumours to paclitaxel (Huzil et al. 2007). 
Arginine 282 within tubulin β sits in the binding site for the anti-cancer drug, paclitaxel. 
Previous studies in the Piller lab have detected R282 as dimethylated and inhibition of 
methylation increased the microtubule-stabilising effect of paclitaxel in Neuro-2a cells (Piller 
et al. 2015). Given that R282 is critical for maintaining the M loop structure of tubulin 
(Navarrete et al. 2015), this suggests that methylation or mutation of R282 may cause 
conformational changes to the spatial structure of the binding site, thus resulting in the 
decreased binding of paclitaxel. 
Further research into arginine methylation and mutations of tubulin would not only benefit 
those born with genetic defects, but also in developing novel drugs for cancer treatment. 
3.4.2.2 Chaperone/ Heat Shock Proteins 
The second largest group of proteins identified with methylated arginine residues was the 
chaperone or heat shock protein family (Table 3.1). Four proteins from the HSPA/Hsp70 
    99 
group were identified as methylated (Heat shock 70 kDa protein- 6, heat shock cognate 
71 kDa protein Figure 3.3), Heat shock protein 75 kDa and Stress-70 protein (Figure 3.4)), 
while one protein was identified as methylated from the HSPC/Hsp90 group (Heat shock 
protein HSP 90-alpha). Heat shock proteins are frequently overexpressed in cancer due to 
their roles in protein folding and cell survival and have also been implicated in cellular 
resistance to anticancer therapies (Reviewed by Ciocca et al. 2013). The significance of 
arginine methylation of Stress-70 protein will be further discussed in the following section. 
3.4.2.2.1 Mortalin 
Stress-70 protein, also known as Mortalin and GRP75, is a 74 kDa protein localised in the 
mitochondria (Londono et al. 2012). It is not actually a heat shock protein but is classified as 
a member of the heat shock protein 70 family due to its sequence homology (Domanico et 
al. 1993). 
Mortalin was identified by mass spectrometry as monomethylated at arginine 513 in A172 
and T98G cells and unmethylated at arginine 513 in U87MG cells (Table 3.1 & Figure 3.4). It 
was also identified as dimethylated at arginine 513 in PC-3 prostate cancer cells in a previous 
study (Livio 2014). It is unclear whether glial cells express Mortalin as they have been 
reported to not express it (Takano et al. 1997). However a more recent study reported 
Mortalin protein expression in normal astrocytes (Cook et al. 2016). Mortalin is involved in 
neurogenesis by the regulation of stem cell proliferation (Deocaris et al. 2008), and this may 
be the case in glial cells as well. The protein expression of Mortalin correlated with the 
progression of glioblastoma, with more Mortalin positive cells in higher grade tumours 
(Takano et al. 1997). Therefore, the expression of Mortalin in glioblastoma cells can be 
viewed as a marker of gliomagenesis. 
It would be beneficial to perform mass spectrometry analysis on the SVG p12 glial cell line to 
obtain information on the methylation status of Mortalin in this non-cancerous cell line. 
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Comparing the arginine residues which are methylated between non-cancerous and 
cancerous cell lines would provide a better understanding of whether and how Mortalin 
methylation is involved in gliomagenesis. 
3.4.2.2.1.1 Significance of Mortalin Methylation 
Mortalin is predominantly localised to the mitochondria (Bhattacharyya et al. 1995), 
however has also been found in other sub-cellular compartments, such as the endoplasmic 
reticulum (Ran et al. 2000), and the cytoplasm (Gestl & Anne Bottger 2012). It has different 
functions based on its localisation due to the availability of different binding partners. Some 
of these functions and binding partners are summarised in Table 3.3. 
Table 3.3: Binding partners, Localisations and Functions of Mortalin 
Binding Partner Subcellular 
localisation 
Function Reference 
Amyloid precursor 
protein (APP) 
Unknown APP transcriptionally activates 
Mortalin expression. 
(Kögel et al. 2005) 
GRP94 Endoplasmic 
reticulum 
Unknown (Takano et al. 
2001) 
p53 Cytosol, 
mitochondria 
Inactivates p53 translocation into 
the nucleus, inhibiting its 
apoptotic functions. 
(Wadhwa et al. 
1998) 
HSP60 Cytoplasm, 
mitochondrial 
matrix 
Complex acts as a mitochondrial 
importer and allows proteins to 
refold. 
(Wadhwa et al. 
2005) 
Voltage-dependent 
anion-selective 
channel (VDAC) 
Mitochondrial 
outer membrane, 
cell membrane 
Modulates the channel properties 
of VDAC. 
(Schwarzer et al. 
2002) 
Telomerase, 
hnRNP-K proteins 
Nucleus Activation of telomerase and the 
hnRNP-K proteins 
(Ryu et al. 2014) 
 
Many of these extra-mitochondrial localisations of Mortalin have been reported in cancer 
cells, for example, nuclear Mortalin localisation has been observed in breast, cervical, lung 
and prostate cancer cell lines (Ryu et al. 2014), cytoplasmic localisation has been reported in 
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uterine (Ran et al. 2000) and colorectal cancer cell lines (Gestl & Anne Bottger 2012), while 
localisation to the endoplasmic reticulum has been detected in cervical, uterine, and liver 
cancer cell lines (Ran et al. 2000). 
Mortalin has previously been identified as methylated at arginine residues (Lim et al. 2010), 
however, no further research into the role methylation may play has so far been published. 
PRMT2 has been shown to co-localise with the androgen receptor in the cytoplasm and 
nucleus of the Hep-2 prostate cancer cell line and may be required for its transport (Meyer 
et al. 2007). It is possible methylation may also play a role in the transport of Mortalin to its 
extra-mitochondrial locations as several PRMTs are over-expressed in cancer cell lines (Yang 
& Bedford 2013) including in those cell lines mentioned above which have Mortalin located 
in compartments other than the mitochondria. 
One of the functions of Mortalin in the cytoplasm is the binding of p53, which prevents p53 
from entering the nucleus to activate apoptotic pathways (Wadhwa et al. 1998). Mass 
spectrometry analysis detected arginine 513 of Mortalin to be monomethylated in A172 and 
T98G cells (Table 3.1). R513 is located within the peptide binding domain of Mortalin and 
p53 binding occurs in this region (Figure 3.12) (Londono et al. 2012). Several proteins are 
known to bind through the interaction of methylated arginine residues with Tudor domains 
(Chen et al. 2011; Côté & Richard 2005; Espejo & Bedford 2015). Methylation of R513 may 
facilitate the binding of Mortalin and p53. It is interesting to note that Mortalin binds to a 
region of p53 (amino acid residues 312-352)(Wadhwa et al. 1998; Wadhwa et al. 2002) that 
contains symmetrically methylated arginine residues (Jansson et al. 2008) which may also 
facilitate binding. Further research into the significance of the arginine methylation of 
Mortalin is needed to gain further insight into how Mortalin (and its methylation) is involved 
in carcinogenesis. 
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Figure 3.12: Structure of Mortalin 
Structure of Mortalin showing the ATP binding domain (green), N-terminal binding domain (NBD, blue), Substrate 
binding domain (SBD, Orange) and peptide binding domain (PBD, red). p53 binds within the PBD and arginine 
513 is located within the peptide binding domain (indicated by a black arrow) (Londono et al. 2012). 
3.4.2.3 Metabolism 
Proteins involved in cellular metabolism were identified to have methylated arginine 
residues which were differently methylated in the different cell lines. For example, R149 of 
ATP synthase subunit α (Figure 3.7) and R248 of GAPDH were detected as methylated in 
T98G cell only, while R112 of L-lactate dehydrogenase A was detected as methylated in SVG 
p12 and T98G cells but not A172 or U87MG cells (Table 3.1). L-lactate dehydrogenase B was 
also detected as methylated at R170 in U87MG cells only. GAPDH has previously been 
reported to be methylated by PRMT1 and this was shown to regulate cell death in 
macrophages by reducing the nuclear translocation of GAPDH (Cho et al. 2018). Cho et al. 
(2018) did not identify which arginine residues in GAPDH are methylated (Cho et al. 2018) in 
macrophages however, R232 was previously identified as monomethylated in mouse brain 
(Guo et al. 2014). Unfortunately, the significance of the arginine methylation of the other 
proteins mentioned is unknown and further work is required to understand the role of 
arginine methylation in these proteins. 
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3.4.2.4 Limitations of Mass Spectrometry 
Mass spectrometry is a powerful tool in proteomics, however there were some limitations in 
the use of mass spectrometry in this thesis. Firstly, trypsin is considered to be inefficient at 
cleaving proteins at dimethylated arginine sites, resulting in peptides that may be too large 
to be detected by the mass spectrometer (Martin et al. 2010). This accounts for 
dimethylated arginine residues making up only 21% of total methylated residues identified 
(Table 3.1). However, trypsin is the most commonly used enzyme in analysis of proteomics 
by mass spectrometry. It is also commonly used in the detection of methylated arginine 
residues (Boisvert et al. 2005b; Côté et al. 2003; Guo et al. 2014; Sinha et al. 2010; Vhuiyan 
et al. 2017). Although inefficient, the use of trypsin digestion in the identification of 
methylated arginine residues is still a valid method of gaining information about proteins of 
interest. The use of another digestive enzyme in conjunction with trypsin would be 
complementary and would ensure a more complete set of data. Chymotrypsin, which 
cleaves at the C-terminus of phenylalanine, tryptophan and tyrosine, was used in this study 
in an attempt to obtain more information on the proteins identified by trypsin digestion, 
however no usable data was obtained. This could have been due to a loss in enzymatic 
activity or an incomplete digestion during sample preparation. Mass spectrometry analysis 
using an alternative digestive enzyme to trypsin, such as chymotrypsin or LysC which cleaves 
at lysine residues, should be repeated on the glial and glioblastoma cell lines in order to 
obtain a more complete profile on the methylation of proteins identified in this study.  
Secondly, the mass spectrometer used in this analysis was five years old at the time of 
analysis and lacks the resolution and sensitivity of newer models. Proteins were resolved 
with SDS-PAGE to limit the number of proteins in each injection, however the sensitivity of 
the mass spectrometer only allows for the most abundant peptides to be detected. While 
the residues identified to be methylated are not false positives, based on sample 
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preparation, the mass shifts detected and the identification of sites detected as methylated 
by previous studies, it is likely that further arginine residues and other proteins not identified 
here also have methylated arginine residues. 
Immuno-affinity purification could be used to enrich for methylated proteins in the sample, 
however this technique was not used in this study. Immuno-affinity purifications require the 
use of a column with antibodies to isolate proteins with the target antigen. This technique is 
not particularly suitable for enriching methylated proteins as the antibody generally only 
recognises one antigen, for example the ASYM24 antibody targets asymmetric dimethylated 
arginine residues within a GAR motif. As discussed previously, the family of PRMTs do not all 
methylate arginine residues within GAR motifs, so any monomethylated or dimethylated 
residues that are not within a GAR motif will not be bound by the antibody. In fact, a 
previous study has reported only 12% of methylated arginine residues were identified within 
a GAR motif (Plett et al. 2017). In this study, the whole cell lysates were used in an attempt 
to obtain a cross-section of different methylation types without limiting the residues 
identified to just one motif. Homology of PRMTs 
Previously, the most complete phylogenetic tree only included the known isoforms of 
human PRMTs (Wolf 2009). The creation of a phylogenetic tree with sequences from human, 
mouse, cow, zebrafish, fruit fly, X. laevis, S. cerevisiae, E. grandis, A. thaliana and O. sativa, 
confirms that PRMTs from eukaryotic species are highly homologous, with yeast PRMT2 
appearing to be the earliest common ancestor of the PRMT family (Figure 3.8). Interestingly, 
a recent report claimed that PRMTs may have arisen from bacterial enzymes and a 
mitochondrial PRMT has been suggested to have originated in proteobacteria before 
transmission to eukaryotes (Hameed et al. 2018). A better understanding of the 
phylogenetic relationship of PRMTs across species will provide an insight into how drugs 
investigated in one species may translate into other species. 
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 PRMTs Expression Differs Between Glial and Glioblastoma Cell Lines 
No complete reports on PRMT protein expression are available for human glioblastoma cell 
lines. In general, PRMT protein levels appeared to be higher in the glioblastoma cells lines 
than in the non-cancerous glial cell line (Figure 3.9 & Figure 3.10). This is interesting 
considering there are no visible differences in the overall levels of methylation in the 
Western blots using ASYM24 and SYM10 (Figure 3.1), even though there are visible 
differences in the densities of the individual protein bands.  
RNA of the normal glial cell line SVG p12 and the glioblastoma cell lines A172, T98G and 
U87MG was extracted, reverse transcribed into cDNA and analysed by qPCR to determine 
expression of PRMTs 1 through 6 and PRMT8 in glial and glioblastoma cell lines relative to 
TATA-binding protein. There was a significant decrease in the RNA expression of PRMT5 in 
U87MG cells compared to all other cells lines (Figure 3.11E), while in A172 cells there were 
significant decreases in the RNA expression of PRMT6 (Figure 3.11F) and PRMT8 (Figure 
3.11G). The protein and RNA expression levels of the PRMTs are summarised in Table 3.4. It 
is interesting to note, that the expression levels of RNA and protein were not correlated and 
in some cases were the opposite. For example, there was decreased RNA expression but 
increased protein expression of PRMT5 in T98G and U87MG (Table 3.4). It has been 
suggested that the correlation between mRNA and protein levels depends on the protein 
and its function as this is influenced by the stability and the turnover rate of the protein 
(Kendrick 2014). For example, cell cycle regulators would have unstable mRNA and protein 
levels due to the constant need for their degradation and production to regulate the cell 
cycle, while the expression levels of structural proteins, like tubulin, would be relatively 
stable (Schwanhäusser et al. 2011), hence why they are frequently used as “housekeeping” 
genes and proteins. PRMTs, as regulators of many cellular processes are highly regulated 
themselves to maintain homeostasis within the cell. A feedback mechanism could exist to 
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limit the amount of protein translated and this could explain why there was an increase in 
PRMT5 protein and a decrease in RNA levels in the glioblastoma cell lines. The increased 
PRMT5 protein expression could signal a halt in transcription or even trigger RNA 
degradation to prevent more PRMT5 protein from being translated. The RNA levels of 
PRMTs can be downregulated by microRNAs (Yang & Bedford 2013). Aberrant expression of 
PRMT5-specific microRNA was found to inversely correlate with increased levels of PRMT5 in 
lymphoid cancer cell lines (Wang et al. 2008), perhaps explaining the increase in PRMT5 
protein in the glioblastoma cell lines compared to the non-cancerous glial cell line (Figure 3.9 
& Figure 3.10). Automethylation of PRMT6 (Frankel et al. 2002) and PRMT8 (Dillon et al. 
2013) contributed to the stability and activity of both PRMTs and automethylation of PRMT4 
regulated PRMT4-mediated transcriptional activation (Kuhn et al. 2011), indicating that 
regulation of the PRMTs contributes to their activity. PRMTs are also regulated by 
phosphorylation, such as the phosphorylation of PRMT5 by JAK2 which regulates the activity 
of PRMT5 (Liu et al. 2011). There was a PRMT5 doublet band visible in A172 cells (Figure 3.9) 
which could be due to phosphorylation or other PTMs present. Hence, the regulation of 
PRMTs is complicated and there are many possible mechanisms as to why mRNA expression 
levels may not correlate with protein expression levels. 
Table 3.4: Summary of PRMT RNA and protein expression of glioblastoma cell lines in 
comparison to non-cancerous glial cells* 
PRMT 
RNA Expression Protein Expression 
SVG p12 A172 T98G U87MG SVG p12 A172 T98G U87MG 
1 Control N.C N.C N.C Control increase decrease N.C 
2 Control N.C decrease N.C Control increase N.C N.C 
3 Control N.C N.C N.C Control decrease N.C N.C 
4 Control N.C N.C N.C Control N.C N.C N.C 
5 Control N.C decrease decrease Control increase increase increase 
6 Control decrease N.C decrease Control increase N.C increase 
8 Control decrease increase N.C Control increase N.C increase 
*Red and Green indicate PRMTs that have decreased or increased, respectively, compared to the non-cancerous 
glial cells, SVG p12. N.C indicates no change was detected. 
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In this study PRMT1 protein was upregulated in A172, compared to non-cancerous glial cells, 
which is consistent with previous studies (Wang et al. 2012a). However, the results 
presented here showed a significant decrease in PRMT1 in T98G cells (Figure 3.9 & Figure 
3.10) which is in contrast to studies where T98G cells had approximately 2-fold higher levels 
of PRMT1 than normal glial cells (Wang et al. 2012a).  However, the Western blot presented 
by Wang et al. (2012a) appears to be have been performed only once and was not quantified 
so the exact change in PRMT1 levels is not comparable to the results presented here.  The 
normal glial cells, SVG p12, used in this thesis are derived from fetal glial cells while Wang et 
al. (2012a) compared T98G cells with normal brain tissue samples (Wang et al. 2012a). Since 
PRMT1 is known to be essential during cell development (Pawlak et al. 2000), it is likely that 
PRMT1 protein levels are higher in fetal glial cells than in developed glial cells. It is also 
unknown if Wang et al. (2012a) isolated the glial cells from the brain tissue samples or if the 
cell lysates used were homogenised brain tissue containing neurons and other brain cells as 
well as glial cells. Furthermore, the exact details of the PRMT1 antibody used were not 
provided and different binding affinities of the antibody used by Wang et al. (2012a) and the 
antibody used in this thesis may explain differences in the PRMT1 protein levels detected. 
The increased PRMT5 protein expression in glioblastoma cells (Figure 3.9 & Figure 3.10) may 
be explained by the fact that PRMT5 increases during glial cell maturation and expression 
levels peaked in adult mice (Huang et al. 2011). SVG p12 cells are derived from foetal glial 
cells and thus, expression levels of PRMT5 may be lower in these cells than in adult non-
cancerous astrocytes. Although, studies have also shown PRMT5 protein expression to be 
lower in non-cancerous glial tissue than in glioblastoma (Han et al. 2014), which is consistent 
with the results presented here. It has also been suggested that PRMT5 may be a biomarker 
for glioblastoma as expression of PRMT5 correlated with the grade of tumour malignancy 
(Han et al. 2014). Interestingly, SDMA expression was found to be higher in cells with 
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increased PRMT5 expression (Han et al. 2014), which is in contrast to the results presented 
here which shows no marked difference in the levels of SDMA in the glioblastoma cell lines 
(Figure 3.1), despite expressing 5- to 7-fold more PRMT5 protein. It is possible that although 
there is an increase in PRMT5 protein, not all the PRMT5 may be active in these cells or 
there may not be adequate molecules of binding partners of PRMT5, such as those discussed 
in section 1.2.3.5, thus preventing PRMT5 from exerting its activity.  
Loss of PRMT8 in glioblastoma multiforme has been linked to the upregulation of several 
genes, such as cxcr4 and efemp1, which encode for chemokine receptors and extracellular 
matrix glycoproteins required for glial cell differentiation and gliomagenesis (Simandi et al. 
2014). Interestingly, the results presented here show that PRMT8 is still being expressed in 
the glioblastoma cell lines (Figure 3.9 & Figure 3.10) and is in fact being expressed at higher 
levels than normal glial cells, thus suggesting that PRMT8 is not a biomarker of 
gliomagenesis as reported by Simandi et al. (2014). 
The overexpression of PRMTs in cancer has frequently been reported in literature. For 
example, protein levels of PRMT4 are increased in prostate cancer (Hong et al. 2004), 
melanoma (Limm et al. 2013) and colorectal cancer (Kim et al. 2010b), however no change in 
PRMT4 was observed in this thesis between the non-cancerous glial cells and the 
glioblastoma cell lines. PRMT1 and PRMT6 are overexpressed in bladder, testicular, breast, 
cervical (Yoshimatsu et al. 2011) and lung cancer (Elakoum et al. 2014; Yoshimatsu et al. 
2011) which is consistent with some of the results presented here. PRMT1 protein 
expression was significantly increased in A172 cells compared to SVG p12 cells and PRMT6 
protein expression was significantly increased in A172 and U87MG cells compared to 
SVG p12 cells. Protein levels of PRMT5 were found to be higher in breast cancer tissue when 
compared to normal breast tissue (Yang et al. 2015a) and PRMT5 overexpression correlated 
with the grade of malignancy in lung cancer (Shilo et al. 2013), which is consistent with the 
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results presented in this thesis in glial and glioblastoma cells. Elevated expression levels of 
PRMT7 in breast cancer are also associated with higher grade tumours (Yao et al. 2014), 
however the protein expression of PRMT7 was not investigated in this thesis. 
Hence protein arginine methylation appears to be involved in carcinogenesis and may be a 
potential target for chemotherapy. It is especially important to develop new drugs for brain 
cancers due to their aggressive nature and the low penetration rate of current 
chemotherapy drugs across the blood-brain barrier.  
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4 The Effect of PRMT1 and 8 Inhibition on lial and 
lioblastoma Cell lines  
While PRMT5 was identified as overexpressed in glioblastoma cell lines compared to normal 
glial cells, there were also significant differences in the protein expression of PRMT1 (section 
3.3). Novel chemical inhibitors of PRMT1 and PRMT8 were identified by high-throughput 
screening (Dillon et al. 2012). To date, no studies have been published on the effect of these 
inhibitors used in cell lines. The PRMT1/8 inhibitor (section 2.5) was available in the Piller lab 
and used in this thesis to chemically inhibit PRMT1 and PRMT8, simultaneously, in glial and 
glioblastoma cell lines for the first time and the results are presented and discussed in this 
chapter. 
 The Effect of PRMT1/8 Inhibition on Cell Number and Viability 
The IC50 of the PRMT1/8 inhibitor was reported to be 23 μM during in vitro dose-response 
methylation assays (Dillon et al. 2012). Since the use of the PRMT1/8 inhibitor in cell lines 
has not been published, glial and glioblastoma cells (Table 2.2) were treated with the 
PRMT1/8 inhibitor at 2 µM, 3 µM and 4 µM for 24 h, in order to determine the optimum 
concentration for inhibiting PRMT1/8 activity without affecting cell viability. The 
concentrations used are further discussed in section 4.4.1. Treatment and control (0.1% 
DMSO) cells were imaged, live and dead cells were counted with a haemocytometer after 
staining with Trypan blue (section 2.6). Cells were harvested and lysed. Whole cell lysates 
were then separated by SDS-PAGE and Western blotting was performed using ASYM24 and 
GAPDH antibodies (section 2.8). 
Following 24 h treatment with 2 μM PRMT1/8 inhibitor (Figure 4.1B, F, J, N), a small number 
of cells were visibly rounded and detached in each cell line. After 24 h treatment with 3 μM 
PRMT1/8 inhibitor (Figure 4.1C, G, K, O) a larger number of SVG p12 (C) and U87MG (G) cells 
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were visibly rounded and detached than of A172 (K) and T98G (O) cells. Interestingly, the 
majority of A172 and T98G cells (Figure 4.1H and L, respectively) appeared to be unaffected 
by treatment with 4 μM PRMT1/8 inhibitor, while the majority of SVG p12 and U87MG cells 
(Figure 4.1D and P, respectively) appeared to be negatively affected with most of the cells 
visibly rounded and detached. 
 
Figure 4.1: Light microscope images of glial and glioblastoma cells treated with the 
PRMT1/8 inhibitor 
Glial cells, SVG p12 (A-D), and glioblastoma cells, A172 (E-H), T98G (I-L) and U87MG (M-P), were treated with 
0.1% DMSO (A, E, I, M), 2 µM (B, F, J, N), 3 µM (C, G, K, O) or 4 µM (D, H, L, P) of the PRMT1/8 inhibitor. Scale 
bar, shown in P, is 100 µm and applies to all images. Red arrows indicate examples of visibly rounded off, non-
adherent cells.  
The viability of each cell line following treatment with PRMT1/8 inhibitor was determined 
and is shown in Figure 4.2. The number of live and dead (blue-stained) cells was counted and 
the percentage of viable cells of the total number of cells was then calculated. SVG p12 and 
U87MG total cell number decreased in a dose-dependent manner with significant decreases 
of up to 50% less cells following treatment with 3 or 4 μM, (Figure 4.2A). A172 total cell 
number also decreased by approximately 40% with 4 μM treatment, while T98G total cell 
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number increased with 2 and 3 μM treatment and then returned to control cell numbers 
with 4 μM (Figure 4.2A). The viability of SVG p12 and U87MG cells significantly decreased by 
40% and 20% with 4 μM PRMT1/8 inhibitor treatment, respectively, while no changes in 
viability were seen in A172 or T98G cells with any of the three PRMT1/8 inhibitor 
concentrations tested (Figure 4.2B). The data used to generate Figure 4.2 are available in 
Appendix 7.3.1. 
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Figure 4.2: The effect of PRMT1/8 inhibitor on glial and glioblastoma total cell number and 
viability 
Bar graph of glial, SVG p12, and glioblastoma, A172, T98G and U7MG, cell count after treatment for 24 h with 
0.1% DMSO (Control; blue), 2 (red), 3 (green) or 4 (orange) µM PRMT/8 inhibitor. Fold change from control of 
total cell number was calculated following counting with trypan blue (A). Bar graph of the percentage of live cells 
after 24 h treatment with DMSO (Control), 2, 3 or 4 µM PRMT/8 inhibitor (B). Data are averages of 3 independent 
experiments and error bars represent the standard deviation of the mean. One-way ANOVA with Tukey’s post-
hoc test was performed using IBM SPSS 25 software, *p < 0.05, **p <0.01, ***p < 0.001. Raw data are shown in 
Appendix 7.3.1.  
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After 24 h of treatment with PRMT1/8 inhibitor, cells were harvested, lysed and separated 
by SDS-PAGE. Western blotting was performed using ASYM24 and GAPDH antibodies (Figure 
4.3). Decreases in the asymmetric di-methylation of many proteins were visible in all cell 
lines, such as the proteins of approximately 75, 36 and 28 kDa in SVG p12 cells, 50 kDa in 
A172 cells, 75, 37 and 28 kDa in T98G cells and 75 kDa in U87MG cells (Figure 4.3 blue 
rectangles). Interestingly, there were also proteins that appeared to increase in their amount 
of asymmetric di-methylation after PRMT1/8 inhibition, which was only observed in the 
glioblastoma cells lines and not in the control glial cell line. For example, there was a visible 
increase in the proteins at approximately 35 and 28 kDa in A172 cells, 50 and 25 kDa in T98G 
cells and 33 kDa in U87MG cells (Figure 4.3 red rectangles).  
  
 
Figure 4.3: The effect of 24 h PRMT1/8 inhibition on asymmetric arginine di-methylation in 
glial and glioblastoma cells 
Western blots of whole cell lysates of control (0.1% DMSO) and 2, 3, or 4 µM inhibitor treated glial, SVG p12, and 
glioblastoma, A172, T98G and U87MG, cells probed with ASYM24 antibody (A) or GAPDH antibody as loading 
control (B). Red boxes indicate an apparent increase in asymmetrically di-methylated proteins, while blue boxes 
indicate an apparent decrease in asymmetric di-methylation. 
 
Based on these results, where the PRMT1/8 inhibitor had the greatest effect on SVG p12 and 
U87MG cell number without decreasing cell viability by more than 50% at 3 µM, this 
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concentration was chosen to further study the effect of the PRMT1/8 inhibitor on the glial 
and glioblastoma cells.  
 The Effect of PRMT1/8 Inhibition on the Cell Cycle of Glial and 
Glioblastoma Cells 
Glial and glioblastoma cells were treated with a 0.1% DMSO or 3 µM PRMT1/8 inhibitor for 
24 or 48 h. The viability of each cell line following treatment was determined using a 
haemocytometer by counting cells stained with trypan blue. The number of live and dead 
(blue-stained) cells was counted and the percentage of viable cells was then calculated (see 
section 2.6).  
SVG p12, A172 and U87MG cells all displayed a significant decrease in the number of cells 
after 24 h treatment with the PRMT1/8 inhibitor, with decreases of 40%, 30% and 50%, 
respectively (Figure 4.4A). Following 48 h of treatment, SVG p12, A172 and U87MG cells 
displayed further significant decreases in cell number of up to 65%, 55% and 60%, 
respectively, when compared to control cells (Figure 4.4A). In contrast, T98G cell numbers 
increased by 30% after 24 h treatment and then decreased by approximately 20% after 48 h 
of treatment to fall just below control cell numbers (Figure 4.4A). The cell viability of SVG 
p12 cells decreased significantly by 40% and 45% after 24 h and 48 h, respectively (Figure 
4.4B). U87MG cells only displayed a significant decrease in cell viability of approximately 
30% after 48 h of treatment (Figure 4.4B). A172 cell viability decreased slightly in a dose-
dependent manner however, there was no significant difference from control cells. T98G 
cells also showed no significant difference in cell viability from control cells (Figure 4.4B). The 
raw data used to generate Figure 4.4 are available in Appendix 7.3.2. 
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Figure 4.4: Time course of the effect of PRMT1/8 inhibition on glial and glioblastoma total 
cell number and viability  
Bar graph of glial, SVG p12, and glioblastoma, A172, T98G and U7MG, cell count when treated with DMSO 
(Control; blue) or 3 µM PRMT/8 inhibitor for 24 (green) or 48 h (yellow). Fold change from control of total cell 
number was calculated following counting with trypan blue (A). Bar graph of the percentage of live cells after 24 or 
48 h treatment with DMSO (Control) or 3 µM PRMT/8 inhibitor (B). Data are averages of 3 independent 
experiments and error bars represent the standard deviation of the mean. Statistical analysis was performed 
using IBM SPSS 25 software, *p < 0.05, **p <0.01, ***p < 0.001. Raw data are shown in Appendix 7.3.2. 
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The decline in both cell number and cell viability of SVG p12 and U87MG cells led to the 
hypothesis that the PRMT1/8 inhibitor produces a cytotoxic effect on these cells, while the 
decline in growth and the stable cell viability in A172 and T98G cells led to the hypothesis 
that the PRMT1/8 inhibitor produces a cytostatic effect by arresting the cell cycle (Figure 
4.4). To determine whether the cell cycle was affected in cells treated with PRMT1/8 
inhibitor and to identify at which phase of the cell cycle the inhibitor caused cells to be 
arrested, flow cytometry analysis was performed (section 2.7). Glial and glioblastoma cell 
lines were treated with 0.1% DMSO, 2.5 mM hydroxyurea (positive control as hydroxyurea is 
known to arrest cells in the S phase of the cell cycle by inhibiting dNTP reductase (Pfeiffer & 
Tolmach 1967); data shown in Appendix 7.3.3) or 3 µM PRMT1/8 inhibitor for 24 h or 48 h. 
Following treatment, cells were fixed in ethanol and analysed by flow cytometry. The data 
from three independent experiments were analysed by FlowJo software (section 2.7.2).  
The flow cytometry analysis (summarised in Table 4.1) showed that the PRMT1/8 inhibitor 
caused a significant cell cycle arrest in the S phase of the cell cycle with an increase of 20% in 
SVG p12 cells (Figure 4.5 and Figure 4.9A), 11% in A172 cells (Figure 4.6 and Figure 4.9B) and 
18% in U87MG cells (Figure 4.8 and Figure 4.9D) after 24 h. Following 48 h of PRMT1/8 
inhibitor treatment, SVG p12 (Figure 4.5 and Figure 4.9A) and A172 (Figure 4.6 and Figure 
4.9B) cells remained arrested with 61% and 30% of cells in the S phase, respectively, 
however the percentage of U87MG cells in the S phase had returned to normal levels with 
31% of cells arrested in the G2/M phase (Figure 4.8 and Figure 4.9D). In contrast, the 
PRMT1/8 inhibitor caused no significant change to the cell cycle of T98G cells after 24 h 
however, after 48 h cells showed an arrest in the G2/M phase of the cell cycle (Figure 4.7 
and Figure 4.9C). The raw data used to generate Table 4.1 and Figure 4.9 are available in 
Appendix 7.3.4. 
 
    119 
Table 4.1: Mean percentage of cells in each phase of the cell cycle of glial and glioblastoma 
cells treated with PRMT1/8 inhibitor 
Cell Line Treatment G1 (%) ± S. D S (%) ± S. D G2/M (%) ± S. D 
SVG p12 Control 27.10 ± 3.86 40.70 ± 1.79 31.00 ± 4.78 
24h 21.03 ± 3.02 60.70 ± 16.75 13.97 ± 19.75 
48h 28.20 ± 2.98 61.23 ± 10.98 10.57 ± 11.50 
A172 Control 67.33 ± 2.20 19.70 ± 0.86 8.71 ± 2.49 
24h 55.17 ± 9.04 30.83 ± 5.42 9.61 ± 4.26 
48h 51.43 ± 8.87 30.93 ± 5.79 16.12 ± 4.44 
T98G Control 68.20 ± 3.09 23.40 ± 1.69 7.94 ± 1.35 
24h 59.13 ± 3.77 28.90 ± 5.00 5.87 ± 4.59 
48h 37.33 ± 18.71 31.57 ± 5.00 21.48 ± 11.90 
U87MG Control 47.83 ± 0.69 36.07 ± 2.64 12.71 ± 3.36 
24h 38.57 ± 4.90 54.40 ± 9.02 2.88 ± 4.08 
48h 30.77± 4.40 34.93 ± 3.44 31.27 ± 1.72 
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Figure 4.5: Flow cytometry and cell cycle analysis of SVG p12 cells 
Representative cell cycle analysis of SVG p12 cells treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor 
for 24 or 48 h. SSC-A vs. FSC-A was gated to exclude cell debris (P1; A). FSC-H vs. FSC-A was gated to exclude 
doublets (P2; B). Cell count vs. PI fluorescence was gated to include live cells (P3; C). Cell cycle analysis was 
performed on gated P3 cells (D). Raw data are shown in Appendix Table 7.30. 
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Figure 4.6: Flow cytometry and cell cycle analysis of A172 cells 
Representative cell cycle analysis of A172 cells treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor for 
24 or 48 h. SSC-A vs. FSC-A was gated to exclude cell debris (P1; A). FSC-H vs. FSC-A was gated to exclude 
doublets (P2; B). Cell count vs. PI fluorescence was gated to include live cells (P3; C). Cell cycle analysis was 
performed on gated P3 cells (D). Raw data are shown in Appendix Table 7.31. 
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Figure 4.7: Flow cytometry and cell cycle analysis of T98G cells 
Representative cell cycle analysis of T98G cells treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor for 
24 or 48 h. SSC-A vs. FSC-A was gated to exclude cell debris (P1; A). FSC-H vs. FSC-A was gated to exclude 
doublets (P2; B). Cell count vs. PI fluorescence was gated to include live cells (P3; C). Cell cycle analysis was 
performed on gated P3 cells (D). Raw data are shown in Appendix Table 7.32. 
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Figure 4.8: Flow cytometry and cell cycle analysis of U87MG cells 
Representative cell cycle analysis of U87MG cells treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor 
for 24 or 48 h. SSC-A vs. FSC-A was gated to exclude cell debris (P1; A). FSC-H vs. FSC-A was gated to exclude 
doublets (P2; B). Cell count vs. PI fluorescence was gated to include live cells (P3; C). Cell cycle analysis was 
performed on gated P3 cells (D). Raw data are shown in Appendix Table 7.33. 
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Figure 4.9: Change in the phases of the cell cycle in glial and glioblastoma cells after 
treatment with PRMT1/8 inhibitor 
Glial, SVG p12 (A), and glioblastoma, A172 (B), T98G (C) and U87MG (D), cells were treated with 0.1% DMSO 
(control) or 3 µM PRMT1/8 inhibitor for 24 or 48 h. Cell cycle analysis was performed using FlowJo software. The 
fold change from control was calculated and the One-way ANOVA with Tukey’s post-hoc test of three 
independent experiments was performed using IBM SPSS 25 software. Error bars represent the standard 
deviation of the mean. *p < 0.05, **p <0.01, ***p < 0.001. Raw data are shown in Appendix 7.3.4. 
 
 The Effect of PRMT1/8 inhibition on DNA Damage Repair 
Cell cycle analysis revealed that treatment with 3 μM PRMT1/8 inhibitor caused S phase 
arrest of the cell cycle in SVG p12, A172 and U87MG cells and G2/M phase arrest of the cell 
cycle in T98G cells. It was hypothesised that inhibition of PRMT1/8 could interfere with the 
DNA damage repair pathways leading to S phase arrest of the cell cycle in these cells. To 
investigate this hypothesis, cells were treated with 0.1% DMSO or 3 μM PRMT1/8 inhibitor 
for 24 h, then exposed to 10 kJ/m2 UV-B light to induce DNA damage and allowed to recover 
for 1, 3 or 24 h. Cells were imaged and the viability of each cell line following treatment was 
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determined using a haemocytometer by counting cells stained with trypan blue (section 2.6). 
The number of live and dead cells were counted and the percentage of viable cells was then 
calculated. 
Following 24 h treatment with the PRMT1/8 inhibitor, there were visibly fewer cells when 
compared to DMSO-treated control cells in SVG p12 (Figure 4.10), A172 (Figure 4.11) and 
U87MG (Figure 4.13) cells. A small number of cells appeared to be rounded and detached. 
There were no visible differences in T98G cells following treatment with the PRMT1/8 
inhibitor (Figure 4.12).  
SVG p12 DMSO control cells exposed to UV (Figure 4.10) only displayed a slight notable 
decrease in cells following the 1 and 3 h recovery periods and still appeared to have normal 
cell morphology. Cell number although apparently decreased was not significantly affected 
(Figure 4.14A) and the cell viability was unchanged (Figure 4.14B). Following the 24 h 
recovery period a large proportion of cells appeared rounded, however cell number (Figure 
4.14A) was similar to control cells not exposed to UV. Cell viability was decreased but not 
significantly (Figure 4.14B). SVG p12 cells treated with PRMT1/8 inhibitor for 24 h and prior 
to exposure to UV (Figure 4.10) displayed similar morphology after the 1 and 3 h recovery 
periods to cells that were treated with PRMT1/8 inhibitor but not exposed to UV. Cell 
number (Figure 4.14A) and viability (Figure 4.14B) were also not significantly changed from 
inhibitor treated cells not exposed to UV. 24 h following UV exposure, inhibitor treated SVG 
p12 cells displayed fewer cells, although total cell number counts (Figure 4.14A) actually 
increased when compared to the previous timepoints. A large proportion of the cells 
appeared to be rounded and detached (Figure 4.10), and this was accompanied by a 
significant decrease in cell viability which was approximately 25% lower than the 3 h 
recovery timepoint (Figure 4.14A). 
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Figure 4.10: Images of SVG p12 cells treated with the PRMT1/8 inhibitor and/or UV-B light 
Glial cells, SVG p12, were treated with 0.1% DMSO or 3 µM PRMT1/8 inhibitor for 24 h. Cells were then exposed 
to 10 kJ/m2 UV-B light and images were taken 1, 3 or 24 h after exposure. Scale bar in bottom right image is 100 
µm and applies to all images.  
 
A172 DMSO-treated control cells exposed to UV (Figure 4.11)  appeared to have no 
differences in morphology after the 1 and 3 h recovery periods when compared to cells 
which had not been exposed to UV. 24 h following UV exposure, DMSO-treated A172 cells 
(Figure 4.11) had a changed morphology. A small number of cells appeared rounded while 
others appeared smaller in size and less elongated. The mean of the total cell number 
(Figure 4.14C) showed no difference after 1 h and increased 3 h and 24 h after UV exposure, 
while the mean cell viability (Figure 4.14D) fluctuated but was not significantly different from 
no-UV treated cells. A172 cells treated with PRMT1/8 inhibitor for 24 h prior to UV exposure 
(Figure 4.11), appeared to have no visible differences 1 h after UV exposure when compared 
to cells which had not been exposed to UV. 3 h following UV exposure, A172 cells appeared 
to have no change in the number of cells from the 1 h recovery period, but cell morphology 
was more rounded. 24 h following UV exposure, cell morphology appeared to have 
recovered as there were visibly less rounded cells than at the 3 h recovery timepoint. Cell 
number of A172 inhibitor treated cells (Figure 4.14C) remained constant 1 and 3 h following 
UV exposure and was increased 24 h following UV exposure. The cell viability of inhibitor 
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treated A172 cells (Figure 4.14D) remained unchanged 1 h after UV exposure, decreased 
slightly 3 h after UV exposure and recovered to control levels by 24 h following UV exposure, 
although none of these changes were statistically significant. 
 
Figure 4.11: Images of A172 cells treated with the PRMT1/8 inhibitor and/or UV-B light 
Glioblastoma cells, A172, were treated with 0.1% DMSO or 3 µM PRMT1/8 inhibitor for 24 h. Cells were then 
exposed to 10 kJ/m2 UV-B light and images were taken 1, 3 or 24 h after exposure. Scale bar in bottom right 
image is 100 µm and applies to all images.  
 
T98G DMSO-treated cells exposed to UV displayed no significant differences in morphology 
(Figure 4.12), cell number (Figure 4.14E) or cell viability (Figure 4.14F). Inhibitor treated T98G 
cells were also not affected by UV exposure and displayed no changes in morphology (Figure 
4.12), cell number (Figure 4.14E) or cell viability (Figure 4.14F) until 24 h post UV exposure 
where the cell viability significantly decreased by approximately 20%. 
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Figure 4.12: Images of T98G cells treated with the PRMT1/8 inhibitor and/or UV-B light 
Glioblastoma cells, T98G, were treated with 0.1% DMSO or 3 µM PRMT1/8 inhibitor for 24 h. Cells were then 
exposed to 10 kJ/m2 UV-B light and images were taken 1, 3 or 24 h after exposure. Scale bar in bottom right 
image is 100 µm and applies to all images.  
 
U87MG DMSO-treated control cells exposed to UV (Figure 4.13) appeared smaller in size 
both 1, 3 and 24 h following exposure. Cells also appeared more rounded and fewer in 
number 24 h following UV exposure. Cell number (Figure 4.14G) was significantly decreased 
3 h after exposure when compared to cells that had not been exposed to UV, however cells 
had recovered 24 h after UV exposure. Cell viability (Figure 4.14H) was not affected 1 and 
3 h post UV exposure, and was slightly but not significantly increased after 24 h. Inhibitor 
treated U87MG cells (Figure 4.13) exposed to UV appeared similar to those not treated and 
exposed to UV, however a larger proportion of rounded, detached cells were visible. Cell 
number (Figure 4.14G) was significantly reduced by approximately 50% at 1 h post UV 
exposure when compared to inhibitor treated cells not exposed to UV. Inhibitor treated cells 
1, 3 and 24 h post UV exposure were also significantly decreased in cell number when 
compared to control untreated U87MG cells (Figure 4.14G). The viability of U87MG cells 
(Figure 4.14H) remained unaffected until 24 h post UV exposure for both DMSO treated 
control and PRMT1/8 inhibitor treated cells. The viability decreased by approximately 10% 
and 30%, respectively, however this did not reach statistical significance. 
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Figure 4.13: Images of U87MG cells treated with the PRMT1/8 inhibitor and/or UV-B light 
Glioblastoma cells, U87MG, were treated with 0.1% DMSO or 3 µM PRMT1/8 inhibitor for 24 h. Cells were then 
exposed to 10 kJ/m2 UV-B light and images were taken 1, 3 or 24 h after exposure. Scale bar in bottom right 
image is 100 µm and applies to all images.  
    130 
 
Figure 4.14: Effect of PRMT1/8 inhibitor in combination with UV-exposure on cell number 
and viability of glial and glioblastoma cells  
Bar graph of fold change from control of total number of cells (A, C, E, G) or percentage of live cells (B, D, F, H). 
Glial, SVG p12 (A, B), and glioblastoma, A172 (C, D), T98G (E, F) and U87MG (G, H) cells were treated with 
DMSO (blue) or 3 µM PRMT/8 inhibitor (purple) for 24 h, followed by 10 kJ/m2 UV-B. Cell counting was performed 
using trypan blue following 24 h of PRMT1/8 inhibitor treatment or 1, 3 or 24 h after UV exposure. Data are 
averages of 4 independent experiments and error bars represent the standard deviation. Statistical analysis was 
performed using IBM SPSS 25 software, *p < 0.05, **p <0.01, ***p < 0.001. Raw data are shown in Appendix 
7.3.5. 
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It was determined that UV exposure negatively affected SVG p12, A172 and U87MG cells 
treated with the PRMT1/8 inhibitor when compared to cells exposed only to UV or only 
treated with the PRMT1/8 inhibitor. To visualise if DNA damage played a role in the 
compounding effect of PRMT1/8 in combination with UV exposure in these cells, the cells 
were fixed and then stained to visualise the DNA damage response marker, histone γ-H2AX, 
using confocal microscopy.  
In the absence of UV exposure, only DAPI staining of the DNA was observed in a large 
number of SVG p12 (Figure 4.15), A172 (Figure 4.16), T98G (Figure 4.17) and U87MG (Figure 
4.18) cells. This data has been summarised in Table 4.2 and in the box and whiskers plot 
(Figure 4.19). Exposure of SVG p12 cells (Figure 4.15) to 10 kJ/m2 UV-B resulted in multiple γ-
H2AX foci which peaked 24 h after exposure. The mean percentage of SVG p12 cells with γ-
H2AX foci increased by up to 13% in cells treated with the PRMT1/8 inhibitor prior to UV 
exposure when compared to cells not treated with the inhibitor.  
Similarly, γ-H2AX foci in A172 cells (Figure 4.16), peaked after 24 h, with 45% of cells 
displaying foci following UV exposure and 69% of cells displaying foci following PRMT1/8 
inhibitor treatment and UV exposure. This is a significant increase in foci of 24%.  
The increase of γ-H2AX foci in U87MG cells (Figure 4.18) was also highest 24 h after UV 
exposure, however the increase was smaller than in the other two cell lines with 20% and 
23% of cells displaying foci in UV exposed cells and those treated with the PRMT1/8 
inhibitor, respectively. However, there was a greater increase in foci observed 3 h after UV 
exposure, with 10% and 21% of cells displaying foci in UV exposed cells and those treated 
with the PRMT1/8 inhibitor, respectively.  
T98G cells (Figure 4.17) displayed only small numbers of γ-H2AX foci when exposed to UV, 
both with and without the PRMT1/8 inhibitor. In T98G cells exposed to UV the highest 
percentage of foci was observed 1 h after exposure with a mean of 4%, while in cells treated 
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with the PRMT1/8 inhibitor prior to UV exposure the highest percentage of foci was 
observed 3 h after exposure with a mean of 5%. The raw data used to generate Figure 4.19 
are available in Appendix 7.3.6. 
Table 4.2: Mean percentage of glial and glioblastoma cells displaying γ-H2AX foci following 
treatment with PRMT1/8 inhibitor and/or exposure to UV-B 
Treatment SVG p12  
(% ± S.D) 
A172   
(% ± S.D) 
T98G  
(% ± S.D) 
U87MG   
(% ± S.D) 
Control 5.77 ± 5.08 3.41 ± 4.14 1.72 ± 3.07 5.27 ± 5.03 
UV only 1h recovery 20.55 ± 22.09 26.19 ± 14.83 3.91 ± 3.91 7.73 ± 3.76 
UV only 3h recovery 21.77 ± 28.44 36.26  ± 31.70 2.70 ± 3.88 10.04 ± 7.30 
UV only 24h recovery 27.31 ± 15.49 44.71 ± 25.53 1.92 ± 2.54 20.02 ± 10.69 
Inh Only (24h) 15.32 ± 15.02 21.19 ± 13.29 4.55 ± 7.04 7.74 ± 7.37 
Inh + UV 1h recovery 33.43 ± 14.19 42.85 ± 17.61 0.66 ± 1.02 13.01 ± 3.88 
Inh + UV 3h recovery 35.03 ± 26.58 61.15 ± 31.67 4.03 ± 7.06 21.66 ± 16.90 
Inh + UV 24h recovery 38.64 ± 22.58 68.98 ± 27.83 4.14 ± 4.53 22.81 ± 13.82 
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Figure 4.15: Effect of PRMT1/8 inhibitor in combination with UV-exposure on DNA damage in SVG p12 cells 
Representative images of immunofluorescence of phosphorylated histone H2AX in SVG p12 cells. Cells were treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor for 
24 h, then exposed to 10 kJ/m2 UV-B. Cells were cultured for 1, 3 or 24 h post UV exposure before fixation and immunofluorescent labelling with γ-H2AX (red) and DAPI (blue). 
Scale bar in bottom right image is 20 μm and applies to all images.  
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Figure 4.16: Effect of PRMT1/8 inhibitor in combination with UV-exposure on DNA damage in A172 cells 
Representative images of immunofluorescence of phosphorylated histone H2AX in A172 cells. Cells were treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor for 24 h, 
then exposed to 10 kJ/m2 UV-B. Cells were cultured for 1, 3 or 24 h post UV exposure before fixation and immunofluorescent labelling with γ-H2AX (red) and DAPI (blue). 
Scale bar in bottom right image is 20 μm and applies to all images.  
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Figure 4.17: Effect of PRMT1/8 inhibitor in combination with UV-exposure on DNA damage in T98G cells 
Representative images of immunofluorescence of phosphorylated histone H2AX in T98G cells. Cells were treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor for 
24 h, then exposed to 10 kJ/m2 UV-B. Cells were cultured for 1, 3 or 24 h post UV exposure before fixation and immunofluorescent labelling with γ-H2AX (red) and DAPI (blue). 
Scale bar in bottom right image is 20 μm and applies to all images.  
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Figure 4.18: Effect of PRMT1/8 inhibitor in combination with UV-exposure on DNA damage in U87MG cells 
Representative images of immunofluorescence of phosphorylated histone H2AX in U87MG cells. Cells were treated with 0.1% DMSO (control) or 3 µM PRMT1/8 inhibitor for 
24 h, then exposed to 10 kJ/m2 UV-B. Cells were cultured for 1, 3 or 24 h post UV exposure before fixation and immunofluorescent labelling with γ-H2AX (red) and DAPI (blue). 
Scale bar in bottom right image is 20 μm and applies to all images.  
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Figure 4.19: The effect of PRMT1/8 inhibitor in combination with UV-exposure on DNA 
damage  
Box and whiskers plot showing the percentage of cells displaying γ-H2AX foci. Glial, SVG p12 (A), and 
glioblastoma, A172 (B), T98G (C) and U87MG (D) cells were treated with DMSO or 3 µM PRMT/8 inhibitor for 
24 h, followed by 10 kJ/m2 UV-B. Data are representative of 3 independent experiments. Data are shown as the 
range with the black horizontal lines indicating the median and error bars indicating the standard deviation. 
Outliers are plotted as individual points. Statistical analysis was performed using IBM SPSS 25 software, *p < 
0.05, **p <0.01, ***p < 0.001. Raw data are shown in Appendix 7.3.6. 
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 Discussion 
In this chapter, the chemical CID5380390, was used to inhibit PRMT1 and PRMT8 
simultaneously. The PRMT1/8 inhibitor was previously identified by high-throughput 
screening and its specificity was previously tested in vitro using radiolabelled S-adenosyl 
methionine (Dillon et al. 2012). To date, it has been used in E. grandis plants to determine 
the role of protein arginine methylation in root growth (Plett et al. 2017) however, there are 
no published reports of its use in mammalian cell lines. In the Piller lab, the PRMT1/8 
inhibitor has recently been used in the mouse neuroblastoma cell line, Neuro-2a to elucidate 
the role of PRMTs 1 and 8 in the methylation of CRMP and tubulins alpha and beta in 
neurons (Jwad 2015).  
 PRMT1/8 is Essential for Survival of Glial Cells but not for 
Glioblastoma Cells  
The original paper reported the use of the PRMT1/8 inhibitor at various concentrations, 
ranging from 0.3 to 100 μM, to test the effect on methyltransferase activity in a cell free 
system (Dillon et al. 2012). A concentration of 10 μM was first used on the glial, SVG p12, 
and glioblastoma, A172, T98G and U87MG, cell lines however, this caused extensive cell 
death across all cell lines. The cells were then treated with the PRMT1/8 inhibitor for 24 h at 
concentrations of 2, 3 and 4 μM. The concentration of 3 μM was chosen as the optimal 
concentration for use in further experiments as there were visible changes in asymmetric di-
methylation (Figure 4.3) indicating that the inhibitor was affecting PRMT1 and 8-mediated 
methylation.  The biggest decreases in asymmetric di-methylation were displayed in SVG p12 
cells, such as, the protein band at approximately 28 kDa and the band at approximately 
36 kDa. In the glioblastoma cell lines, there was an interesting effect where asymmetric di-
methylation of some proteins was decreased, while the asymmetric di-methylation of other 
proteins increased. An example of this is displayed in A172 cells with a decrease in 
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asymmetric di-methylation of the proteins at approximately 50 kDa and an increase in 
asymmetric di-methylation of the proteins at approximately 35 and 28 kDa. As the inhibitor 
acts by binding to an active cysteine residue contained only in the PRMT1 and 8 proteins 
(Weerapana et al. 2010), the increase in asymmetric di-methylation could be due to a 
feedback mechanism which upregulates PRMT1 and 8 protein levels to compensate for the 
inhibited PRMT 1 and 8 enzymes. It could also be due to the upregulation of other PRMTs to 
compensate for the lack of PRMT1 and 8 enzymatic activity. Dhar et al. (2013) reported a 
scavenging effect by Type II PRMTs following the knockdown of PRMT1 (a Type I PRMT), 
however it is also possible that other Type I PRMTs could fill in for PRMTs 1 and 8 by 
methylating PRMT1 and 8 substrates in their absence. 
The concentration of 3 μM was also considered optimal for use in these cell lines as the cell 
number was decreased in all cell lines except T98G (Figure 4.2A), and cell viability was 
affected only in SVG p12 cells which significantly decreased by approximately 30% after 24 h 
treatment (Figure 4.2B) and 40% following 48 h treatment (Figure 4.4B).  The viability of 
U87MG cells also significantly decreased by approximately 20% after 48 h treatment at a 
concentration of 3 μM (Figure 4.4B). This suggests that the inhibition of PRMTs 1 and 8 
caused a cytotoxic effect in SVG p12 cells and a cytostatic effect in the glioblastoma cell 
lines. Cytostasis is the reversible inhibition of cell growth and proliferation and while 
inhibition of cell growth also occurs with cytotoxicity, inhibition is followed by necrosis or 
apoptosis of cells (Korn et al. 2001). 
The cytotoxic effect of PRMT1 and 8 inhibition in SVG p12 cells is consistent with reports 
that PRMT1 null mice are unable to survive past embryonic day 6.5 (Pawlak et al. 2000). 
Additionally, PRMT1 knockdown cells had multiple hypomethylated proteins, leading to 
genomic instability, polyploidy (Yu et al. 2009) and increased resistance to apoptosis 
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(Sakamaki et al. 2011; Yamagata et al. 2008). This suggests that PRMT1 is important for 
cellular development and the proper function of apoptotic pathways.  
PRMT8 is reported to be exclusively expressed in neurons and absent in glioblastoma cells or 
expressed at much lower levels than in non-cancerous tissue (Simandi et al. 2014) and 
knockdown of PRMT8 correlated with the dysfunction of genes involved in the development 
of glioblastoma (Simandi et al. 2014). However, PRMT8 is clearly expressed in the cell lines 
studied in this thesis as evidenced by data presented in Chapter 3 (see Figure 3.9). U87MG 
cells have been reported to only express PRMT8 v2 and knockdown of PRMT8 caused the 
cells to cease proliferating (Hernandez & Dominko 2016). This may explain why U87MG cells 
were more sensitive (decrease in cell viability) to the effects of the PRMT1/8 inhibitor than 
the A172 and T98G cell lines. 
It is surprising that the PRMT1/8 inhibitor has little effect on T98G cells considering the 
importance of PRMT1 in cellular function. Cell number of T98G cells increased following 24 h 
treatment (Figure 4.2A and Figure 4.4A) with the inhibitor and there were no discernible 
changes in cell viability (Figure 4.2B and Figure 4.4B). This suggests that the T98G cells can 
overcome the effects of the inhibitor either by metabolising the inhibitor or overcoming its 
inhibitory effects. It is more likely, that the T98G cell line is not dependent on PRMT1 which 
is supported by the data presented in Chapter 3 (see Figure 3.9). Western blot analysis 
showed that T98G cells had significantly lower PRMT1 protein expression, while having 
higher PRMT8 protein (Figure 3.10) and RNA expression (Figure 3.11) than the non-
cancerous glial cell line, SVG p12. However, since the inhibitor only targets PRMT1 and 8, it 
may be another PRMT compensating for protein arginine methylation in these cells. 
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 Inhibition of PRMT1 and 8 Causes Cell Cycle Arrest in Glial and 
Glioblastoma Cells 
The observed cytostatic effect of the PRMT1/8 inhibitor on glioblastoma cells suggests the 
possible activation of a cell cycle checkpoint. This was tested using flow cytometry analysis 
on cells treated with 0.1% DMSO or 3 μM PRMT1/8 inhibitor for 24 or 48 h. SVG p12 (Figure 
4.5), A172 (Figure 4.6) and U87MG (Figure 4.8) cells were all significantly arrested in the S 
phase of the cell cycle following 24 h treatment with the PRMT1/8 inhibitor. Following 48 h 
treatment with the PRMT1/8 inhibitor, A172 cells still had the same percentage of cells 
arrested in the S phase (Figure 4.6) while there was a smaller percentage of SVG p12 cells 
arrested in the S phase (Figure 4.5). U87MG cells displayed a significant build-up of cells in 
the G2/M phase after 48 h treatment with the PRMT1/8 inhibitor (Figure 4.8). T98G cells 
were unaffected after 24 h treatment and displayed a significant arrest in the G2/M phase 
after 48 h treatment with the PRMT1/8 inhibitor (Figure 4.7).  
PRMTs have been implicated in the regulation of the cell cycle by methylating or associating 
with regulatory proteins of the cell cycle (Raposo & Piller 2018). Recent work has revealed 
that PRMT1 binds to the tumour suppressor, BGT2, to play a role in pre-B cell differentiation 
(Dolezal et al. 2017). The BGT2-PRMT1 complex destabilizes the binding of CDK4 to cyclin D3 
through the methylation of CDK4 at arginines 55, 73, 82 and 163, halting cell cycle 
progression and leading to pre-B cell differentiation (Dolezal et al. 2017). E2F1 is 
competitively methylated by PRMT1 and PRMT5 (Zheng et al. 2013). Methylation by PRMT1 
stabilizes E2F1 during DNA damage (Glorian et al. 2017) and assists in E2F1-dependent 
apoptosis (Zheng et al. 2013), while methylation by PRMT5 promotes cellular proliferation 
(Cho et al. 2012; Zheng et al. 2013). Interestingly, recent publications have brought to light 
the interplay between arginine methylation and serine phosphorylation, adding an extra 
layer of complexity to the regulation of the cell cycle. For example, methylation of p16 at 
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arginine 138 by PRMT1 increases as phosphorylation of p16 at serine 140 decreases, and 
vice versa in 293T cells (Lu et al. 2017). These modifications work antagonistically to regulate 
the interaction of p16 with CDK4 (Lu et al. 2017), thus regulating cell proliferation and 
apoptosis.  
There are currently no known cell cycle protein substrates or interacting partners for the 
other PRMTs.  
A172 cells expressed significantly more PRMT1 and PRMT8 protein compared to the normal 
glial cell line, SVG p12, while T98G cells expressed significantly less than SVG p12 cells (Figure 
3.10). T98G and U87MG cell lines all expressed up to 1.5-fold more PRMT8 than the SVG p12 
cells (Figure 3.10). PRMT1 and PRMT8 are highly homologous (Lee et al. 2005b) and it is 
possible that the upregulation of PRMT8 protein compensates for the lack of PRMT1 in T98G 
cells. This could explain the G2/M phase arrest observed in T98G cells 24 h after PRMT1/8 
inhibition. As mentioned previously, PRMT1 is essential for cellular development (Pawlak et 
al. 2000) and is the dominant type I PRMT (Tang et al. 2000), which suggests that the effect 
observed in SVG p12 and A172 cells treated with the PRMT1/8 inhibitor could be due mainly 
to the inhibition of PRMT1 in these cell lines. It is unclear which of PRMT1 or 8 produced the 
effect observed in U87MG cells. It is possible that the arrest in the S phase of the cell cycle 
observed after 24 h treatment with the PRMT1/8 inhibitor was caused by the inhibition of 
PRMT1 and the arrest in the G2/M phase of the cell cycle after 48 h treatment was caused by 
the inhibition of PRMT8. Alternatively, the U87MG cells could have overcome the inhibition 
of PRMT1 and the arrest in the G2/M phase of the cell cycle after 48 h treatment was simply 
due to the synchronised cycling of the cells following release from the S phase arrest. In this 
case, if extended timepoints were analysed by flow cytometry, it is likely that the cells would 
return to the G1 phase and continue to cycle as normal. 
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 PRMT1/8 Inhibition Interferes with the DNA Damage Response 
Considering the arrest of SVG p12, A172 and U87MG cells in the S phase of the cell cycle, it 
was hypothesised that the cause of the arrest could be due to either DNA damage or 
replication stress preventing the cells from progressing in the cell cycle.  
To determine if the S phase arrest induced by treatment with PRMT1/8 inhibitor was caused 
by DNA damage, the cells were treated with 0.1% DMSO or 3 μM PRMT1/8 inhibitor for 24 h. 
Cells were then exposed to 10 kJ/m2 UV-B and allowed to recover for 1, 3 or 24 h after 
exposure. Brightfield microscopy of the cells revealed cells that were treated with the 
inhibitor and exposed to UV had visibly fewer cells and appeared to have more rounded and 
detached cells than cells only exposed to UV. This was common across all cell lines (Figures 
4.10-4.13). Counting of trypan blue-stained cells with a haemocytometer also revealed 
significantly lower cell numbers in SVG p12 (Figure 4.14A) and U87MG (Figure 4.14G) cells 
treated with PRMT1/8 inhibitor and exposed to UV. SVG p12 cell numbers increased 24 h 
after UV exposure but only recovered to a number similar to inhibitor treated cells not 
exposed to UV (Figure 4.14A). A172 cell numbers (Figure 4.14C) followed the same pattern 
as SVG p12 cells however, this was not significant. The ability of the cells to recover in cell 
number after 24 h could be due to the PRMT1/8 inhibitor not having been replaced in the 
cell culture media at the time of UV exposure (24 h after initial treatment). This would allow 
the cells to either metabolise the inhibitor or overcome its effects, therefore allowing the 
cells to continue proliferating. T98G cells displayed little change in cell number with 
PRMT1/8 inhibitor treatment and UV exposure. 24 h after UV exposure, the cell viability of 
T98G (Figure 4.14F) cells was significantly lower in PRMT1/8 treated cells. The decrease in 
cell number combined with the stable cell viability indicates that treatment of the cells with 
the PRMT1/8 inhibitor for 24 h combined with UV exposure caused a cytostatic effect and 
only became cytotoxic 24 h after UV exposure. This is consistent with the results discussed 
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earlier and suggests that the different response of the T98G cells may be due to the low level 
of PRMT1 protein expression.  
The number of cells containing DNA damage foci in the UV exposed cells with and without 
PRMT1/8 inhibitor treatment was determined. There are many methods of quantifying γ-
H2AX positive cells. These include counting the number of foci per cell (Paull et al. 2000; 
Staszewski et al. 2008), visualising individual foci for colocalization studies (Momota et al. 
2003; Richard et al. 2008), counting the number of cells positive for γ-H2AX foci (Fernandez-
Capetillo et al. 2002; MacPhail et al. 2003; Soutoglou et al. 2007; Yuan & Chen 2010) and 
quantifying fluorescence intensity using microscopy (Oh et al. 2011) or flow cytometry 
(Huang & Darzynkiewicz 2006; Olive & Banáth 2004), all of which are valid methods. At a 
higher magnification, individual foci were visible within each cell (Appendix Figure 7.5B) 
however this method is time-intensive thus, it was decided to count the number of cells with 
foci present in order to be able to count a larger population of cells. 
Again, SVG p12 (Figure 4.15) and A172 (Figure 4.16) cells displayed similar responses with a 
significant increase in the percentage of cells displaying γ-H2AX foci in PRMT1/8 inhibitor 
treated cells exposed to UV when compared to untreated cells exposed to UV (Figure 4.19). 
U87MG cells (Figure 4.18) displayed a significant increase in the percentage of cells 
displaying γ-H2AX foci in PRMT1/8 inhibitor treated cells exposed to UV when compared to 
untreated cells exposed to UV although this was 16 and 46% lower than in SVG p12 and 
A172 cells, respectively (Figure 4.19). The percentage of γ-H2AX foci appears to correlate 
with the protein expression levels of PRMT1 in the glioblastoma cell lines. For example, A172 
cells had the highest expression of PRMT1 protein and the highest percentage of cells 
displaying γ-H2AX foci following PRMT1/8 inhibitor treatment, followed by U87MG cells 
while T98G cells had the least amount of PRMT1 protein and no response to UV. This 
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suggests that T98G cells are not dependent on PRMT1 for regulation of DNA damage repair 
pathways.  
The different response of SVG p12 and A172 cells (compared to T98G cells) supports the 
hypothesis that the effect observed was due to the inhibition of PRMT1 in these cells and 
that PRMT1 regulates DNA damage repair in these cell lines. The prolonged appearance of γ-
H2AX foci and the increase in foci in PRMT1/8 treated cells, compared to untreated cells, 
suggests that there was a delay in the repair of UV-induced lesions which is consistent with 
previous studies (Oh et al. 2011). This implicates PRMT1 in the regulation of DNA repair 
pathways in SVG p12 and A172 cells. It is unclear, at this stage, if U87MG cells are also 
dependent on PRMT1 regulation of DNA repair pathways as there was less of an observed 
effect in this cell line upon inhibition of PRMT1 and 8. 
The response of SVG p12 cells to UV exposure (decreased cell number, decreased cell 
viability after 24 h, and γ-H2AX foci) indicates that the DNA damage checkpoint is 
functioning as it is supposed to, however the response of A172 cells to UV exposure 
(decreased cell number, no decrease in cell viability and γ-H2AX foci) indicates that A172 
cells have a faulty DNA damage checkpoint as the cells can continue to proliferate without 
repairing the DNA damage or initiating apoptotic pathways, which is expected for cancerous 
cells. 
 DNA Damage Response to UV  
While UV-B irradiation (used in this study) does not directly induce DSBs, UV irradiation 
leads to the formation of DNA lesions, specifically cyclobutene pyrimidine dimers (CPDs) and 
6-4 pyrimidine photoproducts (Clingen et al. 1995). Both types of lesions cause bends in the 
DNA helix and can interfere with transcription, and therefore replication (Kim et al. 1995; 
Wang & Taylor 1991). Replication forks are unable to pass through the lesions, so DNA 
replication is inhibited. Lesions caused by UV are usually repaired by NER which involves 
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more than 30 proteins to successfully execute the repair (de Laat et al. 1999). Damage 
recognition by the XPC-hHR23B complex initiates NER (Sugasawa et al. 1998), while XPA and 
RPA bind to the damage site to form a pre-incision complex (He et al. 1995). Unwinding of 
the DNA helicase is performed by XPB, XPD and TFIIH (Araújo et al. 2001), followed by the 
removal of the lesion by XPG and XPF-ERCC1 (O'Donovan et al. 1994). Repair of the resulting 
gap occurs by DNA polymerase δ/ε and a DNA ligase, such as LIG1 (Nocentini 1999).  
NER is efficient at removing 6-4 pyrimidine photoproducts however, CPDs are repaired at 
lower rates (Tung et al. 1996) contributing to mutations in the genetic code (Garinis et al. 
2005). Unrepaired CPDs have been reported to be the major contributor to non-melanoma 
skin cancer (Jans et al. 2005). Unrepaired CPDs then lead to the collapse of the stalled 
replication forks forming single strand breaks (SSBs) or double strand breaks (DSBs) (Garinis 
et al. 2005) (see Figure 4.20). In response to DNA DSBs, histone H2AX is phosphorylated by 
the kinases ATM or ATR at serine 139 (γ-H2AX) (see Figure 4.20) (Helt et al. 2005; Rogakou et 
al. 1998). The detection of γ-H2AX in this study (Figure 4.15; Figure 4.16; Figure 4.18) 
indicates that the replication stress induced by UV-B exposure led to the formation of DSBs 
hence, triggering DNA repair pathways other than NER. DSBs are recognised by Ku70/Ku80 in 
the NHEJ repair pathway (Truong et al. 2013) while γ-H2AX foci are localised around DSBs in 
HR reviewed by (Roos & Kaina 2013; Thiriet & Hayes 2005), thus the presence of γ-H2AX foci 
indicate the activation of the HR pathway in this study. HR is also preferentially activated in S 
phase cells following the collapse of stalled replication forks during DNA replication (Jazayeri 
et al. 2006). NHEJ activation or lack thereof, could be determined by using an antibody for 
Ku70/Ku80 or by the EJ5-GFP vector assay (Bennardo et al. 2008), which measures NHEJ-
mediated repair, to confirm the dominant repair pathway occurring in this scenario.  
As mentioned previously, repair of stalled replication forks forming DSBs is preferentially 
facilitated by HR (Jazayeri et al. 2006). In response to DSBs, ATM or ATR phosphorylate H2AX 
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at serine 139 (γ-H2AX) (Helt et al. 2005; Rogakou et al. 1998). γ-H2AX signals the recruitment 
of the MRN complex (made up of the proteins MRE11, RAD50 and Nijmegen Breakage 
Syndrome 1 (Nbs1)) to the site of damage (Paull et al. 2000). Phosphorylation of ATM by 
Nbs1 then recruits ATM to the DNA damage site (Dupre et al. 2006) and in doing so, 
activates the checkpoint response (Girard et al. 2002).  
The effector kinases, Chk1 and Chk2 inhibit the Cdc25 protein family which in turn inhibits 
the CDK2/cyclin A complex, leading to S phase arrest of the cell cycle (Sørensen et al. 2004). 
Chk1 and 2 also activate p53 by phosphorylation (Shieh et al. 2000) to activate p21 (el-Deiry 
et al. 1993), thus halting the cell cycle until the DNA damage can be repaired. p53 can then 
promote DNA repair, apoptosis or senescence by activating or inhibiting proteins in the 
appropriate pathway (Meek 2004)(see Figure 4.20).  
The fact that UV-B irradiation does not directly induce DSBs immediately could explain why 
there was an observed delay in γ-H2AX foci appearance in this study. The mean percentage 
of cells with γ-H2AX foci peaked 24 h after UV-B exposure (Figure 4.19) compared to γ-H2AX 
peak fluorescence 30 mins after exposure to ionizing radiation (Paull et al. 2000) which 
cleared within 24 h of exposure (Clarke et al. 2017). It has also been reported that γ-H2AX 
foci are only induced in cells that are in the S phase or transition into the S phase during the 
treatment time due to the induction of DSBs at DNA lesions during DNA replication 
(Staszewski et al. 2008). This would also suggest that the percentage of cells observed with 
γ-H2AX foci would be limited by the percentage of cells in the S phase in SVG p12, A172 and 
U87MG cells. However, SVG p12 cells had a mean of 60%  and 61% of cells in the S phase 
after 24 and 48 h treatment with the PRMT1/8 inhibitor (Table 4.1), respectively, and 40% of 
cells were observed to display γ-H2AX foci 24 h after UV exposure (Figure 4.19). A172 cells 
displayed the highest mean percentage of cells with γ-H2AX foci (69%)(Figure 4.19), yet only 
30.8% of cells were in the S phase (Table 4.1), while 54% and 34% of U87MG cells were in 
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the S phase 24 h and 48 h after PRMT1/8 inhibitor treatment (Table 4.1) and only 23% cells 
were observed to display γ-H2AX foci 24 h after UV exposure (Figure 4.19). This would 
suggest that the number of cells displaying γ-H2AX foci were not limited by the percentage 
of cells in the S phase of the cell cycle. Although γ-H2AX foci induction was reported to be 
lower in non-S phase cells, γ-H2AX fluorescence was extremely dose-dependent and 
fluorescence levels differed between cell lines (Halicka et al. 2005; Zhao et al. 2010) which is 
consistent with the results presented here.  
PRMT1 has been implicated in the regulation of DNA repair pathways (Revied by Raposo & 
Piller 2018)). Arginine methylation of Heterogeneous Nuclear Ribonucleoprotein U-Like 1 
(hnRNPUL1) by PRMT1 regulates recruitment of hnRNPUL1 to sites of DNA damage and also 
regulates the interaction of hnRNPUL1 with Nbs1 (Gurunathan et al. 2015). PRMT1-deficient 
cells have an impaired ability to recruit Rad51 to DNA damage sites, causing chromosome 
instability (Yu et al. 2009). PRMT1 also regulates activity of DNA polymerase β by 
methylation of arginine 137 within the PCNA binding site (El-Andaloussi et al. 2007). This 
prevents the binding of DNA polymerase β and PCNA, implicating PRMT1 in the regulation of 
BER.  
PRMT1 is also implicated in HR regulation as methylation of MRE11 and p53 binding protein 
(53BP1) by PRMT1, regulates their DNA exonuclease activity (Boisvert et al. 2005c; Dery et 
al. 2008) and localisation to DNA damage sites (Boisvert et al. 2005a), respectively. Cells 
deficient in MRE11 displayed dramatic chromosomal instability (Buis et al. 2008) and MRE11 
knockdown cells were arrested in the S phase during DNA replication (Boisvert et al. 2005b). 
Patient-derived cells with MRE11 mutations leading to reduced levels of active MRE11 (A-
TLD), had reduced levels of ATM-mediated phosphorylation of p53 and Chk2 as the MRN 
complex is required for the proper activation of ATM (Uziel et al. 2003). As low levels of p53 
activate the transcription of p21 to induce cell cycle arrest while higher levels of p53 activate 
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pro-apoptotic genes (Chen et al. 1996), it is possible that the observed S phase arrest and 
the lack of cell death characterised by the consistently high viability of A172 and U87MG 
cells, were caused by the reduced phosphorylation of p53 and Chk2 (Figure 4.20). However, 
this would need to be confirmed experimentally using antibodies targeting phosphorylation 
of p53 or Chk2. In SVG p12 cells, large numbers of cells experienced cell death (Figure 4.2) 
when treated with the PRMT1/8 inhibitor. It is possible that as foetal glial cells, SVG p12 cells 
require PRMT1 activity for the methylation of different substrates compared to the 
glioblastoma cell lines, which were all derived from adult tumours (Table 2.2), and this may 
be the reason for the activation of cellular death pathways in SVG p12 cells. 
Therefore, it is likely that inhibition of PRMT1/8- mediated methylation may indirectly arrest 
the cell cycle due to the dysregulation of the DNA repair protein, MRE11, leading to the 
activation of the S phase checkpoint and the observed S phase arrest.  
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Figure 4.20: Cellular response to UV-induced DNA damage in normal and PRMT1 inhibited 
cells 
UV irradiation cause cyclobutene pyrimidine dimers (CPD lesions). If CPDs remain unrepaired they can cause 
replication forks to collapse during DNA replication leading to DNA double Strand breaks (DSBs). In normally 
functioning cells, histone H2AX (orange) is phosphorylated in response to DSBs and acts as a signal for the MRN 
complex (brown) and ATM (red) to localise at the damage site. Activation of ATM by MRN-mediated 
phosphorylation activates cell cycle arrest via p53 (green) and Chk1/2 (yellow), apoptotic pathways via p53 or to 
homologous repair (HR) via BRCA1/2, 53BP1 and Rad51. In PRMT1-inhibited cells, the MRN complex fails to 
localise to sites of DNA damage. The self- phosphorylated ATM is only partially activated and localises to the 
DNA damage site but is not efficient at phosphorylating p53 and Chk1/2. Low levels of p53 and Chk1/2 are 
sufficient to arrest the cell cycle, however DNA repair and apoptotic pathways are not activated. Yellow circles 
with “M” indicate arginine methylation, the dark blue circles with “P” indicate phosphorylation and red crosses 
indicate DSBs.  
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 The NER Response to UV may be Upregulated in T98G Cells 
Interestingly, T98G cells displayed little to no response to UV-B exposure (Figure 4.17). The 
highest percentage of cells displaying γ-H2AX foci was 5% which was 3 h following UV 
exposure in PRMT1/8 treated cells. Numerous studies have previously used γ-H2AX foci as a 
DNA damage marker in T98G cells, indicating that this signalling pathway is active in this cell 
line (Burdak-Rothkamm et al. 2006; Peña-Rico et al. 2011). T98G cells have increased mRNA 
and protein expression of the NER repair protein, ERCC1, than other glioma cell lines which 
correlated with the resistance of T98G cells to radiation (Liu et al. 2009). This could mean 
that T98G cells are more effective in repairing CPD lesions through the NER pathway or are 
more efficient at replicating DNA despite the CPD lesions. This would lead to the collapse of 
fewer replication forks and thus, fewer DSBs would be induced. With fewer DSBs, there 
would also be less phosphorylation of histone H2AX, as observed in Figure 4.17. This 
indicates that the T98G cell line may have faulty DNA damage checkpoint activation as cells 
are continuously replicating despite lesions and mutations being present.  
T98G cells are known to have mutations and deletions in cell cycle and DNA repair pathways, 
including P1819S mutation in BRCA2, R138T mutation in Cyclin A2, p16 and p14 deletions, 
L42R mutation in PTEN; and M237I and M144I mutations in p53 ((Forbes et al. 2017), 
http://cancer.sanger.ac.uk, accessed 9 October 2017). M144 and M237 of p53 are located 
within the core domain which is the DNA binding domain of p53 (Bista et al. 2012) and 
acetylation within the DNA binding domain is required for activation of p53 (Gu & Roeder 
1997). Studies have found that cells with mutations of p53 within the DNA-binding domain 
are unable to bind DNA (Kern et al. 1992) and are less efficient in triggering apoptosis (Clarke 
et al. 1993; Roos et al. 2007). Furthermore, p53-null glioblastoma cells were not affected by 
drugs targeting histone deacetylases or lysine demethylases (Chandra 2016), suggesting that 
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p53 may act as a biomarker to predict the response of glioblastoma tumours to 
chemotherapy drugs. 
The mutations of p53 could explain why T98G cells continued to proliferate following 
treatment with the PRMT1/8 inhibitor (Figure 4.2; Figure 4.4) when the other cell lines were 
affected in a cytotoxic (SVG p12 cells; (Figure 4.2; Figure 4.4) or cytostatic manner (A172 and 
U87MG cells; (Figure 4.2; Figure 4.4). This suggests that the PRMT1/8 inhibitor would not be 
a suitable drug for the treatment of glioblastoma tumours with p53 mutations, as apoptotic 
pathways are unable to be activated via p53. A drug targeting p53-independent apoptotic 
pathways may be a better candidate for the treatment of glioblastoma with p53 mutations 
or deletions, such as in the T98G cell line, making them an important cell line for screening 
potential novel anti-cancer drugs. 
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5 Final Discussion 
Protein arginine methylation is a post translational modification that plays important roles in 
cellular signalling (Bedford & Clarke 2009), transcription (Carr et al. 2015; Cheng et al. 2007) 
and RNA splicing (Hadjikyriacou et al. 2015) and transport (Pahlich et al. 2006). Aberrantly 
expressed PRMTs have been reported in a variety of cancers, including breast (Oh et al. 
2014; Zhong et al. 2014), lung (Gu et al. 2012a), bladder (Gu et al. 2012a), prostate (Hong et 
al. 2004), ovarian (Bao et al. 2013) and mantle cell lymphoma (Pal et al. 2007). It has become 
evident that arginine methylation is also a regulator of the cell cycle (Raposo & Piller 2018) 
and aberrant expression of PRMTs contributes to deregulation of the cell cycle, contributing 
to carcinogenesis. 
In this thesis, it was discovered that although there were differences in the asymmetric and 
symmetric dimethylation of individual proteins, there were no visibly obvious differences in 
the overall level of methylation between the glial and glioblastoma cell lines (Figure 3.1). 
This was interesting considering there were increases in the protein expression of the 
individual PRMTs in the glioblastoma cell lines when compared to the non-cancerous glial 
cell line (Figure 3.9 & Figure 3.10). Protein expression of PRMTs 1, 2, 5, 6 and 8 were all 
upregulated in A172 cells, PRMTs 5, 6 and 8 were upregulated in U87MG cells and PRMTs 5 
and 6 were upregulated in T98G cells. It was expected that the overexpression of PRMTs 
would be a compensation for the lack of other PRMTs in the cells, but this was not the case 
with only A172 and T98G cells having less protein expression of PRMT3 and PRMT1, 
respectively. Hence, it may not be the aberrant expression of the PRMTs themselves that 
leads to deregulation of the cell cycle, but it may be that the proteins, or even amino acid 
residues, being methylated are different to the proteins that are methylated in a non-
cancerous state. Instead of their methyltransferase activity, PRMT upregulation may be 
important for other functions within the cell. For example, PRMT8 mediates neuronal axon 
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outgrowth by acting as a phospholipase in phosphatidylcholine metabolism pathways which 
is essential for proper neurological function (Kim et al. 2015a). 
 During the optimisation of the qRT-PCR conditions, sequencing of PCR amplicons for 
individual PRMTs was carried out to determine if the correct product was being amplified 
(section 2.11). Some of the returned sequences matched the expected sequence perfectly 
and some did not match the expected sequence at all so new primers were used for 
following qPCR reactions. The sequence obtained for the PRMT1 amplicon from U87MG cells 
did match the expected sequence, however, it contained single base mutations of T96C and 
G108A (Appendix 7.3.8; Figure 7.15). Upon further analysis, these mutations were found to 
be in a non-coding region of PRMT1 (Katsanis et al. 1997), and hence not affected the 
resulting RNA or protein sequence. Therefore, these results were not included in Chapter 3 
as the mutations were not relevant at the protein level. However, this does highlight that 
PRMTs, like other proteins, are susceptible to mutations in cancer cells and it is possible that 
mutations in the overexpressed PRMTs may prevent them from being active. So, while there 
were higher protein levels of the PRMTs, this does not necessarily mean the proteins were 
enzymatically active and it does not necessarily result in more detectable methylation. It is 
also possible that mutations in the PRMTs may change the specificity of the PRMTs, causing 
them to methylate alternative protein substrates or residues and thus affecting the binding 
or activity of the protein substrate. Further, mutations in the PRMTs may interfere with the 
affinity of the antibody binding and could result in increased or decreased binding to the 
PRMT. This is more likely to occur in the case of monoclonal antibodies than in the case of 
the polyclonal antibodies used in this thesis. 
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The mass spectrometry analysis identified proteins with methylated arginine residues (Table 
3.1). As discussed in chapter 3, 79% of the arginine residues were identified to be 
monomethylated and this could have been due to incomplete cleavage at dimethylated 
arginine residues by trypsin digestion. However, PRMT7 has been proposed to only catalyse 
monomethylated arginine residues (Zurita-Lopez et al. 2012), which is an intermediate of 
both Type I and II PRMTs. As the protein and RNA expression levels of PRMT7 were not 
characterised in this thesis, it is possible that PRMT7 is responsible for methylating some of 
the residues identified to be monomethylated. However, it has also been reported that 
PRMT7 is a Type II PRMT, catalysing the symmetric dimethylation of arginine residues (Lee et 
al. 2005a). Hence, it is also possible that the monomethylated residues detected are actually 
dimethylated but were in the intermediate state at the time of cell lysis.  
In this thesis, a novel inhibitor of PRMTs 1 and 8 was used to determine the effect of 
PRMT1/8 inhibition in glial and glioblastoma cells. It was discovered that the PRMT1/8 
inhibitor had a cytotoxic effect on non-cancerous glial cells at 3 μM but a cytostatic effect on 
glioblastoma cells at the same concentration (Figure 4.4). The PRMT1/8 inhibitor caused an 
arrest in the S phase of the cell cycle in all the cell lines except in the T98G cells (Figure 4.9). 
The S phase arrest was hypothesised to be caused by the activation of the intra-S checkpoint 
due to DNA damage. The DNA damage repair proteins, MRE11 and 53BP1, are known 
substrates of PRMT1 (Boisvert et al. 2005a; Boisvert et al. 2005b) and it was hypothesized 
that the inhibition of methylation of MRE11 and 53BP1 would prevent DNA damage repair 
thus activating the intra-S checkpoint. Cells treated with the PRMT1/8 inhibitor were more 
sensitive to UV exposure and took longer to recover in cell number (Figure 4.14 & Figure 
4.19). This suggests that the PRMT1/8 inhibitor may be a potential cancer treatment, if used 
in combination with existing chemotherapy agents that cause DNA damage. However, due 
to the cytotoxic effect of the PRMT1/8 inhibitor in non-cancerous cells, treatment of cancer 
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with the PRMT1/8 inhibitor would need to be targeted specifically and exclusively to the 
tumour site. For example, intraoperative chemotherapy may be a suitable method of 
delivering the PRMT1/8 inhibitor to the tumour site. Degradable polymers in the form of 
wafers have been approved by the FDA to be implanted into the tumour cavity during 
surgery for the delivery of the drug carmustine, which has improved the survival of 
glioblastoma patients (Lefranc et al. 2009). This method could also be harnessed for other 
drugs, such as the PRMT1/8 inhibitor alone or in combination, to target recurrences near the 
tumour resection site and protect healthy tissue from harmful side effects. 
 Implications for Cancer Treatment 
PRMT1 (Baldwin et al. 2015; Mathioudaki et al. 2008), PRMT2 (Zhong et al. 2012), PRMT4 
(Ohkura et al. 2005), PRMT5 (Sohail et al. 2015), PRMT7 (Gros et al. 2006), and PRMT8 
(Hernandez & Dominko 2016) have been reported to have isoforms with differing subcellular 
locations and are expressed in different cancer types (Baldwin et al. 2014). Although Baldwin 
et al. (Baldwin et al. 2014) speculate that the cancer-specific isoforms may have different 
substrates, this is based on the different localisations of the isoforms which would allow 
access to different substrates (Baldwin et al. 2014). It is currently unknown if these isoforms 
behave differently in their substrate-specificity or their activity. These cancer-specific PRMT 
isoforms could be targets for future anti-cancer drug development. Drugs could potentially 
target the aberrant isoforms in cancerous cells without affecting the other isoforms required 
for normal cell function. 
The opportunity may further exist to use PRMT inhibitors in combination with classic 
chemotherapy drugs.  The currently widely used chemotherapy drug Taxol (Paclitaxel) binds 
to tubulin-β, causing stabilisation of microtubules during mitosis and inhibiting cell division 
(Parness & Horwitz 1981). Recently, protein arginine methylation in the Taxol-binding region 
of tubulin-β was proposed to affect the binding ability of the drug (Piller et al. 2015). This 
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could pave the way for the use of methylation inhibitors as a parallel treatment with Taxol. 
Inhibiting arginine methylation of tubulin-β would allow Taxol full access to the tubulin-β 
binding site to inhibit cell division in a cancer- targeted therapy. Alternatively, Taxol 
derivatives that bind with higher affinity to methylated tubulin may be developed. 
PRMT inhibitors could also be used in combination with chemotherapy drugs to combat 
chemoresistance. There are multiple known pathways of chemoresistance (Reviewed by Pan 
et al. 2016)). Activation of the NF-κB pro-inflammatory pathway can activate the production 
of anti-apoptotic proteins resulting in tumour growth (Chen et al. 2007); polymorphisms in 
ATP-binding cassette (ABC) multidrug efflux pumps can prevent drugs from crossing the 
blood-brain barrier and even pump drugs back out of target cells (Sharom 2008); or DNA 
repair pathways can be upregulated to repair damage caused by DNA-damaging drugs 
(Itamochi et al. 2008; Soengas & Lowe 2003). As discussed previously, PRMT1 methylates or 
associates with DNA repair proteins and in many cases, this regulates or enhances the 
binding of DNA repair proteins to the damage sites (Boisvert et al. 2005a; Boisvert et al. 
2005c; El-Andaloussi et al. 2007; El-Andaloussi et al. 2006; Guo et al. 2010; Gurunathan et al. 
2015; He et al. 2011). An inhibitor targeting PRMT1 could be used to disrupt the binding of 
DNA repair proteins to the DNA damage sites, thus preventing cancer cells from evading 
apoptosis. This treatment would need to be delivered in a tumour-targeting vector as 
PRMT1 knockdown is known to be embryonically lethal (Yu et al. 2009) and would also be 
damaging to non-cancerous cells. 
Other drugs should be looked at with the possibility of combinatorial cancer therapies. As 
discussed previously, PRMT5 interacts with CDK4 to regulate pRb/E2F-mediated 
transcription. Knockdown of PRMT5 made HepG2 cells more sensitive to the CDK4 inhibitor 
fascaplysin (Yang et al. 2016). While this is a promising study, fascaplysin has only been used 
on cell lines (Chen et al. 2017; Hamilton 2014; Lu et al. 2009; Segraves et al. 2004), and 
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would require further study in order to be used for cancer therapy. PD0332991 (Palbociclib), 
was the first CDK4/6 inhibitor to be approved for cancer therapy. It is used in the treatment 
of pRb positive breast cancer (DeMichele et al. 2015), mantle cell lymphoma (MCL) (Leonard 
et al. 2012), and liposarcoma (Dickson et al. 2013). This CDK4 inhibitor may also be a 
potential candidate for combination therapy with PRMTs. An earlier study showed that 
knockdown of PRMT7 sensitised HeLa cells to the DNA topoisomerase I inhibitor 
Camptothecin, although the authors did not investigate the mechanism of how this occurs 
(Verbiest et al. 2008). PRMT7 does not have many known substrates and its PRMT type 
status has been a controversial topic in the past with some earlier studies claiming it to be a 
type II PRMT (Lee et al. 2005a), while others proposed it to be a type III PRMT (Zurita-Lopez 
et al. 2012). Further research on the exact mechanism of methylation by PRMT7 is required 
before it can be considered as a target for combinatorial therapy.  
As mentioned previously, PRMTs are often overexpressed in cancers, leading to aberrant 
methylation patterns.  Inhibitors of arginine methylation may be useful to treat tumours by 
correcting increased levels of protein methylation which may deregulate the cell cycle, DNA 
damage repair and other important cellular functions. Arginine methyltransferase inhibitor- 
1 (AMI-1), inhibits the coactivator function of PRMTs (Bedford & Richard 2005) while AdOx 
inhibits S-adenosyl homocysteine hydrolase preventing methylation from occurring by a 
negative feedback mechanism (Pahlich et al. 2006). Although AdOx does not inhibit PRMTs 
directly, several studies have shown that treatment of cell lines with high concentrations of 
AdOx induces a G2/ M phase arrest of the cell cycle (Dasgupta et al. 2008; Heit et al. 2009; 
Schwerk & Schulze-Osthoff 2005).  Inhibition of methylation with AdOx also showed a similar 
decreased growth rate and reduced migration activity when compared to PRMT1 
knockdown cells (Chuang et al. 2017). This may be useful in treating tumours, if the 
inhibition of methylation by AdOx can be targeted towards tumour cells only. However, 
    160 
AdOx also causes a decrease in DNA, RNA and lysine methylation, thus further studies would 
be required to determine its suitability for treatment in vivo as well as the actual role of 
DNA, RNA and lysine methylation in cancer development. It is likely that AdOx is simply a 
cytotoxic compound rather than a selective chemotherapy drug, as the side effects of global 
methylation inhibition by AdOx would be far worse than the potential therapeutic outcomes. 
Other non-specific PRMT inhibitors have been identified- MS023 binds to the active site of 
type I PRMTs (Eram et al. 2016); while DS-437 acts on PRMTs 5 and 7 (Smil et al. 2015) and 
MS049 acts on PRMTs 4 and 6 (Shen et al. 2016). Inhibitors which are more specific to 
individual PRMTs would be preferential for combinatorial cancer therapy to minimise 
potential off-target effects. Promising specific PRMT inhibitors will be discussed below and 
have recently been reviewed (Hu et al. 2016). 
PRMT1, being the most abundant PRMT (Tang et al. 2000), has been the target of the 
majority of PRMT-specific inhibitor development. However, it has been historically difficult 
to generate type I PRMT inhibitors due to the sequence homology between the PRMTs and 
the dependence of the cells on type I enzymes such as PRMT1. Cyanine-derivative 
compounds have been synthesized based on the structure of AMI-1, such as E-84 which 
preferentially binds to PRMT1 over other PRMTs and has been demonstrated to decrease 
leukemia cell proliferation (Hu et al. 2015). As investigated in this thesis, the PRMT1 and 8 
inhibitor identified by Dillon et al. (Dillon et al. 2012) may be a potential treatment for 
PRMT1-dependent cells, if it can be applied to the tumour in a targeted manner. 
The PRMT5-specific inhibitor, EPZ015666 (GSK3235025), inhibited growth in a panel of five 
mantle cell lymphoma (MCL) cell lines and inhibited tumour growth in a dose-dependent 
manner in MCL xenograft models (Chan-Penebre et al. 2015). The inhibitor structure was 
altered and renamed EPZ015938 and entered phase I clinical dose-escalation trials in 2016 as 
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compound GSK3326595 for the treatment of solid tumours and non-Hodgkin’s lymphoma 
(NCT02783300) (Castillo-Aguilera et al. 2017). 
More specific inhibition of individual methylated residues with peptide or small molecule 
inhibitors will present fewer side effects and will be the most likely successful design of 
personalised cancer treatment of the future. In line with this, a recent review discussed first-
generation inhibitors of arginine methylation currently in pre-clinical or phase I/II clinical 
trials (Hamamoto & Nakamura 2016). 
An important observation in this thesis was the large unexpected variability between the 
three glioblastoma cell lines. This variability raises the issue of studies using only one cell line 
and, while the results may be accurate for the cell line studied, the results may not reflect 
other cell lines or cancers of the same cancer type due to differences in the individual 
patient’s cancer. More urgency is required to develop personalised cancer treatment where 
cancer cells taken at the time of biopsy are sequenced to determine the mutations present 
in key genes or proteins, allowing for a treatment regime to be tailored to the patient’s 
particular cancer mutations. This would require a clear and detailed understanding of all 
cellular regulatory pathways involved in cell cycle, metabolism and cancer in all tissue/cell 
types which is far from being available and research efforts should focus on establishing and 
collating that information as a priority for all disease treatment in the future. 
 Future Directions 
Protein arginine methylation should be further investigated regarding its role in 
carcinogenesis, especially in brain cancers such as glioblastoma, which are notoriously 
difficult to treat.  
It was mentioned in Chapter 3, that differences in protein or RNA expression between the 
SVG p12 (control) cells and the glioblastoma cell lines may have been due to the SVG p12 cell 
line being derived from foetal glial cells, while the glioblastoma cell lines were derived from 
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adult tumours. To explore this, non-tumorigenic glial cells could be isolated from adult mice 
and the expression compared to glioblastoma mouse models, such as the PDGFB model 
which has deletions in the p53, p14 and p16 genes (Miyai et al. 2017).  
Using mass spectrometry analysis with alternative digestive enzymes would be useful to 
detect different peptides and further identify methylated arginine residues not detected in 
this study. The mass spectrometer used in this study is considered an older model with 
lower sensitivity than more recent models, hence the use of a newer model of mass 
spectrometer would allow for a higher sensitivity and therefore the detection of less 
abundant peptide fragments, leading to the detection of proteins which are lower in 
abundance. Since completing the experimental component of this thesis, the Mass 
Spectrometry Facility at Western Sydney University has invested in a new mass 
spectrometer and new software, Progenesis Q, which has a higher sensitivity and is able to 
analyse the expression levels of proteins in the sample. This could be used as another 
method of characterising the expression level of the PRMTs, or other proteins of interest, to 
complement the data already obtained by Western blotting. 
The proteins identified as methylated by mass spectrometry analysis should be further 
investigated with regards to the significance of the methylation. The arginine residues of 
tubulin β implicated in neuronal syndromes, as discussed earlier, could be further 
investigated by altering the amino acid residue using site-directed mutagenesis. Studies 
found that altering the amino acid residue changed the localisation of the tubulin subunit or 
affected its ability to form heterodimers with tubulin α (Poirier et al. 2010; Tischfield et al. 
2010). Changing the arginine residue to a lysine residue, which can also be methylated, or to 
an alanine would determine if it is the positive charge of the arginine residue or the 
methylation of the residue that is required for the proper functioning of tubulin. If the 
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methylation of the residue is important, the lysine residue could still be methylated by lysine 
methyltransferases and detected as methylated using mass spectrometry. 
The arginine methylation of Mortalin should be further investigated to determine if 
methylation affects the binding of Mortalin with p53. As Mortalin and p53 are binding 
partners, co-immunoprecipitation of Mortalin from a p53 column, and vice versa, in cells 
treated with various methylation inhibitors would determine if methylation plays a role in 
the binding of Mortalin and p53.  
Protein arginine methylation should also be further investigated regarding its role in the DNA 
damage response. Future work in this area should focus on determining if PRMT1 or PRMT8 
are responsible for the observed effects seen in this study. Although, it was suggested earlier 
in this thesis that PRMT8 was responsible for the effects observed in T98G cells and PRMT1 
is responsible for the effects observed in the other cell lines, it would be beneficial to 
confirm this hypothesis. One way of confirming this would be to independently knock down 
PRMT1 and PRMT8 using siRNA and perform cell cycle analysis using flow cytometry. If this 
hypothesis is correct, PRMT1 knockdown would be expected to cause an S phase arrest of 
the cell cycle while the PRMT8 knockdown should cause a G2/M phase arrest of the cell 
cycle. However, knockdown of any PRMT, and in particular knockdown of the most 
dominant type I PRMT, PRMT1, would lead to alterations in expression of the other PRMTs 
in order to compensate for the knockdown. In the Piller and Plett laboratory, it has 
previously been observed in a variety of cell, tissues and species that inhibition of PRMTs can 
lead to the upregulation of protein levels of other PRMTs, making the study of PRMT effects 
and the interpretation of the results not always straight forward. Most published studies 
have not discussed this or checked the expression of other PRMTs after knockdown or 
knockout of a specific PRMT, and this should be performed in knockdown/out studies. 
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Further studies should also be performed to confirm the effect of the PRMT1/8 inhibiter on 
DNA repair pathways. MRE11 protein from control and inhibitor treated cells could be 
immunoprecipitated (IP) and then Western blotted using the ASYM24 or SYM10 antibodies 
to determine how the levels of methylation change following treatment with the PRMT1/8 
inhibitor. The MRE11 eluate should also contain Rad50 and Nbs1 (as these proteins form the 
MRN complex with MRE11) and as the protein lysates are not denatured prior to IP, Rad50 
and Nbs1 should co-IP with MRE11. The IP elutions from control and inhibitor-treated cells 
could then be silver stained following SDS-PAGE to determine if the PRMT1/8 inhibitor 
influences the complex formation of MRE11 with Rad50 and Nbs1. Similar studies could also 
be performed on 53BP1 and other PRMT1 substrates involved in DNA repair pathways.  
The work performed in Chapter 4 could be repeated using the PRMT1/8 inhibitor in 
conjunction with a chemotherapy drug that induces DNA damage, such as etoposide or 
temozolomide, to further elucidate the regulation of the DNA damage response mediated by 
PRMT1.  
Testing the PRMT1/8 inhibitor on cells in a chemotherapy-resistant model could determine if 
the PRMT1/8 inhibitor is a viable drug for combination cancer therapy or if PRMT1 or PRMT8 
are viable targets for cancer therapy. Exposing cells to low doses of DNA damage-inducing 
cancer drugs, over a long period of time would cause the cells to develop pathways of 
resistance to continue proliferating in the presence of the drug. For example, U87MG grown 
in low concentrations of cisplatin, developed resistance to the DNA crosslinks induced by 
cisplatin, allowing the study of cisplatin in combination with other chemotherapeutic drugs 
(Servidei et al. 2001). This should be performed with drugs currently used in the treatment 
of glioblastoma, such as, etoposide or temozolomide. Treatment with the PRMT1/8 inhibitor 
or targeting PRMT1 and/or PRMT8 specifically could prevent DNA repair proteins from being 
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able to exert their repair activity and therefore, sensitise cells to DNA damage-inducing 
chemotherapy drugs.   
 Conclusion 
This thesis characterised protein arginine methylation and the expression of PRMTs in glial 
and glioblastoma cell lines and found there to be an increased protein expression of PRMTs 
1, 5, 6 and 8 in glioblastoma cells compared to the normal glial cells. Several proteins were 
identified to contain differentially methylated arginine residues between the four cell lines. 
Among these proteins, methylated arginine residues identified in tubulin and Mortalin have 
previously been reported to be functionally important in neurological malformations or 
disorders and cancer development, respectively, confirming that arginine methylation is an 
important regulator of cellular function. 
The effect of PRMT1 and 8 inhibition in glial and glioblastoma cell lines was investigated and 
the PRMT1/8 inhibitor was found to be cytotoxic to normal glial cells but cytostatic to 
PRMT1-dependent glioblastoma cells. The PRMT1/8 inhibitor also sensitised PRMT1-
dependent cells to UV exposure, suggesting that PRMT1 may be a therapeutic target in 
combination with DNA damaging chemotherapy agents. Further investigation into PRMT1 as 
a therapeutic agent may lead to the discovery of novel drugs that can be used for cancer 
treatment. 
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Figure 7.1: Email correspondence from Public Health England regarding U87MG cell line 
The U87MG cell line used in current research studies was reported to differ from the cell originally isolated and 
deposited to the ATCC as U87MG. Correspondence from Public Health England indicates the U87MG cell line is 
still a glioblastoma cell line. 
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Table 7.1: Raw data for calculating primer efficiency (Table 2.4) 
 
 
 
Figure 7.2: Standard curves generated from slopes of primer sets in Table 2.4. 
The efficiency of the primer pairs was assessed by plotting the cycle threshold value (CT) at each cDNA 
concentration against the logarithm of the fold dilution of the sample. The slope of a linear-regression trendline is 
indicative of primer efficiency. 
  
cDNA dilution 
(1:5)
0.2 0.04 0.008 0.00016 0.000032 0.0000064
Log starting 
quantity
-0.7 -1.4 -2.1 -3.8 -4.5 -5.2
Primer Set Cт Mean Cт Mean Cт Mean Cт Mean Cт Mean Cт Mean Slope R2 Efficiency %
PRMT1 33.09 34.04 33.76 35.71 34.89 33.95 -0.301 0.348 0.336 33.552
PRMT2 27.38 28.62 30.31 31.52 33.07 33.78 -1.365 0.975 0.854 85.351
PRMT3 23.55 25.58 27.75 30.60 31.24 33.44 -2.045 0.980 0.902 90.219
PRMT4 23.23 25.26 27.84 29.94 32.46 33.14 -2.154 0.974 0.907 90.716
PRMT5 21.66 23.73 25.99 28.43 31.09 34.69 -2.617 0.964 0.910 91.049
PRMT6 28.66 30.80 33.11 34.54 34.51 36.94 -1.565 0.913 0.872 87.220
PRMT8 33.47 32.86 35.85 33.16 33.22 34.10 0.019 0.001 11.573 1157.282
β-actin 15.44 18.20 20.14 22.62 24.62 26.26 -2.225 0.980 0.910 91.011
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 Table 7.2: Raw data for calculating primer efficiency of new primer sets (Table 2.5) 
 
 
 
Figure 7.3: Standard curves generated from new primer sets in Table 2.5. 
The efficiency of the primer pairs was assessed by plotting the cycle threshold value (CT) at each cDNA 
concentration against the logarithm of the fold dilution of the sample. The slope of a linear-regression trendline is 
indicative of primer efficiency. 
  
cDNA dilution 
(1:5)
0.2 0.04 0.008 0.00016 0.000032 0.0000064
Log starting 
quantity
-0.7 -1.4 -2.1 -3.8 -4.5 -5.2
Primer Set Cт Mean Cт Mean Cт Mean Cт Mean Cт Mean Cт Mean Slope R2 Efficiency %
PRMT1v2 23.30 24.76 26.79 28.66 30.44 33.40 -2.024 0.963 0.901 90.117
PRMT1v3 22.54 24.16 26.55 28.36 30.40 32.98 -2.119 0.969 0.906 90.564
PRMT8v2 35.13 35.24 32.47 35.28 32.18 34.86 0.181 0.051 2.105 210.521
TBP 24.27 26.21 28.82 30.24 32.81 36.15 -2.332 0.946 0.914 91.425
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Table 7.3: Raw data for calculating primer efficiency of new primer sets (Table 2.7)* 
 
* N.D indicates that no fluorescence was detected. 
 
Figure 7.4: Standard curves generated from new primer sets in Table 2.7 
The efficiency of the primer pairs was assessed by plotting the cycle threshold value (CT) at each cDNA 
concentration against the logarithm of the fold dilution of the sample. The slope of a linear-regression trendline is 
indicative of primer efficiency.  
  
cDNA dilution 
(1:5)
0.2 0.04 0.008 0.00016 0.000032 0.0000064
Log starting 
quantity
-0.7 -1.4 -2.1 -3.8 -4.5 -5.2
Primer Set Cт Mean Cт Mean Cт Mean Cт Mean Cт Mean Cт Mean Slope R2 Efficiency %
PRMT8 v3 32.55 35.41 36.68 37.33 N.D N.D -1.380 0.748 0.855 85.504
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Figure 7.5: Representative images of confocal controls and γ-H2AX foci 
Cells were grown on coverslips until 80% confluency was reached and then prepared as described in section 
2.12.1. Cells were incubated with PBS instead of the primary antibody for 1-2 h, then the protocol was continued 
as described in section 2.12.1 (A). At the time of imaging, the gain of the BP 560-615 nm channel was adjusted 
so that no fluorescence was detected (A). Representative images of U87MG cells displaying γ-H2AX foci (B). 
Scale bar= 20 μm. 
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Figure 7.6: Repeat of ASYM24 Western blot  
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with ASYM24 (A). 10 μg of 
protein was loaded for each sample for the loading control, β- tubulin (B). This was performed using the same 
samples as in Figure 3.1C and D. 
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 All Proteins Identified by Mass Spectrometry 
Table 7.4: All Proteins identified by mass spectrometry in SVG p12 cells 
 
Accession 
No. Protein
Highest 
Score         
(-10lgP)
Highest 
Coverage      
(%)
Methylated 
Arginine 
Residues
Sequence Identified times identified
1433E 14-3-3 protein epsilon 337 42 2
1433T 14-3-3 protein theta 236 38
R41 not 
methylated 2
1433Z 14-3-3 protein zeta/delta 856 53
  
methylated 2
CH60 60kDa heat shock protein 3660 49 3
RL4 60S ribosomal protein L4 369 8 1
GRP78 78kDa glucose-regulated protein 1741 37 3
THIL
  
mitochondrial 253 10 2
ACTG Actin, cytoplasmic 2 2281 61 R312 DLYANTVLSGGSTMYPGIADR 2
SAHH Adenosylhomocysteinase 162 4 1
ENOA Alpha enolase 2377 58 3
ACTN3 Alpha-actinin-3 203 6 R306, R314, 
R740, R752 RTVPWLENR, VGWEQLLTSIAR, TINEVENQVLTR
1
ANXA1 Annexin A1 527 34 3
ANXA2 Annexin A2 1633 60 3
ANXA5 Annexin A5 443 26 3
ATPA
    
mitochondrial 1440 43 R17, R253 RAGLVSR, RSTVAQLVK 2
ATPB
    
mitochondrial 899 39 2
ATPO ATP synthase subunit O, mitochondrial 83 18 1
ENOB Beta enolase 1196 22 3
ACTBL Beta-actin-like protein 2 349 23 R313 DLYANTVLSGGSTMYPGIADR 1
CDC42 Cell division control protein 42 75 7 1
CLIC1 Chloride intracellular channel protein 1 307 7 1
CKAP4 Cytoskeleton-associated protein 4 673 26 3
EF1A1 Elongation factor 1-alpha 1 507 32 R166 MDSTEPPYSQKR 1
EF2 Elongation factor 2 547 16 1
ENPL Endoplasmin 740 21 3
ECHM Enoyl-CoA hydratase, mitochondrial 311 12 1
IF4A1 Eukaryotic initiation factor 4A-I 284 17 R368 IGRGGRFGRK 1
XPO2 Exportin-1 428 11 1
ALDOA Fructose-bisphosphate aldolase A 851 50 3
G3P GAPDH 593 41 3
G6PI Glucose-6-phosphate isomerase 281 20 R75, R80 SRGVEAARERMFNGEK 1
GSTP1 Glutathione S-transferase P 238 23 1
HS71A/1B Heat shock 70 kDa protein 1A/1B 512 26 1
HSP76 Heat shock 70 kDa protein 6 256 8 R519 LSKEEVER 1
HSP7C Heat shock cognate 71 kDa protein 974 28 3
TRAP1
  
mitochondrial 211 2 R14, R16, R20 RLRPLLR 1
HS90A Heat shock protein HSP 90-alpha 613 24 R345 ALLFVPR 2
HS90B Heat shock protein HSP 90-beta 700 28 1
HSP72 Heat shock-related 70 kDa protein 2 383 13 1
HNRPQ
  
ribonucleoprotein Q 107 6
  
R551 GGAQQQRGRGVRGAR 1
HNRPU
  
ribonucleoprotein U 342 14 R733, R739 RGNMPQRGGGGGGSGGIGYPYPR 1
IMB1 Importin subunit beta-1 921 17 3
ITA1 Integrin alpha-1 145 7 1
ITB1 Integrin beta-1 204 17 2
LPPRC
   
protein, mitochondrial 135 8 1
LDHA L-lactate dehydrogenase A chain 686 35 R106, R112 QQEGESRLNLVQR 3
LDHB L-lactate dehydrogenase B chain 322 32 1
MDHM Malate dehydrogenase, mitochondrial 335 28 3
ACADM
   
dehydrogenase, mitochondrial 271 7 1
NB5R3 NADH-cytochrome b5 reductase 3 236 6 1
PGK1 Phosphoglycerate kinase 1 438 36 1
PGAM1 Phosphoglycerate mutase 1 289 34 1
POTEE POTE ankyrin domain family member E 1483 8 2
POTEF POTE ankyrin domain family member F 434 8 R196, R207 RCQLNVLDNKKR 1
PD1A3 Protein disulfide-isomerase A3 144 9 1
PDIA1 Protein disulfide-isomerase A1 689 29 3
AXA2L Putative annexin A2-like protein 1361 56 R63, R205
 
AEDGSVIDYELIDQDAQDLYDAGVKR 3
KPYM Pyruvate kinase PKM 1182 42 1
RAB5C Ras-related protein Rab-5C 93 5 1
RAS7A Ras-related protein Rab-7a 115 6 1
RTN4 Reticulon-4 467 5 1
GLYM
  
mitochondrial 125 9 1
SERPH Serpin H1 950 14 2
SERPH Serpin H1 905 11
GRP75
    
mortalin) 1345 24
  
covered 2
TCPH T-complex protein 1 subunit eta 634 14 1
TERA Transitional endoplasmic reticulum 
ATPase 
143 10 R239
AIGVKPPR
1
TPIS Triosephosphate isomerase 949 72 3
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Accession 
No. Protein
Highest 
Score         
(-10lgP)
Highest 
Coverage      
(%)
Methylated 
Arginine 
Residues
Sequence Identified times identified
  
  
  
  
  
   
   
    
  
 
  
   
 
 
     
      
    
 
  
    
    
  
   
  
  
   
  
  
  
     
     
        
  
    
    
        
 
  
  
  
  
 
    
 
    
   
     
 
   
  
  
     
      
  
  
    
 
  
  
  
  
 
       
    
   
 
 
  
    
    
 
 
    
 
  
  
    
 
    
  
  
  
   
 
 
 
 
         
 
      
 
   
  
  
  
  
  
   
   
    
  
 
  
   
 
 
     
      
    
 
  
    
    
  
   
  
  
   
  
  
  
     
     
        
  
    
    
        
 
  
  
  
  
 
    
 
    
   
     
 
   
  
  
     
      
  
  
    
 
  
  
  
  
 
       
    
   
 
p p  
TBA1A Tubulin alpha-1A chain 1432 45 1
TBA1B Tubulin alpha-1B chain 1884 48 R79 not 
methylated
2
TBA1C Tubulin alpha-1C chain 1759 45 R79 not 
methylated, 
AVCMLSNTTAVAEAWAR 1
TBA3C Tubulin alpha-3C/D 1277 41 R79 AVFVDLEPTVVDEVR 2
TBB5 Tubulin beta chain 1584 50 R156 not 
methylated, 
3
TBB2A Tubulin beta-2A chain 113 6 1
TBB2B Tubulin beta-2B chain 113 6 1
TBB3 Tubulin beta-3 chain 637 32 R156; R282 
not covered
VREEYPDR 1
TBB4B Tubulin beta-4B chain 1349 50 R282 not 
covered
2
TBB6 Tubulin beta-6 chain 713 32 R390 AVCMLSNTTAVAEAWAR 1
VINC Vinculin 96 2 1
VDAC1
  
channel protein 1 297 23 3
XRCC6
X-ray repair cross-complementing 
protein 6 352 5 1
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Table 7.5: All Proteins identified by mass spectrometry in A172 cells 
 
  
Accession 
No. Protein
Highest 
Score        
(-10lgP)
Highest 
Coverage      
(%)
Methylated 
Arginine 
Residues
Sequence Identified times identified
1433E 14-3-3 protein epsilon 194 29 1
1433T 14-3-3 protein theta 190 33 1
1433Z 14-3-3 protein zeta/delta 266 30 1
CH60 60kDa heat shock protein 1978 51 3
RL7A 60S ribosomal protein L7a 325 28 1
GRP78 78kDa glucose-regulated protein 1294 47 3
ACTG Actin, cytoplasmic 2
2873 64
R256 SYELPDGQVITIGNER
1
ENOA Alpha enolase 131 11 1
ACTN3 Alpha-actinin-3 78 4 R740, R752 VGWEQLLTSIAR, TINEVENQVLTR 2
ACTN4 Alpha-actinin-4 599 23 2
ANXA1 Annexin A1 911 40 3
ANXA2 Annexin A2 2578 75 3
ATPA ATP synthase subunit alpha, 514 26 2
ATPB ATP synthase subunit beta, 391 26 3
ACTBL Beta-actin-like protein 2 691 26 R63, R255, 
R313
RGVLTLK, SYELPDGQVITIGNER, 
DLYANTVLSGGSTMYPGIADR
3
CALR Calreticulin 178 19 1
CATD Cathepsin 196 13 1
CLIC1 Chloride intracellular channel protein 1 400 37 2
CKAP4 Cytoskeleton-associated protein 4 249 17 2
EF1A1 Elongation factor 1-alpha 1 344 25 2
EF2 Elongation factor 2 525 15 2
ENPL Endoplasmin 377 19 1
FLNA Filamin-A 2622 29 1
FLNB Filamin-B 796 16 1
ALDOA Fructose-bisphosphate aldolase A 640 42 3
G3P GAPDH 862 28 3
HSP76 Heat shock 70 kDa protein 6 150 10 1
HSP7C Heat shock cognate 71 kDa protein 624 26 R469, R509 FELTGIPPAPR, GRLSKEDIERMVQEAEK 3
TRAP1 Heat shock protein 75 kDa, 233 7 R16 LRPLLR 2
HS90A Heat shock protein HSP 90-alpha 493 13 R345 ALLFVPR 3
HS90B Heat shock protein HSP 90-beta 992 28 3
HNRPK Heterogeneous nuclear 195 16 1
HNRPU
Heterogeneous nuclear 
ribonucleoprotein U
525 14
R709 2
HXK1 Hexokinase-1 303 15 2
IMB1 Importin subunit beta-1 171 7 1
LPPRC
Leucine-rich PPR motif-containing 
protein, mitochondrial
302 12
1
LDHA L-lactate dehydrogenase A chain 175 21 1
LDHB L-lactate dehydrogenase B chain 256 24 2
MDHM Malate dehydrogenase, mitochondrial 752 38 3
PGK1 Phosphoglycerate kinase 1 191 11 1
POTEE POTE ankyrin domain family member E 1294 9 R954 SYELPDGQVITIGNER 2
PHB Prohibitin 188 18 1
PD1A6 Protein disulfide-isomerase A6 442 8 2
AXA2L Putative annexin A2-like protein 2042 61 R63 GVDEVTIVNIVTNR 3
KPYM Pyruvate kinase PKM 1177 39 3
GLYM
Serine hydroxymethyltransferase, 
mitochondrial
169 18
1
SERPH Serpin H1 466 21 3
GRP75
Stress-70 protein, mitochondrial (aka 
mortalin)
603 28
R513 LLGQFTLVGIPPAPR 1
TLN-1 Talin-1 472 7 R2210 RAIADMLRACK 1
TALDO Transaldolase 145 10 1
TERA Transitional endoplasmic reticulum 327 19 1
TPIS Triosephosphate isomerase 272 33 2
TBA1A Tubulin alpha-1A chain 550 38 1
TBA1B Tubulin alpha-1B chain 844 32 2
TBA1C Tubulin alpha-1C chain 844 32 3
TBA3C Tubulin alpha-3C/D chain 663 27 R79 AVFVDLEPTVVDEVR 3
TBB5 Tubulin beta chain 793 40 3
TBB3 Tubulin beta-3 chain 475 24 R156 VREEYPDR 2
TBB4B Tubulin beta-4B chain 775 44 3
TBB6 Tubulin beta-6 chain 378 21 R390 ISEQFSAMFR 1
VIME Vimentin 2015 67 3
VDAC2
Voltage-dependent anion-selective 
channel protein 2
103 7
1
XRCC5 X-ray repair cross-complementing 289 6 1
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Table 7.6: All Proteins identified by mass spectrometry in T98G cells 
 
Accession 
No. Protein
Highest 
Score         
(-10lgP)
Highest 
Coverage      
(%)
Methylated 
Arginine 
Residues
Sequence Identified times identified
CH10 10kDa heat shock protein, 
mitochrondrial
262 45 1
1433B 14-3-3 protein beta/alpha 108 17 1
1433E 14-3-3 protein epsilon 114 9 1
1433G 14-3-3 protein gamma 101 12 1
1433T 14-3-3 protein theta 127 12 1
1433Z 14-3-3 protein zeta/delta 250 29 R80, R83 QQMAREYR 3
3HIDH
3-hydroxyisobutyrate dehydrogenase, 
mitochondrial 300 9 1
4F2 4F2 cell-surface antigen heavy chain 427 19 2
CH60 60kDa heat shock protein 1072 28 2
GRP78 78kDa glucose-regulated protein 2303 46 3
THIL
Acetyl-CoA acetyltransferase, 
mitochondrial 122 3 1
ACTG Actin, cytoplasmic 2 3636 54
R39, R206, 
R254, R312
AVFPSIVGRPR; GYSFTTTAER; SYELPDGQVITIGNER, 
DLYANTVLSGGTTMYPGIADR 3
ADT3 ADP/ATP translocase 3 147 24 R152 TRLAADVGKSGTER 2
ENOA Alpha-enolase 579 41 2
ANXA1 Annexin A1 669 31 3
ANXA2 Annexin A2 1819 57 R290 DKVLIR 3
ANXA4 Annexin A4 426 23 2
ANXA5 Annexin A5 460 30 3
ATPA
ATP synthase subunit alpha, 
mitochondrial 803 36 R149 TGAIVDVPVGDELLGR 3
ATPB ATP synthase subunit beta, 
mitochondrial
1019 30 3
ATPO ATP synthase subunit O, mitochondrial 351 47 1
ACTBL Beta-actin-like protein 2 909 25 R63, R313 RGVLTLK, DLYANTVLSGGSTMYPGIADR 2
CMC2 Calcium-binding mitochondrial carrier 
protein Aralar2
150 13 R170, R174 QAFVQRDNARTGR 1
CATD Cathepsin D 301 26 2
CD44 CD44 antigen 290 8 1
CDC42
Cell division control protein 42 
homolog 122 19 1
Chloride intracellular channel 357 22 1
Cytochrome b-c1 complex subunit 
2, mitochondrial 122 5 R12 KLLTRAGSFSR
1
CKAP4 Cytoskeleton-associated protein 4 930 34 3
D-3-phosphoglycerate 120 6 1
EF1A1 Elongation factor 1-alpha 1 216 11 2
ENPL Endoplasmin 471 13 2
ALDOA Fructose-bisphosphate aldolase A 578 47 2
ALDOC Fructose-bisphosphate aldolase C 577 35 1
GAPDH 624 39 R248 VPTANVSVVDLTCR 3
GSTP1 Glutathione S-transferase P 429 23 1
HSP76 Heat shock 70 kDa protein 6 102 6 3
HSP7C Heat shock cognate 71 kDa protein 350 15 R49, R264 TTPSYVAFTDTER, AVRRLR 2
TRAP1 Heat shock protein 75 kDa, 167 5 2
HS90A Heat shock protein HSP 90-alpha 103 4 2
HS90B Heat shock protein HSP 90-beta 180 6 2
H14 Histone H1.4 96 23 1
1A02 HLA class I histocompatibility antigen, 
A-2 alpha chain
207 13 2
IMB1 Importin subunit beta-1 278 4 2
LAMB1 Laminin subunit beta-1 883 11 1
LDHA L-lactate dehydrogenase A chain 189 15 R106, R112 QQEGESRLNLVQR 2
LDHB L-lactate dehydrogenase B chain 141 14 1
MDHM Malate dehydrogenase, mitochondrial 1603 47 3
MIC60 MICOS complex xubunit MIC60 224 14 1
NB5R3 NADH-cytochrome b5 reductase 3 183 5 2
PRX1 Peroxiredoxin-1 378 53 2
Phosphoglycerate kinase 1 644 26 1
POTEI POTE ankyrin domain family member I 366 4 1
Profilin-1 158 22 1
PHB Prohibitin 436 30 1
Prostglandin reductase 1 337 16 1
PDIA1 Protein disulfide-isomerase A1 545 15 3
PD1A3 Protein disulfide-isomerase A3 574 28 R107 IFRDGEEAGAYDGPR 2
AXA2L Putative annexin A2-like protein 1232 58 R63 GVDEVTIVNIVTNR 1
P5CR1 Pyrroline-5-carboxylate reductase 1, 
mitochondrial
278 25 1
Pyruvate kinase 963 33 1
Ras-related protein Rab-1A 300 19 1
RAB5C Ras-related protein Rab-5C 107 5 2
SERPH Serpin H1 184 8 R339 ADLSRMSGK 2
SFXN1 Sideroflexin-1 486 13 3
GRP75 Stress-70 protein (Mortalin) 2125 43 R513 LLGQFTLIGIPPAPR 3
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Accession 
No. Protein
Highest 
Score         
(-10lgP)
Highest 
Coverage      
(%)
Methylated 
Arginine 
Residues
Sequence Identified times identified
    
  
  
  
  
   
  
    
   
  
  
  
  
 
   
 
  
 
 
 
 
    
    
    
    
   
 
 
 
 
     
   
    
 
  
 
   
  
  
  
     
        
     
    
    
 
     
  
  
  
    
   
  
   
   
  
     
  
  
  
   
   
 
  
  
 
  
 
  
   
  
  
    
  
  
 
 
 
         
 
      
 
   
    
  
  
  
  
   
  
    
   
  
  
  
  
 
   
 
  
 
 
 
 
    
    
    
    
   
 
 
 
 
     
   
    
 
  
 
   
  
  
  
     
        
     
    
    
 
     
  
  
  
    
   
  
   
   
  
     
  
  
  
   
   
 
  
  
 
 p  ( ) Q
Transaldolase 186 23 R313 RKFAADAVK 1
Transgelin-2 319 61 1
TKT Transketotase 235 12 1
TPIS Triosephosphate isomerase 248 24 3
TBA1A Tubulin alpha-1A chain 146 9 1
Tubulin alpha-1B chain 492 17 3
TBA1C Tubulin alpha-1C chain 304 9 2
Tubulin alpha-3C chain 307 14 R79 AVFVDLEPTVVDEVR 2
TBB5 Tubulin beta chain 424 11 R282 not 
covered
2
VDAC1 Voltage-dependent anion-selective 
channel protein 1
533 36 3
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Table 7.7: All Proteins identified by mass spectrometry in U87MG cells  
 
Accession 
No. Protein
Highest 
Score         
(-10lgP)
Highest 
Coverage      
(%)
Methylated 
Arginine 
Residues
Sequence Identified times identified
1433E 14-3-3 protein epsilon 209 6 2
1433T 14-3-3 protein theta 383 7 2
1433Z 14-3-3 protein zeta/delta 266 18 1
CH60 60kDa heat shock protein 2725 78 3
GRP78 78kDa glucose-regulated protein 2598 89 3
ACTG Actin, cytoplasmic 2 2154 64 R254 SYELPDGQVITIGNER 2
ENOA Alpha enolase 3474 89 3
ACTN2 Alpha-actinin-2 111 5 R438, R442 DYESASLTEVRALLRK 1
ACTN3 Alpha-actinin-3 50 1 R740, R752 VGWEQLLTSIAR, TINEVENQVLTR 1
ACTN4 Alpha-actinin-4 482 16 1
ANXA1 Annexin A1 1437 54 3
ANXA2 Annexin A2 1658 63 3
ANXA5 Annexin A5 480 25 2
ATPA ATP synthase subunit alpha, mitochondrial 1250 89 2
ATPB ATP synthase subunit beta, mitochondrial 1167 41 3
ACTBL Beta-actin-like protein 2 1168 70 R63, R255, 
R313
RGVLTLK, SYELPDGQVITIGNER, 
DLYANTVLSGGSTMYPGIADR 3
CALX Calnexin 187 8 1
CATD Cathepsin D 757 34 1
CD44 CD44 antigen 323 17 1
CLIC1 Chloride intracellular channel protein 1 400 18 1
CKAP4 Cytoskeleton-associated protein 4 441 13 2
DPYL2
Dihydropyrimidinase-relate protein 2 (CRMP2) 687 15
R16 KNIPRITSDR 1
EF1A1 Elongation factor 1-alpha 1 450 27 2
EF2 Elongation factor 2 676 35 1
ENPL Endoplasmin 2277 81 2
ALDOA Fructose-bisphosphate aldolase A 2730 63 3
G3P GAPDH 1663 76 3
GSTK1 Glutathione S-transferase kappa 1 365 7 2
HS71A/1B Heat shock 70 kDa protein 1A/1B 247 17 1
HSP76 Heat shock 70 kDa protein 6 223 17 1
HSP7C Heat shock cognate 71 kDa protein 1314 56 R469 DNNLLGKFELTGIPPAPR 3
TRAP1 Heat shock protein 75 kDa, mitochondrial 104 2 R16 LRPLLR 1
HS90A Heat shock protein HSP 90-alpha 998 57 R345 ALLFVPR 2
HS90B Heat shock protein HSP 90-beta 1208 62 2
1A02
HLA class I histocompatibility antigen, A-2 
alpha chain
273 8
1
IMB1 Importin subunit beta-1 342 8 2
ITB1 Integrin beta-1 360 18 1
LPPRC
Leucine-rich PPR motif-containing protein, 
mitochondrial
358 18
1
LDHA L-lactate dehydrogenase A chain 175 19 1
LDHB L-lactate dehydrogenase B chain 425 23 R170 VIGSGCNLDSAR 2
MDHM Malate dehydrogenase, mitochondrial 1251 47 3
MIC60 MICOS complex subunit MIC60 408 12 1
MAP4 Microtubule-associated protein 4 119 6 1
AHNK
Neuroblast differentiation-associated protein 
AHNAK
497 34
1
PGK1 Phosphoglycerate kinase 1 1456 47 3
PGAM1 Phosphoglycerate mutase 1 197 10 1
POTEE POTE ankyrin domain family member E 1217 43 R196, R954 RCQLNVLDNKKR, SYELPDGQVITIGNER 3
PDIA1 Protein disulfide-isomerase A1 387 21 2
PD1A3 Protein disulfide-isomerase A3 366 24 2
AXA2L Putative annexin A2-like protein 1321 54 R63 GVDEVTIVNIVTNR 2
KPYM Pyruvate kinase PKM 4917 111 R376 AEGSDVANAVLDGADCIMLSGETAKGDYPLEAVR 2
GLYM
Serine hydroxymethyltransferase, 
mitochondrial
200 9
1
SERPH Serpin H1 123 3 1
AT1A1
Sodium/potassium-transporting ATPase 
subunit alpha-1
537 17
1
GRP75
Stress-70 protein, mitochondrial (aka 
mortalin)
1838 54 R513 not 
methylated 3
TALDO Transaldolase 145 5 1
TERA Transitional endoplasmic reticulum ATPase 182 5 1
TPIS Triosephosphate isomerase 789 30 2
TBA1A Tubulin alpha-1A chain 550 31 1
TBA1B Tubulin alpha-1B chain 1057 24 R79 AVFVDLEPTVIDEVR 2
TBA1C Tubulin alpha-1C chain 1057 24 R79 AVFVDLEPTVIDEVR 3
TBA3C Tubulin alpha-3C/D 483 25 R79 AVFVDLEPTVVDEVR 1
TBB5 Tubulin beta chain 793 36 3
TBB3 Tubulin beta-3 chain 475 27 R156 VREEYPDR 1
TBB4B Tubulin beta-4B chain 775 35 2
TBB6 Tubulin beta-6 chain 132 11 R390 ISEQFSAMFR 1
UBA1 Ubiquitin-like modifier-activating enzyme 1 869 31 1
VIME Vimentin 2015 85 2
VINC Vinculin 354 17 1
VDAC1
Voltage-dependent anion-selective channel 
protein 1
819 30
1
VDAC2
Voltage-dependent anion-selective channel 
protein 2
10 5
1
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 Data used to Generate  Figure 3.9 & Figure 3.10 
 
Figure 7.7: Repeat Western blots of PRMT1 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti-PRMT1. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH (A). Representative Western blot using Anti-
PRMT1 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
Table 7.8: Raw data used to generate Figure 3.10A 
 
 
 
 
Repeat # Sample PRMT1 Density
GAPDH 
Density
PRMT1/ 
GAPDH
Relative 
Density 
SVGp12 4085.004 14790.58 0.276 1.000
A172 6846.078 15390.9 0.445 1.611
T98G 2916.501 16393.78 0.178 0.644
U87MG 3650.501 15890.61 0.230 0.832
SVGp12 11555.62 18201.36 0.635 1.000
A172 11618.74 17058.65 0.681 1.073
T98G 796.92 15417.62 0.052 0.081
U87MG 11643.93 18007.35 0.647 1.018
SVGp12 2107.418 11372.86 0.185 1.000
A172 2483.731 8014.74 0.310 1.672
T98G 959.175 8283.255 0.116 0.625
U87MG 1314.861 7300.983 0.180 0.972
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 1.452 0.330 0.190
 T98G 0.450 0.319 0.184
 U87MG 0.941 0.097 0.056
1
2
3
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Figure 7.8: Repeat Western blots of PRMT2 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti- PRMT2. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH (A). Representative Western blot using Anti-
PRMT2 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
 
Table 7.9: Raw data used to generate Figure 3.10B 
 
Repeat # Sample PRMT2 Density
GAPDH 
Density
PRMT2/ 
GAPDH
Relative 
Density 
SVGp12 900.092 7655.936 0.118 1.000
A172 2288.267 7497.936 0.305 2.596
T98G 1723.146 7821.057 0.220 1.874
U87MG 1345.397 7487.936 0.180 1.528
SVGp12 3446.154 7697.912 0.448 1.000
A172 12017.2 6978.912 1.722 3.846
T98G 5925.104 8670.974 0.683 1.526
U87MG 4554.154 7333.317 0.621 1.387
SVGp12 4751.075 6925.054 0.686 1.000
A172 8286.522 6414.108 1.292 1.883
T98G 7182.329 6349.229 1.131 1.649
U87MG 5712.104 6361.986 0.898 1.309
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 2.775 0.994 0.574
 T98G 1.683 0.176 0.102
 U87MG 1.408 0.111 0.064
1
2
3
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Figure 7.9: Repeat Western blots of PRMT3 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti- PRMT3. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH. (A) Representative Western blot using Anti-
PRMT3 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
 
Table 7.10: Raw data used to generate Figure 3.10C 
 
Repeat # Sample PRMT3 Density
GAPDH 
Density
PRMT3/ 
GAPDH
Relative 
Density 
SVGp12 940.648 12879.41 0.073 1.000
A172 355.799 12942.37 0.027 0.376
T98G 630.92 12584.78 0.050 0.686
U87MG 901.213 12925.94 0.070 0.955
SVGp12 2235.355 17099.58 0.131 1.000
A172 1033.335 16303.88 0.063 0.485
T98G 3629.891 21554.75 0.168 1.288
U87MG 3351.82 16181.18 0.207 1.585
SVGp12 1957.468 6925.054 0.283 1.000
A172 712.79 6414.108 0.111 0.393
T98G 4395.359 6349.229 0.692 2.449
U87MG 3447.853 6361.986 0.542 1.917
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 0.418 0.058 0.034
 T98G 1.475 0.896 0.517
 U87MG 1.485 0.489 0.282
1
2
3
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Figure 7.10: Repeat Western blots of PRMT4 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti- PRMT4. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH (A). Representative Western blot using Anti-
PRMT4 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
 
Table 7.11: Raw data used to generate Figure 3.10D 
 
Repeat # Sample PRMT4 Density
GAPDH 
Density
PRMT4/ 
GAPDH
Relative 
Density 
SVGp12 3028.28 16443.80 0.184 1.000
A172 896.72 16294.95 0.055 0.299
T98G 3382.23 18314.54 0.185 1.003
U87MG 5467.74 13616.65 0.402 2.180
SVGp12 12044.27 8499.03 1.417 1.000
A172 14752.75 7949.21 1.856 1.310
T98G 12101.02 9892.34 1.223 0.863
U87MG 8160.78 8185.78 0.997 0.703
SVGp12 3458.08 6925.054 0.499 1.000
A172 3352.40 6414.108 0.523 1.047
T98G 4959.83 6349.229 0.781 1.564
U87MG 3609.08 6361.986 0.567 1.136
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 0.885 0.524 0.303
 T98G 1.143 0.371 0.214
 U87MG 1.340 0.759 0.438
1
2
3
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Figure 7.11: Repeat Western blots of PRMT5 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti- PRMT5. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH (A). Representative Western blot using Anti-
PRMT5 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
 
Table 7.12: Raw data used to generate Figure 3.10E 
 
Repeat # Sample PRMT5 Density
GAPDH 
Density
PRMT5/ 
GAPDH
Relative 
Density 
SVGp12 708.58 10815.93 0.066 1.000
A172 6924.44 14604.10 0.474 7.237
T98G 7074.02 13293.35 0.532 8.123
U87MG 13239.10 22568.48 0.587 8.954
SVGp12 2825.69 11154.03 0.253 1.000
A172 7749.92 7887.33 0.983 3.879
T98G 7710.02 8415.67 0.916 3.616
U87MG 10134.22 7047.15 1.438 5.677
SVGp12 3571.56 20277.28 0.176 1.000
A172 10333.41 16646.02 0.621 3.524
T98G 13774.43 14452.15 0.953 5.411
U87MG 11973.97 13396.49 0.894 5.075
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 4.880 2.049 1.183
 T98G 5.717 2.269 1.310
 U87MG 6.568 2.088 1.206
1
2
3
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Figure 7.12: Repeat Western blots of PRMT6 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti- PRMT6. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH (A). Representative Western blot using Anti-
PRMT6 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
 
Table 7.13: Raw data used to generate Figure 3.10F 
 
Repeat # Sample PRMT6 Density
GAPDH 
Density
PRMT6/ 
GAPDH
Relative 
Density 
SVGp12 5839.61 6403.05 0.912 1.000
A172 5319.00 4157.76 1.279 1.403
T98G 6236.83 5515.02 1.131 1.240
U87MG 14548.29 2903.23 5.011 5.495
SVGp12 1206.78 7332.15 0.165 1.000
A172 4267.52 7726.08 0.552 3.356
T98G 5328.40 8538.38 0.624 3.792
U87MG 8522.15 9878.62 0.863 5.242
SVGp12 1270.23 15074.12 0.084 1.000
A172 3559.74 14432.87 0.247 2.927
T98G 3214.87 14300.77 0.225 2.668
U87MG 6458.20 17709.97 0.365 4.328
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 2.562 1.027 0.593
 T98G 2.566 1.279 0.738
 U87MG 5.021 0.614 0.354
1
2
3
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Figure 7.13: Repeat Western blots of PRMT8 
Western blot of whole cell lysates of non-cancerous glial, SVG p12, and glioblastoma, A172, T98G, U87MG, cell 
lines. 30 μg of protein was loaded for each cell line and membranes were probed with Anti- PRMT8. 10 μg of 
protein was loaded for each sample for the loading control, GAPDH (A). Representative Western blot using Anti-
PRMT8 antibody showing the full membrane (B). This was used to test the antibody and no GAPDH loading 
control Western blot was performed, hence it was not used for quantification. 
 
Table 7.14: Raw data used to generate Figure 3.10G 
  
Repeat # Sample PRMT8 Density
GAPDH 
Density
PRMT8/ 
GAPDH
Relative 
Density 
SVGp12 1980.79 16832.1 0.118 1.000
A172 7956.004 16151.05 0.493 4.186
T98G 5718.267 15382.24 0.372 3.159
U87MG 5498.631 17704.95 0.311 2.639
SVGp12 2094.104 8396.497 0.249 1.000
A172 9056.874 8069.79 1.122 4.500
T98G 2108.175 8945.497 0.236 0.945
U87MG 4651.589 7236.447 0.643 2.577
SVGp12 1837.205 8338.326 0.220 1.000
A172 7146.702 9545.447 0.749 3.398
T98G 4810.53 9387.631 0.512 2.326
U87MG 3336.054 7488.711 0.445 2.022
Average S.D SEM
 SVGp12 1.000 0.000 0.000
 A172 4.028 0.568 0.328
 T98G 2.143 1.118 0.646
 U87MG 2.413 0.340 0.196
1
2
3
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 Raw Data used to Generate Figure 3.11 
Table 7.15: Raw data from qRT-PCR of PRMT1 used to generate Figure 3.11A 
Repeat # Sample PRMT1 Cт TBP Cт Relative Expression 
1 SVGp12 22.96 23.94 1.00 
A172 22.35 23.72 1.05 
T98G 24.04 23.48 0.86 
U87MG 23.35 23.90 0.96 
2 SVGp12 20.57 23.16 1.00 
A172 20.95 23.16 0.96 
T98G 20.65 22.44 0.93 
U87MG 23.17 23.77 0.81 
3 SVGp12 22.75 25.86 1.00 
A172 22.67 25.13 0.94 
T98G 24.95 25.66 0.78 
U87MG 23.48 25.60 0.90 
4 SVGp12 24.05 22.26 1.00 
A172 23.99 23.96 1.17 
T98G 24.06 22.95 1.06 
U87MG 24.48 23.03 1.02 
  Average S.D SEM   
 
  
 SVGp12 1.000 0.000 0.000 
 A172 1.030 0.104 0.052 
 T98G 0.907 0.120 0.060 
 U87MG 0.923 0.092 0.046 
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Table 7.16: Raw data from qRT-PCR of PRMT2 used to generate Figure 3.11B 
Repeat # Sample PRMT2 Cт TBP Cт Relative Expression 
1 SVGp12 23.76 23.94 1.00 
A172 23.93 23.72 0.95 
T98G 24.54 23.48 0.85 
U87MG 25.76 23.90 0.73 
2 SVGp12 26.11 23.16 1.00 
A172 26.52 23.16 0.94 
T98G 26.42 22.44 0.89 
U87MG 26.15 23.77 1.05 
3 SVGp12 24.30 25.86 1.00 
A172 23.54 25.13 1.05 
T98G 24.70 25.66 0.92 
U87MG 28.92 25.60 0.47 
4 SVGp12 23.93 22.26 1.00 
A172 23.38 23.96 1.28 
T98G 26.40 22.95 0.72 
U87MG 22.01 23.03 1.46 
  Average S.D SEM   
 SVGp12 1.000 0.000 0.000 
 A172 1.055 0.157 0.079 
 T98G 0.845 0.087 0.044 
 U87MG 0.926 0.426 0.213 
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Table 7.17: Raw data from qRT-PCR of PRMT3 used to generate Figure 3.11C 
Repeat # Sample PRMT3 Cт TBP Cт Relative Expression 
1 SVGp12 22.94 23.94 1.00 
A172 19.77 23.72 1.36 
T98G 23.80 23.48 0.88 
U87MG 24.95 23.90 0.81 
2 SVGp12 25.93 23.16 1.00 
A172 23.51 23.16 1.28 
T98G 22.08 22.44 1.39 
U87MG 24.27 23.77 1.26 
3 SVGp12 23.75 25.86 1.00 
A172 23.22 25.13 0.99 
T98G 23.49 25.66 1.01 
U87MG 26.01 25.60 0.77 
4 SVGp12 21.92 22.26 1.00 
A172 23.43 23.96 0.92 
T98G 22.43 22.95 0.98 
U87MG 20.83 23.03 1.28 
  Average S.D SEM   
 SVGp12 1.000 0.000 0.000 
 A172 1.138 0.215 0.108 
 T98G 1.064 0.224 0.112 
 U87MG 1.029 0.275 0.138 
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Table 7.18: Raw data from qRT-PCR of PRMT4 used to generate Figure 3.11D 
Repeat # Sample PRMT4 Cт TBP Cт Relative Expression 
1 SVGp12 25.30 23.94 1.00 
A172 22.92 23.72 1.24 
T98G 26.68 23.48 0.84 
U87MG 25.93 23.90 0.94 
2 SVGp12 23.64 23.16 1.00 
A172 22.86 23.16 1.08 
T98G 23.50 22.44 0.95 
U87MG 24.48 23.77 0.98 
3 SVGp12 24.85 25.86 1.00 
A172 23.07 25.13 1.11 
T98G 25.09 25.66 0.96 
U87MG 28.11 25.60 0.71 
4 SVGp12 22.68 22.26 1.00 
A172 22.918 23.96 1.13 
T98G 22.751 22.95 1.06 
U87MG 21.809 23.03 1.23 
  Average S.D SEM   
 SVGp12 1.000 0.000 0.000 
 A172 1.139 0.068 0.034 
 T98G 0.949 0.089 0.045 
 U87MG 0.964 0.215 0.108 
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Table 7.19: Raw data from qRT-PCR of PRMT5 used to generate Figure 3.11E 
Repeat # Sample PRMT5 Cт TBP Cт Relative Expression 
1 SVGp12 22.92 23.94 1.00 
A172 21.82 23.72 1.09 
T98G 24.92 23.48 0.79 
U87MG 26.93 23.90 0.68 
2 SVGp12 22.77 23.16 1.00 
A172 23.87 23.16 0.84 
T98G 22.93 22.44 0.92 
U87MG 25.41 23.77 0.68 
3 SVGp12 23.65 25.86 1.00 
A172 23.36 25.13 0.96 
T98G 24.52 25.66 0.90 
U87MG 27.93 25.60 0.65 
4 SVGp12 22.96 22.26 1.00 
A172 23.77 23.96 1.03 
T98G 24.05 22.95 0.90 
U87MG 24.92 23.03 0.79 
  Average S.D SEM   
 SVGp12 1.000 0.000 0.000 
 A172 0.980 0.106 0.053 
 T98G 0.878 0.058 0.029 
 U87MG 0.701 0.061 0.030 
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Table 7.20: Raw data from qRT-PCR of PRMT6 used to generate Figure 3.11F 
Repeat # Sample PRMT6 Cт TBP Cт Relative Expression 
1 SVGp12 25.92 23.94 1.00 
A172 28.91 23.72 0.65 
T98G 27.32 23.48 0.79 
U87MG 27.36 23.90 0.82 
2 SVGp12 26.97 23.16 1.00 
A172 27.69 23.16 0.91 
T98G 26.38 22.44 1.01 
U87MG 26.72 19.84 0.76 
3 SVGp12 28.93 25.86 1.00 
A172 30.59 25.13 0.74 
T98G 28.81 25.66 1.00 
U87MG 30.04 25.60 0.84 
4 SVGp12 23.83 22.26 1.00 
A172 25.91 23.96 0.84 
T98G 23.70 22.95 1.09 
U87MG 24.48 23.03 0.97 
  Average S.D SEM   
SVGp12 1.000 0.000 0.000 
 A172 0.786 0.113 0.056 
 T98G 0.972 0.128 0.064 
 U87MG 0.845 0.090 0.045 
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Table 7.21: Raw data from qRT-PCR of PRMT8 used to generate Figure 3.11G 
Repeat # Sample PRMT8 Cт  TBP Cт Relative Expression 
1 SVGp12 30.04461 23.94 1.000 
A172 33.79748 23.72 0.660 
T98G 28.75891 23.48 1.096 
U87MG 33.93054 23.90 0.661 
2 SVGp12 31.53423 23.16 1.000 
A172 33.32163 23.16 0.779 
T98G 28.69929 22.44 1.387 
U87MG 32.64402 23.77 0.907 
3 SVGp12 28.09992 25.86 1.000 
A172 31.25028 25.13 0.602 
T98G 27.46546 25.66 1.071 
U87MG 27.18733 25.60 1.107 
4 SVGp12 28.09992 22.26 1.000 
A172 31.25028 23.96 0.714 
T98G 27.46546 22.95 1.180 
U87MG 27.18733 23.03 1.242 
  Average S.D SEM 
 
SVGp12 1.000 0.000 0.000 
 A172 0.680 0.091 0.052 
 T98G 1.185 0.175 0.101 
 U87MG 0.892 0.223 0.129 
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 Chapter 4 Supporting Data 
 Raw data used to Generate Figure 4.2A & B 
Table 7.22: Raw Data from SVG p12 cell counting used to generate Figure 4.2A & B 
 
 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
Control 1154600 100400 1255000 1 92
2μM 944985 150015 1095000 0.873 86.3
3μM 554600 385400 940000 0.749 59
4μM 389400 270600 660000 0.526 59
Control 545160 44840 590000 1 92.4
2μM 445000 55000 500000 0.847 89
3μM 214800 185200 400000 0.678 53.7
4μM 179820 225180 405000 0.686 44.4
Control 929625 75375 1005000 1 92.5
2μM 550070 119930 670000 0.667 82.1
3μM 289960 150040 440000 0.438 65.9
4μM 165120 264880 430000 0.428 38.4
Average S.D
Control 1 0
2μM 0.796 0.112
3μM 0.622 0.163
4μM 0.547 0.131
Control 92.30 0.26
2μM 85.80 3.48
3μM 59.53 6.12
4μM 47.27 10.59
% Viability
Total Cell 
Number 
(fold 
change 
from 
control)
1
2
3
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Table 7.23: Raw data from A172 cell counting used to generate Figure 4.2A & B 
 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
Control 809970 60030 870000 1 93.1
2μM 235110 19890 255000 0.293 92.2
3μM 479850 45150 525000 0.603 91.4
4μM 360045 44955 405000 0.466 88.9
Control 494860 50140 545000 1 90.8
2μM 394980 40020 435000 0.798 90.8
3μM 389820 55180 445000 0.817 87.6
4μM 289900 35100 325000 0.596 89.2
Control 1179740 40260 1220000 1 96.7
2μM 1065120 54880 1120000 0.918 95.1
3μM 819820 75180 895000 0.734 91.6
4μM 732105 32895 765000 0.627 95.7
Average S.D
Control 1 0
2μM 0.670 0.332
3μM 0.718 0.107
4μM 0.563 0.086
Control 93.53 2.97
2μM 92.70 2.19
3μM 90.20 2.25
4μM 91.27 3.84
% Viability
Total Cell 
Number 
(fold 
change 
from 
control)
1
2
3
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Table 7.24: Raw data from T98G cell counting used to generate Figure 4.2A & B 
 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
1 Control 955300 69700 1025000 1 93.20
2μM 1419455 145545 1565000 1.527 90.70
3μM 1570840 159160 1730000 1.688 90.80
4μM 1424280 135720 1560000 1.522 91.30
Control 505180 74820 580000 1 87.10
2μM 749280 90720 840000 1.448 89.20
3μM 489780 50220 540000 0.931 90.70
4μM 464625 60375 525000 0.905 88.50
Control 1015000 45000 1060000 1 95.75
2μM 1170000 55000 1225000 1.156 95.51
3μM 835000 105000 940000 0.887 88.83
4μM 780000 70000 850000 0.802 91.76
Average S.D
Control 1 0
2μM 1.377 0.196
3μM 1.169 0.450
4μM 1.076 0.389
Control 92.02 4.45
2μM 91.80 3.30
3μM 90.11 1.11
4μM 90.52 1.77
% Viability
Total Cell 
Number 
(fold 
change 
from 
control)
2
3
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Table 7.25: Raw data from U87MG cell counting used to generate Figure 4.2A & B 
 
 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
1 Control 1054415 80585 1135000 1 92.90
2μM 535055 29945 565000 0.498 94.70
3μM 569780 50220 620000 0.546 91.90
4μM 304980 85020 390000 0.344 78.20
Control 985000 30000 1015000 1 97.04
2μM 690296 174704 865000 0.852 79.80
3μM 185000 20000 205000 0.202 90.24
4μM 355000 95000 450000 0.443 78.89
Control 1004880 55120 1060000 1 94.80
2μM 719670 85330 805000 0.759 89.40
3μM 689680 50320 740000 0.698 93.20
4μM 364900 80100 445000 0.420 82.00
Average S.D
Control 1 0
2μM 0.703 0.184
3μM 0.482 0.254
4μM 0.402 0.052
Control 94.91 2.07
2μM 87.97 7.55
3μM 91.78 1.48
4μM 79.70 2.02
% Viability
Total Cell 
Number 
(fold 
change 
from 
control)
2
3
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 Raw Data used to Generate Figure 4.4A & B 
Table 7.26: Raw data from SVG p12 cell counting used to generate Figure 4.4A & B 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
Control 1154600 100400 1255000 1 92
24 h 488800 451200 940000 0.749 65
48 h 321550 223450 545000 0.434 53
Control 545160 44840 590000 1 92.4
24 h 210800 189200 400000 0.678 52.7
48 h 80550 69450 150000 0.254 53.7
Control 929625 75375 1005000 1 92.5
24 h 229190 200810 430000 0.428 59.3
48 h 67900 132100 200000 0.199 51.4
Average S.D
Control 1 0
24 h 0.618 0.169
48 h 0.296 0.123
Control 92.300 0.265
24 h 59.000 6.155
48 h 52.700 1.179
1
2
3
% Viability
Total Cell 
Number (fold 
change from 
control)
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Table 7.27: Raw data from A172 cell counting used to generate Figure 4.4A & B 
 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
Control 809970 60030 870000 1 93.1
24 h 479850 45150 525000 0.603 91.4
48 h 259985 15015 275000 0.316 94.54
Control 494860 50140 545000 1 90.8
24 h 389820 55180 445000 0.817 87.6
48 h 214965 40035 255000 0.468 84.3
Control 1179740 40260 1220000 1 96.7
24 h 819820 75180 895000 0.734 91.6
48 h 239975 50025 290000 0.324 82.75
Average S.D
Control 1 0
24 h 0.718 0.107
48 h 0.369 0.085
Control 93.533 2.974
24 h 90.200 2.254
48 h 87.197 6.407
3
2
1
Total Cell 
Number (fold 
change from 
control)
% Viability
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Table 7.28: Raw data from T98G cell counting used to generate Figure 4.4A & B 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
Control 955300 69700 1025000 1 93.2
24 h 1570840 159160 1730000 1.991 90.8
48 h 831250 43750 875000 0.854 95
Control 505180 74820 580000 1 87.1
24 h 489780 50220 540000 0.931 90.7
48 h 449820 60180 510000 0.879 88.2
Control 1015000 45000 1060000 1 95.75
24 h 835000 105000 940000 0.896 88.83
48 h 844545 70455 915000 0.863 92.3
Average S.D
Control 1 0
24 h 1.273 0.622
48 h 0.865 0.013
Control 92.018 4.447
24 h 90.110 1.110
48 h 91.833 3.424
1
2
3
Total Cell 
Number (fold 
change from 
control)
% Viability
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Table 7.29: Raw data from U87MG cell counting used to generate Figure 4.4A & B 
 
 
  
Repeat # Sample Live Cells Dead Cells Total Cells Fold Change from Control % Viability
Control 1054415 80585 1135000 1 92.9
24 h 569780 50220 620000 0.546 91.9
48 h 110000 90000 200000 0.176 55
Control 985000 30000 1015000 1 97.04
24 h 185000 20000 205000 0.202 90.24
48 h 204977.5 120022.5 325000 0.320 63.07
Control 1004880 55120 1060000 1 94.8
24 h 689680 50320 740000 0.698 93.2
48 h 335000 65000 400000 0.377 83.75
Average S.D
Control 1.000 0.000
24 h 0.482 0.254
48 h 0.291 0.104
Control 94.915 2.075
24 h 91.781 1.482
48 h 67.273 14.829
1
2
3
Total Cell 
Number (fold 
change from 
control)
% Viability
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 Representative Flow Cytometry Profile of Cells Treated with 
Hydroxyurea 
 
 
Figure 7.14: Representative Flow cytometry profile of cells treated with Hydroxyurea 
Representative cell cycle analysis of SVG p12, A172, T98G and U87MG cells treated with 10 μM hydroxyurea for 
24 h. SSC-A vs. FSC-A was gated to exclude cell debris (P1; A). FSC-H vs. FSC-A was gated to exclude 
doublets (P2; B). Cell count vs. PI fluorescence was gated to include live cells (P3; C). Cell cycle analysis was 
performed on gated P3 cells (D). 
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 Raw Data used to Generate Table 4.1 and Figure 4.9 
Table 7.30: Raw data of SVG p12 cells used to generate Table 4.1 and Figure 4.9A 
 
 
Table 7.31: Raw data of A172 cells used to generate Table 4.1 and Figure 4.9B 
 
 
 
  
Repeat # Cell Line Treatment Time (h) G1 S G2/M G1 S G2/M
1 SVG p12 DMSO 24 21.7 42.3 37.7 1 1 1
1 SVG p12 Inhibitor 24 16.8 39.7 41.9 0.774 0.939 1.111
2 SVG p12 DMSO 24 29.1 38.2 28.4 1 1 1
2 SVG p12 Inhibitor 24 22.7 80.7 0 0.780 2.113 0
3 SVG p15 DMSO 24 30.5 41.6 26.9 1 1 1
3 SVG p16 Inhibitor 24 23.6 61.7 0 0.774 1.483 0
1 SVG p12 DMSO 48 36 16.8 52 1 1 1
1 SVG p12 Inhibitor 48 33.3 28.9 31.7 0.925 1.720 0.610
2 SVG p17 DMSO 48 27.5 40 27.9 1 1 1
2 SVG p18 Inhibitor 48 21.7 58.6 0 0.789 1.465 0
3 SVG p19 DMSO 48 28.7 40.2 26.3 1 1 1
3 SVG p20 Inhibitor 48 29.6 53 0 1.031 1.318 0
Mean S.D Mean S.D Mean S.D
Control 1 0 1 0 1 0
24h 0.776 0.004 1.511 0.587 0.307 0.641
48h 0.915 0.121 1.501 0.203 0.203 0.032
Fold Change from Control
 Fold Change from Control
G1 S G2/M
Phase (%)
Repeat # Cell Line Treatment Time (h) G1 S G2/M G1 S G2/M
1 A172 DMSO 24 64.4 18.5 12.2 1 1 1
1 A172 Inhibitor 24 43.7 38.5 15.1 0.679 2.081 1.238
2 A172 DMSO 24 67.9 20.5 7.42 1 1 1
2 A172 Inhibitor 24 65.8 27 4.72 0.969 1.317 0.636
3 A172 DMSO 24 69.7 20.1 6.52 1 1 1
3 A172 Inhibitor 24 56 27 9 0.803 1.343 1.380
1 A172 DMSO 48 54.8 28.7 12.6 1 1 1
1 A172 Inhibitor 48 38.9 38.7 19.8 0.710 1.348 1.571
2 A172 DMSO 48 57.7 26.4 17.3 1 1 1
2 A172 Inhibitor 48 58 29.3 9.87 1.005 1.110 0.571
3 A172 DMSO 48 58.2 26.3 15.4 1 1 1
3 A172 Inhibitor 48 57.4 24.8 18.7 0.986 0.943 1.214
Mean S.D Mean S.D Mean S.D
Control 1 0 1 0 1 0
24h 0.817 0.1189849 1.580 0.322519 1.085 0.322519
48h 0.920 0.1349835 1.134 0.166391 1.119 0.414166
 Fold Change from Control
Phase (%) Fold Change from Control
G1 S G2/M
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Table 7.32: Raw data of T98G cells used to generate Table 4.1 and Figure 4.9C 
 
 
Table 7.33: Raw data of U87MG cells used to generate Table 4.1 and Figure 4.9D 
 
 
 
  
Repeat # Cell Line Treatment Time (h) G1 S G2/M G1 S G2/M
1 T98G DMSO 24 65.4 25.3 8.81 1 1 1
1 T98G Inhibitor 24 61.6 26.8 11.2 0.942 1.059 1.271
2 T98G DMSO 24 72.5 23.7 8.97 1 1 1
2 T98G Inhibitor 24 53.8 35.8 0 0.742 1.511 0
3 T98G DMSO 24 66.7 21.2 6.04 1 1 1
3 T98G Inhibitor 24 62 24.1 6.42 0.930 1.137 1.063
1 T98G DMSO 48 67.1 22.1 8.48 1 1 1
1 T98G Inhibitor 48 24.1 35.1 29.9 0.359 1.588 3.526
2 T98G DMSO 48 59.6 27 5.24 1 1 1
2 T98G Inhibitor 48 24.1 35.1 29.9 0.404 1.3 5.706
3 T98G DMSO 48 71 20.7 5.42 1 1 1
3 T98G Inhibitor 48 63.8 24.5 4.65 0.898592 1.183575 0.857934
Mean S.D Mean S.D Mean S.D
Control 1 0 1 0 1 0
24h 0.871 0.0112 1.235 0.241 0.778 0.681
48h 0.599 0.239 1.258 0.353 3.450 2.29
S G2/M
Phase (%) Fold Change from Control
 Fold Change from Control
G1
Repeat # Cell Line Treatment Time (h) G1 S G2/M G1 S G2/M
1 U87MG DMSO 24 47.8 39.7 8.02 1 1 1
1 U87MG Inhibitor 24 45.5 41.8 8.65 0.952 1.053 1.079
2 U87MG DMSO 24 48.7 33.5 15.7 1 1 1
2 U87MG Inhibitor 24 35.2 62.4 0 0.723 1.863 0
3 U87MG DMSO 24 47 35 14.4 1 1 1
3 U87MG Inhibitor 24 35 59 0 0.745 1.686 0
1 U87MG DMSO 48 44 32.3 24.8 1 1 1
1 U87MG Inhibitor 48 24.6 39.8 29.3 0.559 1.232 1.181
2 U87MG DMSO 48 41.4 24.7 27.6 1 1 1
2 U87MG Inhibitor 48 34.6 32.5 33.5 0.836 1.316 1.214
3 U87MG DMSO 48 49.7 16.4 29.5 1 1 1
3 U87MG Inhibitor 48 33.1 32.5 31 0.666 1.982 1.051
Mean S.D Mean S.D Mean S.D
Control 1 0 1 0 1 0
24h 0.806 0.126 1.534 0.426 0.359 0.623
48h 0.686 0.139 1.509 0.411 1.150 0.086
 Fold Change from Control
G1 S G2/M
Phase (%) Fold Change from Control
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 UV Counting and Viability Data used to Generate Figure 4.15 
Table 7.34: UV counting and viability data from SVG p12 cells used to generate Figure 
4.14A & B 
 
 
 
Table 7.35: UV counting and viability data from A172 cells used to generate Figure 
4.14C & D 
 
SVGp12
Treatment
cells/ml Fold diff from DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff 
from DMSO viability (%)
DMSO 300000 1 90 320000 1 89.06 320000 1 89.06 215000 1 93.02
3uM Inh Only 115000 0.38 82.61 175000 0.55 74.29 175000 0.55 74.29 170000 0.79 85.29
Uv 1h rec 220000 0.73 86.36 290000 0.91 93.10 240000 0.75 89.58 125000 0.58 84.00
UV 3h rec 280000 0.93 92.86 285000 0.89 94.03 405000 1.27 90.12 135000 0.63 72.73
UV 24h rec 265000 0.88 83.02 370000 1.16 68.92 345000 1.08 62.32 205000 0.95 73.21
Both 1h rec 130000 0.43 76.92 185000 0.58 81.08 150000 0.47 86.67 105000 0.49 76.19
Both 3h rec 150000 0.50 83.33 165000 0.52 81.82 220000 0.69 86.36 115000 0.53 86.96
Both 24h rec 215000 0.72 74.42 195000 0.61 35.90 270000 0.84 37.04 180000 0.84 83.33
Treatment Cell No S.D Viability S.D
DMSO 1.00 0.00 90.29 1.88
3uM Inh Only 0.57 0.17 79.12 5.69
Uv 1h rec 0.74 0.13 88.26 3.96
UV 3h rec 0.93 0.26 87.43 9.94
UV 24h rec 1.02 0.12 71.87 8.68
Both 1h rec 0.49 0.06 80.22 4.81
Both 3h rec 0.56 0.09 84.62 2.45
Both 24h rec 0.75 0.11 57.67 24.76
Replicate 3 - 31/1/18Replicate 1- 19/12/2017 Replicate 2 - 26/1/18 Replicate 4 - 13/2/18
Average
A172
Treatment
cells/ml Fold diff from DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff 
from DMSO viability (%)
DMSO 240000 1 85.42 70000 1 83.33 280000 1 44.64 320000 1 90.57
3uM Inh Only 175000 0.73 82.86 60000 0.86 78.57 245000 0.88 87.76 265000 0.83 89.06
Uv 1h rec 130000 0.54 96.15 90000 1.29 83.33 225000 0.80 88.89 375000 1.17 92.00
UV 3h rec 200000 0.83 82.50 110000 1.57 72.73 250000 0.89 65.63 410000 1.28 90.24
UV 24h rec 210000 0.88 73.81 175000 2.50 90.00 320000 1.14 92.19 420000 1.31 94.05
Both 1h rec 120000 0.50 83.33 60000 0.86 75.00 275000 0.98 89.09 300000 0.94 83.12
Both 3h rec 190000 0.79 84.21 70000 1.00 64.29 85000 0.30 52.94 365000 1.14 84.93
Both 24h rec 160000 0.67 62.50 100000 1.43 85.00 285000 1.02 87.72 385000 1.20 93.33
Treatment Cell No S.D Viability S.D
DMSO 1.00 0.00 75.99 21.12
3uM Inh Only 0.82 0.07 84.56 4.80
Uv 1h rec 0.95 0.34 90.09 5.40
UV 3h rec 1.14 0.35 77.77 10.82
UV 24h rec 1.46 0.72 87.51 9.28
Both 1h rec 0.82 0.22 82.64 5.79
Both 3h rec 0.81 0.37 71.59 15.69
Both 24h rec 1.08 0.32 82.14 13.54
Average
Replicate 3 - 13/2/18 Replicate 4 - 22/02/18Replicate 2 - 26/1/18Replicate 1-  19/12/2017
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Table 7.36: UV counting and viability data from T98G cells used to generate Figure 
4.14E & F 
 
 
Table 7.37: UV counting and viability data from U87MG cells used to generate Figure 
4.14G & H 
 
T98G
Treatment
cells/ml Fold diff from DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff 
from DMSO viability (%)
DMSO 265000 1 84.91 190000 1 86.84 450000 1 91.11 430000 1 94.19
3uM Inh Only 265000 1 83.02 195000 1.03 82.05 410000 0.91 86.59 405000 0.94 95.06
Uv 1h rec 440000 1.66 93.18 300000 1.58 91.67 360000 0.80 90.28 280000 0.65 87.88
UV 3h rec 245000 0.92 89.80 270000 1.42 92.59 300000 0.67 91.67 320000 0.74 80.00
UV 24h rec 145000 0.55 82.76 345000 1.82 92.75 505000 1.12 82.35 405000 0.94 92.59
Both 1h rec 250000 0.94 92.00 200000 1.05 72.50 320000 0.71 85.94 250000 0.58 88.00
Both 3h rec 275000 1.04 90.91 180000 0.95 91.67 255000 0.57 86.27 270000 0.63 72.00
Both 24h rec 135000 0.51 66.67 280000 1.47 87.50 340000 0.76 63.37 320000 0.74 67.19
Treatment Cell No S.D Viability S.D
DMSO 1.00 0.00 89.26 4.18
3uM Inh Only 0.98 0.05 86.68 5.92
Uv 1h rec 1.35 0.52 90.75 2.25
UV 3h rec 1.00 0.34 88.51 5.79
UV 24h rec 1.16 0.53 87.61 5.84
Both 1h rec 0.90 0.21 84.61 8.46
Both 3h rec 0.85 0.23 85.21 9.13
Both 24h rec 0.91 0.42 71.18 11.01
Average
Replicate 3 - 31/1/18Replicate 1-  19/12/2017 Replicate 2 - 26/1/18 Replicate 4 - 13/2/18
U87MG
Treatment cells/ml
Fold diff 
from DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff from 
DMSO viability (%) cells/ml
Fold diff 
from DMSO viability (%)
DMSO 780000 1 89.74 770000 1 87.66 380000 1 90.79 605000 1 94.21
3uM Inh Only 775000 0.99 88.07 575000 0.75 88.70 275000 0.72 85.45 215000 0.36 88.37
Uv 1h rec 375000 0.48 93.33 370000 0.48 85.14 360000 0.95 90.28 420000 0.69 92.86
UV 3h rec 385000 0.49 89.61 495000 0.64 95.96 215000 0.57 90.70 430000 0.71 89.47
UV 24h rec 350000 0.45 64.29 600000 0.78 84.00 295000 0.78 86.44 455000 0.75 91.21
Both 1h rec 215000 0.28 88.37 240000 0.31 93.75 185000 0.49 86.49 235000 0.39 82.98
Both 3h rec 350000 0.45 92.86 400000 0.52 90.00 150000 0.39 86.67 245000 0.40 83.87
Both 24h rec 210000 0.27 26.19 450000 0.58 75.00 170000 0.45 79.41 265000 0.44 84.91
Treatment Cell No S.D Viability S.D
DMSO 1.00 0.00 90.60 2.74
3uM Inh Only 0.70 0.26 87.65 1.48
Uv 1h rec 0.65 0.22 90.40 3.76
UV 3h rec 0.60 0.09 91.44 3.07
UV 24h rec 0.69 0.16 81.48 11.85
Both 1h rec 0.37 0.09 87.90 4.50
Both 3h rec 0.44 0.06 88.35 3.91
Both 24h rec 0.43 0.13 66.38 27.10
Average
Replicate 3 - 31/1/18Replicate 1-  19/12/2017 Replicate 2-  26/1/2018 Replicate 4 - 13/2/18
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 Data used to Generate Figure 4.19 
Table 7.38: Data from SVG p12 cells used to generate Figure 4.19A 
 
Image No. Treatment no. cells w/ foci
Total no. 
cells % Image No. Treatment
no. cells 
w/ foci
Total no. 
cells % Image No. Treatment
no. cells 
w/ foci
Total no. 
cells %
1 1 4 39 10.26 39 1 2 25 8.00 77 1 1 74 1.35
2 1 3 34 8.82 40 1 2 39 5.13 78 1 1 81 1.23
3 1 6 32 18.75 41 1 0 20 0.00 79 1 2 85 2.35
4 1 2 33 6.06 42 1 1 20 5.00 80 1 0 76 0.00
5 1 4 43 9.30 43 1 1 22 4.55 81 2 2 25 8.00
6 2 9 27 33.33 44 2 1 14 7.14 82 2 1 23 4.35
7 2 8 20 40.00 45 2 2 35 5.71 83 2 2 24 8.33
8 2 10 32 31.25 46 2 0 24 0.00 84 2 3 30 10.00
9 2 15 42 35.71 47 2 0 36 0.00 85 3 3 78 3.85
10 3 19 41 46.34 48 3 2 12 16.67 86 3 4 86 4.65
11 3 15 29 51.72 49 3 1 29 3.45 87 3 4 77 5.19
12 3 40 77 51.95 50 3 2 30 6.67 88 3 2 70 2.86
13 3 26 52 50.00 51 3 1 31 3.23 89 4 8 72 11.11
14 4 30 36 83.33 52 4 0 19 0.00 90 4 4 77 5.19
15 4 32 50 64.00 53 4 2 12 16.67 91 4 5 76 6.58
16 4 21 35 60.00 54 4 0 9 0.00 92 4 6 61 9.84
17 4 18 41 43.90 55 4 0 30 0.00 93 5 26 73 35.62
18 5 10 35 28.57 56 4 0 15 0.00 94 5 17 74 22.97
19 5 12 35 34.29 57 4 1 24 4.17 95 5 23 75 30.67
20 5 16 29 55.17 58 5 1 11 9.09 96 5 11 50 22.00
21 5 10 20 50.00 59 5 4 11 36.36 97 6 7 38 18.42
22 6 5 10 50.00 60 5 1 17 5.88 98 6 8 26 30.77
23 6 12 22 54.55 61 5 1 12 8.33 99 6 5 32 15.63
24 6 4 10 40.00 62 5 1 12 8.33 100 6 7 31 22.58
25 6 7 16 43.75 63 5 7 20 35.00 101 7 3 28 10.71
26 6 5 12 41.67 64 6 3 18 16.67 102 7 4 22 18.18
27 6 4 11 36.36 65 6 3 26 11.54 103 7 5 34 14.71
28 6 8 14 57.14 66 6 2 8 25.00 104 7 3 18 16.67
29 7 9 12 75.00 67 6 2 6 33.33 105 8 2 8 25.00
30 7 17 23 73.91 68 6 6 16 37.50 106 8 2 8 25.00
31 7 13 21 61.90 69 7 3 19 15.79 107 8 4 11 36.36
32 7 6 11 54.55 70 7 4 21 19.05 108 8 7 21 33.33
33 7 11 16 68.75 71 7 3 22 13.64
34 8 4 6 66.67 72 7 2 16 12.50
35 8 6 10 60.00 73 8 5 9 55.56
36 8 9 16 56.25 74 8 1 9 11.11
37 8 7 14 50.00 75 8 2 14 14.29
38 8 11 16 68.75 76 8 0 9 0.00
Mean % S.D
5.77 5.08
20.55 22.09
21.77 28.44
27.31 15.49
15.32 15.02
33.43 14.19
35.03 26.58
38.64 22.58
Replicate 1- 13/12/17 Replicate 2- 13/3/18 Replicate 3- 12/4/18
Treatment
UV only 24h recovery
UV only 3h recovery
UV only 1h recovery
Inh + UV 3h recovery
Inh + UV 24h recovery
Inh + UV 1h recovery
Inh Only (24h)
Control
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Table 7.39: Data from A172 cells used to generate Figure 4.19B 
 
 
  
Image 
No. Treatment
no. cells 
w/ foci
Total no. 
cells %
Image 
No. Treatment
no. cells 
w/ foci
Total no. 
cells % Image No. Treatment
no. cells 
w/ foci
Total no. 
cells %
1 1 0 26 0.00 58 1 0 27 0.00 92 1 0 42 0.00
2 1 0 28 0.00 59 1 0 38 0.00 93 1 0 60 0.00
3 1 2 33 6.06 60 1 0 25 0.00 94 1 0 49 0.00
4 1 3 32 9.38 61 2 3 8 37.50 95 1 0 47 0.00
5 1 2 37 5.41 62 2 3 19 15.79 96 2 6 36 16.67
6 1 1 37 2.70 63 2 2 28 7.14 97 2 6 34 17.65
7 1 1 9 11.11 64 2 2 29 6.90 98 2 5 45 11.11
8 1 3 41 7.32 65 3 4 29 13.79 99 2 8 56 14.29
9 1 1 26 3.85 66 3 3 18 16.67 100 3 13 53 24.53
10 1 4 35 11.43 67 3 3 34 8.82 101 3 11 71 15.49
11 1 1 24 4.17 68 3 6 40 15.00 102 3 16 70 22.86
12 1 0 10 0.00 69 4 5 40 12.50 103 3 14 58 24.14
13 2 7 14 50.00 70 4 8 43 18.60 104 4 5 53 9.43
14 2 2 15 13.33 71 4 5 33 15.15 105 4 2 72 2.78
15 2 4 17 23.53 72 4 17 56 30.36 106 4 7 56 12.50
16 2 0 10 0.00 73 5 12 44 27.27 107 4 3 67 4.48
17 2 5 15 33.33 74 5 10 43 23.26 108 5 24 67 35.82
18 2 6 17 35.29 75 5 12 36 33.33 109 5 16 61 26.23
19 2 5 13 38.46 76 5 7 28 25.00 110 5 14 35 40.00
20 2 2 13 15.38 77 6 7 26 26.92 111 5 13 36 36.11
21 2 6 20 30.00 78 6 7 24 29.17 112 6 8 30 26.67
22 2 4 17 23.53 79 6 10 28 35.71 113 6 11 41 26.83
23 2 3 11 27.27 80 6 6 21 28.57 114 6 9 43 20.93
24 2 3 22 13.64 81 6 9 21 42.86 115 6 8 32 25.00
25 2 4 14 28.57 82 7 29 46 63.04 116 7 8 43 18.60
26 3 14 29 48.28 83 7 12 17 70.59 117 7 5 52 9.62
27 3 8 19 42.11 84 7 9 19 47.37 118 7 9 65 13.85
28 3 16 30 53.33 85 7 12 25 48.00 119 7 6 44 13.64
29 3 15 41 36.59 86 8 12 14 85.71 120 8 21 39 53.85
30 3 13 35 37.14 87 8 12 13 92.31 121 8 5 22 22.73
31 4 20 31 64.52 88 8 18 22 81.82 122 8 9 50 18.00
32 4 31 37 83.78 89 8 13 16 81.25 123 8 6 40 15.00
33 4 18 20 90.00 90 8 19 21 90.48
34 4 15 21 71.43 91 8 15 19 78.95
35 5 26 33 78.79
36 5 13 21 61.90
37 5 14 16 87.50
38 5 13 18 72.22
39 5 19 29 65.52
40 6 10 20 50.00
41 6 9 13 69.23
42 6 10 19 52.63
43 6 12 18 66.67
44 6 10 18 55.56
45 6 18 24 75.00
46 7 11 12 91.67
47 7 9 10 90.00
48 7 13 16 81.25
49 7 10 11 90.91
50 7 14 17 82.35
51 7 13 13 100.00
52 7 17 20 85.00
53 8 5 6 83.33
54 8 5 6 83.33
55 8 6 8 75.00
56 8 7 8 87.50
57 8 20 23 86.96
Mean % S.D
3.41 4.14
26.19 14.83
36.26 31.70
44.71 25.53
21.19 13.29
42.85 17.61
61.15 31.67
68.98 27.83
Replicate 2- 13/3/18Replicate 1- 13/12/17 Replicate 3- 13/4/18
Treatment
Inh + UV 1h recovery
Inh + UV 3h recovery
Inh + UV 24h recovery
Control
UV only 1h recovery
UV only 3h recovery
UV only 24h recovery
Inh Only (24h)
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Table 7.40: Data from T98G cells used to generate Figure 4.19C 
Image No. Treatment no. cells w/ foci
Total no. 
cells % Image No. Treatment
no. cells w/ 
foci
Total no. 
cells % Image No. Treatment
no. cells w/ 
foci
Total no. 
cells %
1 1 0 62 0.00 34 1 2 87 2.30 64 1 0 69 0.00
2 1 0 50 0.00 35 1 4 46 8.70 65 1 0 74 0.00
3 1 0 54 0.00 36 1 4 60 6.67 66 1 0 74 0.00
4 1 0 53 0.00 37 2 3 51 5.88 67 1 1 82 1.22
5 2 1 73 1.37 38 2 9 66 13.64 68 2 1 108 0.93
6 2 0 62 0.00 39 2 15 68 22.06 69 2 2 92 2.17
7 2 0 38 0.00 40 3 8 90 8.89 70 2 2 74 2.70
8 2 1 75 1.33 41 3 9 96 9.38 71 2 0 92 0.00
9 3 5 67 7.46 42 3 3 76 3.95 72 3 4 96 4.17
10 3 6 72 8.33 43 3 2 71 2.82 73 3 0 74 0.00
11 3 1 51 1.96 44 4 9 79 11.39 74 3 0 99 0.00
12 3 0 59 0.00 45 4 3 49 6.12 75 3 0 89 0.00
13 4 0 70 0.00 46 4 5 62 8.06 76 4 0 78 0.00
14 4 0 105 0.00 47 4 10 112 8.93 77 4 0 122 0.00
15 4 0 119 0.00 48 5 5 54 9.26 78 4 0 81 0.00
16 4 0 80 0.00 49 5 4 71 5.63 79 4 0 124 0.00
17 5 0 61 0.00 50 5 3 44 6.82 80 5 0 116 0.00
18 5 0 96 0.00 51 5 3 48 6.25 81 5 0 87 0.00
19 5 0 95 0.00 52 6 2 76 2.63 82 5 2 81 2.47
20 5 1 85 1.18 53 6 1 56 1.79 83 5 0 75 0.00
21 6 1 82 1.22 54 6 0 95 0.00 84 5 0 124 0.00
22 6 0 84 0.00 55 6 1 44 2.27 85 6 0 99 0.00
23 6 0 58 0.00 56 7 12 64 18.75 86 6 0 130 0.00
24 6 0 63 0.00 57 7 10 60 16.67 87 6 0 91 0.00
25 7 0 45 0.00 58 7 4 40 10.00 88 6 0 97 0.00
26 7 0 62 0.00 59 7 8 76 10.53 89 7 0 107 0.00
28 7 1 87 1.15 60 8 7 70 10.00 90 7 0 62 0.00
29 7 2 63 3.17 61 8 7 52 13.46 91 7 0 110 0.00
30 8 0 36 0.00 62 8 5 84 5.95 92 7 0 109 0.00
31 8 2 79 2.53 63 8 6 62 9.68 93 8 1 92 1.09
32 8 1 65 1.54 94 8 2 71 2.82
33 8 1 62 1.61 95 8 1 95 1.05
8 0 82 0.00
Mean % S.D
1.72 3.07
3.91 3.91
2.70 3.88
1.92 2.54
4.55 7.04
0.66 1.02
4.03 7.06
4.14 4.53
Replicate 1- 13/4/18 Replicate 2- 13/3/18 Replicate 3- 29/3/18
Inh + UV 24h recovery
Control
Treatment
UV only 1h recovery
UV only 3h recovery
UV only 24h recovery
Inh Only (24h)
Inh + UV 1h recovery
Inh + UV 3h recovery
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Table 7.41: Data from U87MG cells used to generate Figure 4.19D 
 
 
  
Image No. Treatment no. cells w/ foci
Total no. 
cells % Image No. Treatment
no. cells 
w/ foci
Total no. 
cells % Image No. Treatment
no. cells 
w/ foci
Total no. 
cells %
1 1 3 70 4.29 33 1 0 99 0.00 34 1 4 33 12.12
2 1 5 119 4.20 34 1 0 104 0.00 35 1 5 57 8.77
3 1 4 73 5.48 35 1 0 94 0.00 36 1 3 48 6.25
4 1 5 91 5.49 36 1 0 81 0.00 37 1 6 36 16.67
5 2 3 57 5.26 37 2 0 48 0.00 38 2 3 20 15.00
6 2 4 54 7.41 38 2 1 57 1.75 39 2 7 27 25.93
7 2 3 89 3.37 39 2 0 59 0.00 40 2 7 51 13.73
8 2 6 56 10.71 40 2 1 43 2.33 41 2 7 60 11.67
9 3 5 95 5.26 41 2 2 58 3.45 42 3 6 45 13.33
10 3 6 120 5.00 42 3 9 87 10.34 43 3 4 60 6.67
11 3 7 86 8.14 43 3 12 76 15.79 44 3 2 61 3.28
12 3 6 82 7.32 44 3 10 99 10.10 45 3 1 57 1.75
13 4 14 147 9.52 45 3 6 77 7.79 46 3 4 70 5.71
14 4 25 127 19.69 46 4 2 89 2.25 47 4 4 18 22.22
15 4 8 103 7.77 47 4 3 92 3.26 48 4 7 59 11.86
16 4 9 115 7.83 48 4 0 82 0.00 49 4 9 53 16.98
17 5 7 86 8.14 49 4 1 64 1.56 50 4 10 57 17.54
18 5 9 94 9.57 50 5 4 37 10.81 51 5 15 41 36.59
19 5 12 112 10.71 51 5 6 23 26.09 52 5 9 33 27.27
20 5 13 118 11.02 52 5 5 25 20.00 53 5 15 42 35.71
21 6 5 53 9.43 53 5 15 137 10.95 54 5 12 36 33.33
22 6 7 68 10.29 54 6 8 43 18.60 55 6 4 27 14.81
23 6 8 83 9.64 55 6 6 63 9.52 56 6 4 29 13.79
24 6 10 102 9.80 56 6 9 50 18.00 57 6 6 45 13.33
25 7 6 143 4.20 57 6 9 45 20.00 58 6 3 34 8.82
26 7 4 67 5.97 58 7 6 26 23.08 59 7 4 10 40.00
27 7 8 94 8.51 59 7 4 47 8.51 60 7 8 17 47.06
28 7 3 79 3.80 60 7 2 54 3.70 61 7 3 12 25.00
29 8 1 28 3.57 61 7 10 45 22.22 62 7 7 15 46.67
30 8 2 21 9.52 62 8 5 15 33.33 63 7 14 31 45.16
31 8 6 38 15.79 63 8 6 49 12.24 64 8 8 24 33.33
32 8 4 25 16.00 64 8 8 75 10.67 65 8 19 46 41.30
65 8 11 46 23.91 66 8 9 22 40.91
66 8 17 117 14.53 67 8 4 28 14.29
68 8 8 16 50.00
Mean % S.D
5.27 5.03
7.73 3.76
10.04 7.30
20.02 10.69
7.74 7.37
13.01 3.88
21.67 16.90
22.81 13.82
Inh + UV 3h recovery
Inh + UV 24h recovery
Control
UV only 1h recovery
UV only 3h recovery
UV only 24h recovery
Inh Only (24h)
Inh + UV 1h recovery
Treatment
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 Sequencing Data 
 
 
Figure 7.15: Sequencing results of the PRMT1 amplicon from U87MG cells  
The PRMT1 149 bp amplicon (A; bold text) from U87MG cells was sequenced and mutations c.T96>C and 
c.G108>A (A & B; red boxes) were detected.  
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Figure 7.16: Paper abstract 
Plett, K. L., A. E. Raposo, S. Bullivant, I. C. Anderson, S. C. Piller and J. M. Plett (2017). "Root morphogenic pathways in 
Eucalyptus grandis are modified by the activity of protein arginine methyltransferases." BMC Plant Biology 17(1): 62. 
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Figure 7.17: Paper abstract 
Raposo, A. E. and S. C. Piller (2018). "Protein arginine methylation: an emerging regulator of the cell cycle." Cell 
Division 13: 3. 
 
